TLR7 / 8 antagonists and uses thereof
By developing TLR7/8 dual antagonist compounds, the problem that the existing technology cannot effectively inhibit TLR7/8 overexpression-related diseases has been solved, and selective antagonism of TLR7/8 is achieved, reducing the symptoms of immune disorders and improving the effect of cancer immunotherapy .
Patent Information
- Application Number
- CN202410927343.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2017-07-18
- Filing Date
- 2018-07-17
- Publication Date
- 2024-11-05
AI Technical Summary
Existing TLR7 and TLR8 inhibitors are unable to effectively inhibit autoimmune disorders and inflammatory diseases associated with TLR7/8 overexpression, and traditional TLR agonists have limited effectiveness in cancer immunotherapy.
A dual antagonist compound of TLR7/8 is provided for the treatment and prevention of TLR7/8-related diseases, and a compound that selectively antagonizes TLR7 or TLR8 by inhibiting the activity of TLR7 and TLR8.
Effectively inhibit the immune response of TLR7/8, relieve the symptoms of autoimmune disorders and inflammatory diseases, and act as an anti-cancer agent in cancer treatment to regulate immune response and improve the effectiveness of immunotherapy.
Smart Images

Figure CN118894840A_ABST
Abstract
Description
[0001] Related Applications
[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 533,820, filed on July 18, 2017. The contents of the foregoing application are hereby incorporated by reference in their entirety.
[0003] Technical Field of the Invention
[0004] The present invention provides compounds of formula (I) as toll-like receptor 7 / 8 (TLR7 / 8) antagonists and their use in treating immune disorders and other diseases associated with TLR7 / 8 overexpression. Background of the Invention
[0006] The Toll-like receptor (TLR) that currently comprises the gene family of 10 kinds of receptors with different specificities is a part of the cell pathogen pattern recognition system, which has evolved to defend various infections (bacteria, viruses, fungi). The activation of TLR causes cytokine response, for example, accompanied by the release of interferon and activation of specific immune cells. The functional expression of selected TLR in tissue is highly different. Some receptors are located on the cell surface, such as TLR4 (stimulated by Escherichia coli lipopolysaccharide LPS) on epithelial cells, or TLR3, 7, 8 and 9 at the endosomal membrane in specific immune cells. The latter are all activated by nucleic acids, but their various types are recognized. For example, TLR9 is activated by single-stranded DNA containing CpG subsequences, TLR7 and 8 are activated by single-stranded RNA, and TLR3 is activated by double-stranded RNA.
[0007] TLRs are involved in various autoimmune and inflammatory diseases, the most obvious example being the role of TLR7 in the pathogenesis of systemic lupus erythematosus (Barrat and Coffman, Immunol Rev, 223: 271-283, 2008). In addition, TLR8 polymorphisms are associated with rheumatoid arthritis (Enevold et al., J Rheumatol, 37: 905-10, 2010). Although various TLR7, TLR8 and TLR9 inhibitors have been described, additional TLR inhibitors are needed. In particular, polynucleotides having inhibitory motifs for one or more of TLR7, TLR8 and TLR9 are needed to precisely inhibit immune responses in subjects (e.g., patients with autoimmune diseases or inflammatory disorders).
[0008] For several years, the whole world has been trying very hard to develop strong immune activation induced by TLR7, 8 or 9 agonists to treat cancer. However, cancer immunotherapy has experienced a long history of failure. However, in recent years, the knowledge about cancer immune surveillance and the function of immune cell subsets has been significantly improved. TLR7 or TLR9 agonists are in clinical development for single or combined therapy of cancer or as vaccine adjuvants. The TLR agonist approach for cancer immunotherapy is different from the early efforts of using, for example, cytokines, interferons or monovalent vaccinations. TLR agonist-mediated immune activation is pleiotropic via specific immune cells (mainly dendritic cells and B cells, followed by other cells), which produces innate and adaptive immune responses. In addition, instead of only inducing a kind of interferon, many different isotypes are induced together, and not only type I (α, β), but also (indirectly) type II (γ, NK cells). SUMMARY OF THE INVENTION
[0010] In one aspect, the present invention provides compounds of formula (I):
[0011]
[0012] and pharmaceutically acceptable derivatives, solvates, salts, hydrates and stereoisomers thereof.
[0013] In another aspect, the present invention provides a compound of formula (I) which is a dual antagonist of TLR7 and TLR8. In another aspect, the present invention provides a compound of formula (I) which is suitable for treating and / or preventing disorders associated with TLR7 / 8. In another aspect, the present invention provides a compound capable of modulating, in particular inhibiting, TLR7 / 8 activity or function in a disease state in a mammal, in particular a human.
[0014] According to another aspect of the present invention, a method for treating and / or preventing an autoimmune disorder is provided.
[0015] According to another aspect, the present invention provides compounds of formula (I) that are selective for TLR7 or TLR8.
[0016] According to another aspect, the present invention provides compounds of formula (I) that are selective for TLR7 and TLR8.
[0017] DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS
[0018] 1. General Description of the Compounds of the Invention
[0019] In certain aspects, the present invention provides antagonists of TLR7 / 8. In some embodiments, such compounds include those of the formulae described herein, or pharmaceutically acceptable salts thereof, wherein each variant is as defined and described herein.
[0020] 2. Compounds and Definitions
[0021] The compounds of the present invention include those generally described above and are further illustrated by the classes, subclasses and species disclosed herein. As used herein, unless otherwise indicated, the following definitions shall apply. For purposes of the present invention, chemical elements are identified according to the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th edition. In addition, the general principles of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, and "March's Advanced Organic Chemistry", 5th edition, editors: Smith, MB and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are incorporated herein by reference.
[0022] As used herein, the term "aliphatic" or "aliphatic group" refers to a straight chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is fully saturated or contains one or more unsaturated units, or a monocyclic hydrocarbon or bicyclic hydrocarbon (also referred to herein as "carbocycle," "alicyclic," or "cycloalkyl") that is fully saturated or contains one or more unsaturated units, but is not aromatic, having a single point of attachment to the rest of the molecule. Unless otherwise specified, an aliphatic group contains 1-6 aliphatic carbon atoms. In some embodiments, an aliphatic group contains 1-5 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1-4 aliphatic carbon atoms. In yet other embodiments, an aliphatic group contains 1-3 aliphatic carbon atoms, and in yet other embodiments, an aliphatic group contains 1-2 aliphatic carbon atoms. In some embodiments, "alicyclic" (or "carbocycle" or "cycloalkyl") refers to a monocyclic C3-C6 hydrocarbon that is fully saturated or contains one or more unsaturated units, but is not aromatic, having a single point of attachment to the rest of the molecule. Exemplary aliphatic groups are linear or branched, substituted or unsubstituted C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, and hybrids thereof, such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl, or (cycloalkyl)alkenyl.
[0023] The term "lower alkyl" refers to a C 1-4 Straight or branched alkyl. Exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl.
[0024] The term "lower haloalkyl" refers to a C 1-4 Straight or branched alkyl.
[0025] The term "heteroatom" refers to one or more of oxygen, sulfur, nitrogen or phosphorus (including any oxidized form of nitrogen, sulfur or phosphorus; the quaternized form of any basic nitrogen; or a substitutable nitrogen of a heterocyclic ring, such as N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR + (as in N-substituted pyrrolidinyl)).
[0026] As used herein, the term "unsaturated" refers to a moiety having one or more units of unsaturation.
[0027] As used herein, the term "divalent C 1-8 (or C 1-6 ) saturated or unsaturated straight or branched hydrocarbon chain” refers to straight or branched divalent alkylene, alkenylene and alkynylene chains as defined herein.
[0028] The term "alkylene" refers to a divalent alkyl group. An "alkylene chain" is a polymethylene group, i.e., -(CH2) n -, wherein n is a positive integer, preferably 1 to 6, 1 to 4, 1 to 3, 1 to 2, or 2 to 3. Substituted alkylene chains are polymethylene chains in which one or more methylene hydrogen atoms are replaced by substituents. Suitable substituents include those described below for substituted aliphatic groups.
[0029] The term "alkenylene" refers to a divalent alkenyl group. A substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced by a substituent. Suitable substituents include those described below for substituted aliphatic groups.
[0030] The term "halogen" means F, Cl, Br or I.
[0031] The term "aryl", used alone or as part of a larger moiety (such as in "aralkyl", "aralkyloxy" or "aryloxyalkyl"), refers to monocyclic and bicyclic ring systems having a total of 5 to 14 ring members, wherein at least one ring in the system is aromatic, and wherein each ring in the system contains 3 to 7 ring members. The term "aryl" can be used interchangeably with the term "aryl ring". In certain embodiments of the present invention, "aryl" refers to an aromatic ring system. Exemplary aryl groups are phenyl, biphenyl, naphthyl, anthracenyl, etc., which optionally include one or more substituents. As used herein, groups in which an aromatic ring is fused to one or more non-aromatic rings are also included within the scope of the term "aryl", such as indanyl, phthalimidyl, naphthalimidyl, phenanthridinyl, or tetrahydronaphthyl, etc.
[0032] The terms "heteroaryl" and "heteroar-" used alone or as part of a larger moiety (e.g., "heteroaralkyl" or "heteroaralkoxy") refer to groups having 5 to 10 ring atoms (preferably 5, 6 or 9 ring atoms), sharing 6, 10 or 14 π electrons in the ring array, and having 1 to 5 heteroatoms in addition to carbon atoms. The term "heteroatom" refers to nitrogen, oxygen or sulfur, and includes any oxidized form of nitrogen or sulfur, as well as any quaternized form of basic nitrogen. Heteroaryl includes, but is not limited to, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl and pteridinyl. As used herein, the terms "heteroaryl" and "heteroaryl-" also include groups in which a heteroaromatic ring is fused to one or more aryl, alicyclic or heterocyclic rings, wherein the attachment group or point of attachment is on the heteroaromatic ring. Non-limiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzothiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolyl, tetrahydroisoquinolyl and pyrido [2,3-b] -1, 4-oxazine -3 (4H) -one. Heteroaryl is optionally monocyclic or bicyclic. The term "heteroaryl" may be used interchangeably with the terms "heteroaryl ring," "heteroaryl," or "heteroaromatic," any of which terms include optionally substituted rings. The term "heteroaralkyl" refers to an alkyl group substituted with a heteroaryl group, wherein the alkyl and heteroaryl portions independently are optionally substituted.
[0033] As used herein, the terms "heterocycle", "heterocyclyl", "heterocyclic group" and "heterocyclic ring" are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7-10-membered bicyclic heterocyclic moiety that is saturated or partially unsaturated and has one or more, preferably 1-4, heteroatoms as defined above in addition to carbon atoms. The term "nitrogen" when used to refer to the ring atoms of the heterocycle includes substituted nitrogen. For example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, nitrogen is N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or + NR (as in N-substituted pyrrolidinyl).
[0034] The heterocyclic ring may be attached to its side group at any heteroatom or carbon atom to produce a stable structure, and any ring atom may be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic groups include, but are not limited to, tetrahydrofuranyl, tetrahydrothiophenyl, pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepine, pyrrolidine, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepine, pyrrolidine, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, pyrrolidine ... Oxazepine Thiazepine The terms "heterocycle", "heterocyclyl", "heterocyclyl ring", "heterocyclic group", "heterocyclic moiety" and "heterocyclic radical" are used interchangeably herein and also include groups in which the heterocyclyl ring is fused to one or more aryl, heteroaryl or alicyclic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl or tetrahydroquinolinyl, wherein the linking group or point of attachment is on the heterocyclyl ring. The heterocyclyl is optionally monocyclic or bicyclic. The term "heterocyclylalkyl" refers to an alkyl substituted with a heterocyclyl, wherein the alkyl and heterocyclyl moieties are independently optionally substituted.
[0035] As used herein, the term "partially unsaturated" refers to a ring moiety containing at least one double or triple bond. The term "partially unsaturated" is intended to include rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties as defined herein.
[0036] As described herein, fused rings are described by embodiments for each ring (Ring A and Ring B). Ring A and Ring B together form a fused heteroaryl ring, as valence permits.
[0037] (For example, when ring A is and ring B is When , then ring A and ring B together are ).
[0038] As described herein, certain compounds of the invention contain "optionally substituted" moieties. In general, the term "substituted," whether or not followed by the term "optionally," means that one or more hydrogen atoms of the designated moiety are replaced with a suitable substituent. "Substituted" applies to any substitution of one or more hydrogen atoms, whether explicit or implicit from the structure (e.g., means at least and means at least Unless otherwise indicated, an "optionally substituted" group has a suitable substituent at each substitutable position of the group, and when more than one position in any given structure is substituted by more than one substituent selected from a specific group, the substituent is the same or different at each position. The combination of substituents contemplated by the present invention is preferably those that result in the formation of stable or chemically feasible compounds. As used herein, the term "stable" refers to a compound that is substantially unchanged when subjected to conditions that allow its production, detection, and in certain embodiments, its recovery, purification, and use for one or more purposes disclosed herein.
[0039] Suitable monovalent substituents on the substitutable carbon atoms of the "optionally substituted" group are independently deuterium; halogen; -(CH2) 0-4 R o ; -(CH2) 0-4 OR o ; -O(CH2) 0-4 R o ,-O-(CH2) 0-4 C(O)OR o ; -(CH2) 0-4 CH(OR o )2; -(CH2) 0-4 SR o ; optionally R o Substituted -(CH2) 0-4 Ph; optionally replaced by R o Substituted -(CH2) 0-4 O(CH2) 0-1 Ph; optionally replaced by R o -CH=CHPh substituted; optionally with R o Substituted -(CH2) 0-4 O(CH2) 0-1 -pyridyl; -NO2; -CN; -N3; -(CH2) 0-4 N(R o )2; -(CH2) 0-4 N(R o )C(O)R o ;-N(R o )C(S)R o ; -(CH2) 0-4 N(R o )C(O)NR o 2;-N(R o )C(S)NR o 2; -(CH2) 0-4 N(R o )C(O)OR o ;-N(R o )N(Ro )C(O)R o ;-N(R o )N(R o )C(O)NR o 2;-N(R o )N(R o )C(O)OR o ;-(CH2) 0-4 C(O)R o ;-C(S)R o ;-(CH2) 0-4 C(O)OR o ;-(CH2) 0-4 C(O)SR o ;-(CH2) 0-4 C(O)OSiR o 3;-(CH2) 0-4 OC(O)R o ;-OC(O)(CH2) 0-4 SR o ,SC(S)SR o ;-(CH2) 0-4 SC(O)R o ;-(CH2) 0-4 C(O)NR o 2;-C(S)NR o 2;-C(S)SR o ;-SC(S)SR o ,-(CH2) 0-4 OC(O)NR o 2;-C(O)N(OR o )R o ;-C(O)C(O)R o ;-C(O)CH2C(O)R o ;-C(NOR o )R o ;-(CH2) 0-4 SSR o ;-(CH2) 0-4 S(O)2R o ;-(CH2) 0-4 S(O)2OR o ;-(CH2) 0-4 OS(O)2R o ;-S(O)2NR o 2;-(CH2) 0-4 S(O)R o ;-N(R o )S(O)2NR o 2;-N(R o)S(O)2R o ;-N(OR o )R o ; -C(NH)NR o 2;-P(O)2R o ;-P(O)R o 2;-OP(O)R o 2;-OP(O)(OR o )2;SiR o 3;-(C 1-4 Straight or branched alkylene)ON(R o )2; or -(C 1-4 Straight or branched alkylene)C(O)ON(R o )2, where each R o The following definitions are optionally substituted and are independently hydrogen, C 1-6 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph, -CH2-(5-6 membered heteroaryl ring) or a 5-6 membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or, notwithstanding the above definitions, two independent occurrences of R o Together with their intervening atoms they form a 3-12 membered saturated, partially unsaturated or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, which is optionally substituted as defined below.
[0040] R o (or through two independent occurrences of R o Suitable monovalent substituents on the ring formed by taking together with their intervening atoms are independently deuterium, halogen, -(CH2) 0-2 R · ,-(halogenated R · ), -(CH2) 0-2 OH, -(CH2) 0-2 OR · , -(CH2) 0-2 CH(OR · )2; -O(halogenated R · ), -CN, -N3, -(CH2) 0-2 C(O)R · , -(CH2) 0-2 C(O)OH, -(CH2) 0-2 C(O)OR · , -(CH2) 0-2 SR · , -(CH2) 0-2 SH, -(CH2) 0-2 NH2, -(CH2)0-2 NHR · , -(CH2) 0-2 NR · 2, -NO2, -SiR · 3, -OSiR · 3, -C(O)SR · ,-(C 1-4 Straight or branched alkylene)C(O)OR · or -SSR · , where each R · is unsubstituted or, when preceded by "halo", is substituted only by one or more halogens, and is independently selected from C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0-1 Ph, or a 5-6 membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur. o Suitable divalent substituents on a saturated carbon atom of include =0 and =S.
[0041] Suitable divalent substituents on a saturated carbon atom of an "optionally substituted" group include the following: =0, =S, =NNR * 2, =NNHC(O)R * , =NNHC(O)OR * , =NNHS(O)2R * , =NR * , =NOR * , -O(C(R * 2)) 2-3 O-or-S(C(R * 2)) 2-3 S-, where each independent occurrence of R * is selected from hydrogen, the substituted C 1-6 aliphatic, or an unsubstituted 5-6 membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur. Suitable divalent substituents bonded to the carbon that may be substituted in the "optionally substituted" group include: -O(CR * 2) 2-3 O-, where each independent occurrence of R * is selected from hydrogen, optionally substituted C 1-6 aliphatic, or an unsubstituted 5-6 membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.
[0042] R * Suitable substituents on the aliphatic group include halogen, -R · ,-(halogenated R ·), -OH, -OR · , -O(halogenated R · ), -CN, -C(O)OH, -C(O)OR · , -NH2, -NHR · , -NR · 2 or -NO2, where each R · is unsubstituted or, when preceded by "halo", substituted only by one or more halogens, and is independently C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0- 1Ph or a 5-6 membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.
[0043] Suitable substituents on the substitutable nitrogen of an "optionally substituted" group include or Among them each are independently hydrogen, and optionally substituted C 1-6 aliphatic, unsubstituted -OPh, or an unsubstituted 5-6 membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or, notwithstanding the above definition, two independent occurrences of Together with their intervening atoms they form an unsubstituted 3-12 membered saturated, partially unsaturated or aromatic mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.
[0044] Suitable substituents on the aliphatic group are independently halogen, -R · ,-(halogenated R · ), -OH, -OR · , -O(halogenated R · ), -CN, -C(O)OH, -C(O)OR · , -NH2, -NHR · , -NR · 2 or -NO2, where each R · is unsubstituted or, when preceded by "halo", substituted only by one or more halogens, and is independently C 1-4 Aliphatic, -CH2Ph, -O(CH2) 0- 1Ph or a 5-6 membered saturated, partially unsaturated or aromatic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.
[0045] In certain embodiments, the terms "optionally substituted", "optionally substituted alkyl", "optionally substituted "optionally substituted alkenyl", "optionally substituted alkynyl", "optionally substituted carbocycle", "optionally substituted aryl", "optionally substituted heteroaryl", "optionally substituted heterocycle" and any other optionally substituted groups as used herein refer to groups that are substituted or unsubstituted by independently replacing one, two or three or more hydrogen atoms thereon with typical substituents, including but not limited to:
[0046] -F, -Cl, -Br, -I, deuterium,
[0047] -OH, protected hydroxy, alkoxy, oxo, thioxo,
[0048] -NO2, -CN, CF3, N3,
[0049] -NH2, protected amino, -NH alkyl, -NH alkenyl, -NH alkynyl, -NH cycloalkyl, -NH-aryl, -NH-heteroaryl, -NH-heterocycle, -dialkylamino, -diarylamino, -diheteroarylamino,
[0050] -O-alkyl, -O-alkenyl, -O-alkynyl, -O-cycloalkyl, -O-aryl, -O-heteroaryl, -O-heterocycle,
[0051] -C(O)-alkyl, -C(O)-alkenyl, -C(O)-alkynyl, -C(O)-carbocyclyl, -C(O)-aryl, -C(O)-heteroaryl, -C(O)-heterocyclyl,
[0052] -CONH2, -CONH-alkyl, -CONH-alkenyl, -CONH-alkynyl, -CONH-carbocyclyl, -CONH-aryl, -CONH-heteroaryl, -CONH-heterocyclyl,
[0053] -OCO2-alkyl, -OCO2-alkenyl, -OCO2-alkynyl, -OCO2-carbocyclyl, -OCO2-aryl, -OCO2-heteroaryl, -OCO2-heterocyclyl, -OCONH2, -OCONH-alkyl, -OCONH-alkenyl, -OCONH-alkynyl, -OCONH-carbocyclyl, -OCONH-aryl, -OCONH-heteroaryl, -OCONH-heterocyclyl,
[0054] -NHC(O)-alkyl, -NHC(O)-alkenyl, -NHC(O)-alkynyl, -NHC(O)-carbocyclyl, -NHC(O)-aryl, -NHC(O)-heteroaryl, -NHC(O)-heterocyclyl, -NHCO2-alkyl, -NHCO2-alkenyl, -NHCO2-alkynyl, -NHCO2-carbocyclyl, -NHCO2-aryl, -NHCO2-heteroaryl, -NHCO2-heterocyclyl, -NHC(O)NH2, -NHC(O)NH-alkyl, -NHC(O)NH-alkenyl, -NHC(O)NH-alkenyl, -NHC(O)NH-carbocyclyl, -NHC(O)NH-aryl, -NHC(O)NH-heteroaryl, -NHC(O)NH-heterocyclyl, NHC(S)NH2, -NHC(S)NH-alkyl, -NHC(S)NH-alkenyl, -NHC(S)NH-alkynyl, -NHC(S)NH-carbocyclyl, -NHC(S)NH-aryl, -NHC(S)NH-heteroaryl, -NHC(S)NH-heterocyclyl, -NHC(NH)NH2, -NHC(NH)NH-alkyl, -NHC(NH)NH-alkenyl, -NHC(NH)NH-alkenyl, -NHC(NH)NH-carbocyclyl, -NHC(NH)NH-aryl, -NHC(NH)NH-heteroaryl, -NHC(NH)NH-heterocyclyl, -NHC(NH)-alkyl, -NHC(NH)-alkenyl, -NHC(NH)-alkenyl, -NHC(NH)NH-carbocyclyl, -NHC(NH)NH-aryl, -NHC(NH)NH-heteroaryl, -NHC(NH)NH-heterocyclyl, -NHC(NH)-alkyl, -NHC(NH)-alkenyl, -NHC(NH)-alkenyl, -NHC(NH)-carbocyclyl, -NHC(NH)-aryl, -NHC(NH)-heteroaryl, -NHC(NH)-heterocyclyl,
[0055] -C(NH)NH-alkyl, -C(NH)NH-alkenyl, -C(NH)NH-alkynyl, -C(NH)NH-carbocyclyl, -C(NH)NH-aryl, -C(NH)NH-heteroaryl, -C(NH)NH-heterocyclyl,
[0056] -S(O)-alkyl, -S(O)-alkenyl, -S(O)-alkynyl, -S(O)-carbocyclyl, -S(O)-aryl, -S(O)-heteroaryl, -S(O)-heterocyclyl-SO2NH2, -SO2NH-alkyl, -SO2NH-alkenyl, -SO2NH-alkynyl, -SO2NH-carbocyclyl, -SO2NH-aryl, -SO2NH-heteroaryl, -SO2NH-heterocyclyl,
[0057] -NHSO2-alkyl, -NHSO2-alkenyl, -NHSO2-alkynyl, -NHSO2-carbocyclyl, -NHSO2-aryl, -NHSO2-heteroaryl, -NHSO2-heterocyclyl,
[0058] -CH2NH2, -CH2SO2CH3,
[0059] -mono-, di- or tri-alkylsilyl groups,
[0060] -alkyl, -alkenyl, -alkynyl, -aryl, -arylalkyl, -heteroaryl, -heteroarylalkyl, -heterocycloalkyl, -cycloalkyl, -carbocycle, -heterocycle, polyalkoxyalkyl, polyalkoxy, -methoxymethoxy, -methoxyethoxy, -SH, -S-alkyl, -S-alkenyl, -S-alkynyl, -S-carbocyclyl, -S-aryl, -S-heteroaryl, -S-heterocyclyl or methylthiomethyl.
[0061] As used herein, the term "pharmaceutically acceptable salt" refers to salts that are suitable for contact with tissues of humans and lower animals without excessive toxicity, irritation, allergic response, etc., and are commensurate with a reasonable benefit / risk ratio, within the scope of reasonable medical judgment. Pharmaceutically acceptable salts are well known in the art. For example, SM Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of the present invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are salts of amino groups formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate and the like.
[0062] Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1-4Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, etc. Where appropriate, other pharmaceutically acceptable salts include non-toxic ammonium, quaternary ammonium and amine cations formed using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates and aryl sulfonates.
[0063] Unless otherwise stated, structures depicted herein are also intended to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational) isomeric) forms of the structure; for example, R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) isomeric mixtures of the compounds of the present invention are within the scope of the present invention. Unless otherwise stated, all tautomeric forms of the compounds of the present invention are within the scope of the present invention.
[0064] Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures include the replacement of hydrogen by deuterium or tritium, or by 13 C or 14 C-enriched carbon instead of carbon is within the scope of the present invention. In some embodiments, the group contains one or more deuterium atoms.
[0065] Furthermore, the compounds of Formula I are intended to include isotopically labeled forms thereof. An isotopically labeled form of a compound of Formula I is identical to that compound except for the fact that one or more atoms of that compound have been replaced by one or more atoms having an atomic mass or mass number different from the atomic mass or mass number of the atoms normally found in nature. Examples of isotopes that are readily commercially available and can be incorporated into compounds of Formula I by known methods include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, for example, respectively 2 H. 3 H. 13 C. 14 C. 15 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F and 36 CI. Compounds of formula I, prodrugs or pharmaceutically acceptable salts thereof containing one or more of the above isotopes and / or other isotopes of other atoms are intended to be part of the present invention. Isotopically labeled compounds of formula I can be used in a number of advantageous ways. For example, compounds wherein a radioactive isotope, such as 3 H or 14Compounds of Formula I labeled with isotopes of C are useful in drug and / or substrate tissue distribution assays. These radioactive isotopes, namely tritium ( 3 H) and carbon-14 ( 14 C) is particularly preferred. 2 H)) is incorporated into a compound of formula I with therapeutic advantages due to the higher metabolic stability of the isotopically labeled compound. Higher metabolic stability translates directly into increased in vivo half-life or lower dosage, which in most cases will represent a preferred embodiment of the present invention. Isotopically labeled compounds of formula I can generally be prepared by performing the procedures disclosed in the synthetic schemes and related descriptions in the Examples section and the Preparation section herein, and replacing non-isotopically labeled reactants with readily available isotopically labeled reactants.
[0066] For this purpose, deuterium ( 2 H) is incorporated into a compound of formula I to manipulate the oxidative metabolism of the compound through the primary kinetic isotope effect. The primary kinetic isotope effect is a change in the rate of a chemical reaction caused by the exchange of isotopic nuclei, which in turn is caused by a change in the ground state energy required for covalent bond formation after the isotope exchange. The exchange of heavier isotopes generally results in a decrease in the ground state energy of a chemical bond, thereby resulting in a decrease in the rate of rate-limiting bond breakage. If bond breakage occurs in or near the saddle point region along the coordinates of a multi-product reaction, the product distribution ratio can be significantly changed. For explanation: If deuterium is bonded to a carbon atom in a non-exchangeable position, then kM / k D = 2-7 rate differences are typical. If this rate difference is successfully applied to a compound of formula I that is susceptible to oxidation, the in vivo profile of the compound can be significantly altered and lead to improved pharmacokinetic properties.
[0067] In discovering and developing therapeutic agents, one skilled in the art is able to optimize pharmacokinetic parameters while maintaining desired in vitro properties. It is reasonable to assume that many compounds with poor pharmacokinetic characteristics are susceptible to oxidative metabolism. Currently available in vitro liver microsomal assays provide valuable information about this type of oxidative metabolic process, which in turn allows the rational design of deuterated compounds of Formula I that have improved stability through resistance to this oxidative metabolism. Significant improvements in the pharmacokinetic characteristics of compounds of Formula I are thus obtained and can be quantitatively expressed in terms of: in vivo half-life (t / 2), concentration at maximum therapeutic effect (C max ), area under the dose-response curve (AUC), and increase in F; and in terms of reduced clearance, dose, and material cost.
[0068] The following is intended to illustrate the above: compounds of formula I with multiple potential attack sites for oxidative metabolism (e.g., benzylic hydrogen atoms and hydrogen atoms bonded to nitrogen atoms) are prepared into a series of analogs in which various combinations of hydrogen atoms are replaced by deuterium atoms, so that some, most or all of these hydrogen atoms have been replaced by deuterium atoms. Half-life determinations enable the degree of improvement in resistance to oxidative metabolism to be advantageously and accurately determined. In this way, it is determined that the half-life of the parent compound can be extended by up to 100% due to this type of deuterium-hydrogen exchange.
[0069] Deuterium-hydrogen exchange in the compound of formula I can also be used to achieve favorable modification of the metabolite spectrum of the starting compound to reduce or eliminate undesirable toxic metabolites. For example, if toxic metabolites are produced by oxidative carbon-hydrogen (CH) bond cleavage, it is reasonable to assume that deuterated analogs will greatly reduce or eliminate the production of unwanted metabolites, even if specific oxidation is not a rate-determining step. Further information about the state of the art of deuterium-hydrogen exchange can be found in, for example, Hanzlik et al., J.Org.Chem.55,3992-3997,1990, Reider et al., J.Org.Chem.52,3326-3334,1987, Foster, Adv.Drug Res.14,1-40,1985, Gillette et al., Biochemistry 33 (10) 2927-2937,1994, and Jarman et al. Carcinogenesis 16 (4), 683-688,1993.
[0070] As used herein, the term "modulator" is defined as a compound that binds and / or inhibits a target with measurable affinity. In certain embodiments, a modulator has an IC of less than about 50 μM, less than about 1 μM, less than about 500 nM, less than about 100 nM, or less than about 10 nM. 50 and / or binding constant.
[0071] As used herein, the terms "measurable affinity" and "measurably inhibit" refer to a measurable change in TLR7 / 8 activity between a sample comprising a compound of the invention, or composition thereof, and TLR7 / 8, and an equivalent sample comprising TLR7 / 8 in the absence of the compound or composition thereof.
[0072] The combinations of substituents and variants contemplated by this invention are only those that result in the formation of stable compounds. As used herein, the term "stable" refers to compounds that have stability sufficient to allow manufacture and to maintain the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., therapeutic or prophylactic administration to a subject).
[0073] The recitation of a list of chemical groups in any definition of a variant herein includes definitions of that variant as any single group or combination of the listed groups. The description of an embodiment of a variant herein includes that embodiment as any single embodiment or in combination with any other embodiment or portion thereof.
[0074] 3. Description of Exemplary Compounds
[0075] According to one aspect, the present invention provides a compound of formula I,
[0076]
[0077] or a pharmaceutically acceptable salt thereof, wherein:
[0078] Ring A is aryl or heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur; each of which is optionally substituted:
[0079] Ring B is a heteroaryl group having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur; each of which is optionally substituted;
[0080] R 1 is -CH3, -CF3 or -CN;
[0081] Each R 2 is independently -H, -R, halogen, -haloalkyl, -OR, -SR, -CN, -NO2, -SO2R, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -NRC(O)R, -NRC(O)N(R)2, -NRSO2R or -N(R)2;
[0082] Each R 3 is independently -H, -R, halogen, -haloalkyl, -OR, -SR, -CN, -NO2, -SO2R, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -NRC(O)R, -NRC(O)N(R)2, -NRSO2R or -N(R)2;
[0083] Each R 4 is independently -H, -R, halogen, -haloalkyl, -OR, -SR, -CN, -NO2, -S02R, -SOR, -C(O)R, -C02R, -C(O)N(R)2, -NRC(O)R, -NRC(O)N(R)2, -NRC(O)OR, -NRSO2R or -N(R)2;
[0084] Each R 5is independently -H, -R, halogen, -haloalkyl, -OR, -SR, -CN, -NO2, -SO2R, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -NRC(O)R, -NRC(O)N(R)2, -NRSO2R or -N(R)2;
[0085] Each R is independently hydrogen, C 1-6 Aliphatic group, C 3-10 Aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur; each of which is optionally substituted: or
[0086] Two R groups on the same atom together with the atom to which they are attached form a C 3-10 Aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur; each of which is optionally substituted;
[0087] k is 0, 1, or 2;
[0088] n is 0, 1, or 2;
[0089] p is 0, 1, or 2;
[0090] r is 1, 2, or 3; and
[0091] t is 1, 2, or 3;
[0092] wherein k is 0 when attached to nitrogen; and k is 1 or 2 when attached to carbon.
[0093] In certain embodiments, R 1 It is -CH3.
[0094] In certain embodiments, R 1 It is -CF3.
[0095] In certain embodiments, R 1 Yes-CN.
[0096] In certain embodiments, k is 0 and R 1 Does not exist.
[0097] In certain embodiments, Ring A is phenyl or a 6-membered monocyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0098] In certain embodiments, Ring A is phenyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, or triazinyl.
[0099] In certain embodiments, Ring A is phenyl or pyridinyl.
[0100] In certain embodiments, Ring A is
[0101]
[0102] In certain embodiments, Ring A is
[0103]
[0104] In certain embodiments, Ring A is
[0105] In certain embodiments, Ring A is
[0106] In certain embodiments, Ring A is
[0107] In certain embodiments, Ring A is
[0108] In certain embodiments, Ring A is
[0109] In certain embodiments, Ring B is a 5-6 membered monocyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0110] In certain embodiments, Ring B is pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, pyrrole, imidazole, isoxazole, oxazole, or thiazole; each of which is optionally substituted.
[0111] In certain embodiments, Ring B is pyridinyl, pyrazinyl, or pyrrole; each of which is optionally substituted.
[0112] In certain embodiments, Ring B is
[0113]
[0114] In certain embodiments, Ring B is
[0115]
[0116] In certain embodiments, Ring B is
[0117] In certain embodiments, Ring B is
[0118] In certain embodiments, Ring B is
[0119] In certain embodiments, each R2 Independently -H.
[0120] In certain embodiments, each R 2 Independently C 1-6 Aliphatic group, C 3-10 Aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur; each of which is optionally substituted.
[0121] In certain embodiments, each R 2 is independently methyl, ethyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, straight or branched pentyl, or straight or branched hexyl; each of which is optionally substituted.
[0122] In certain embodiments, each R 2are independently phenyl, naphthyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctyl, [4.3.0]bicyclononyl, [4.4.0]bicyclodecyl, [2.2.2]bicyclooctyl, fluorenyl, indanyl, tetrahydronaphthyl, acridinyl, acridinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzotriazolyl, benzotetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazoline yl, carbazolyl, NH-carbazolyl, carbolyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolene (indolenyl), dihydroindolinyl, indolizinyl, indolyl, 3H-indolyl, isoindolinyl, isoindolene, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazole oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl; -1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, o-phenanthrenyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl , pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl,
[0123] 1,3,4-triazolyl, oxetanyl, azetidinyl or xanthenyl; each of which is optionally substituted.
[0124] In certain embodiments, each R 2is independently halogen, -haloalkyl, -OR, -SR, -CN, -NO2, -SO2R, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -NRC(O)R, -NRC(O)N(R)2, -NRSO2R or -N(R)2.
[0125] In certain embodiments, each R3 is independently -H.
[0126] In certain embodiments, each R 3 Independently C 1-6 Aliphatic group, C 3-10 Aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur; each of which is optionally substituted.
[0127] In certain embodiments, each R3 is independently methyl, ethyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, straight or branched pentyl, or straight or branched hexyl; each of which is optionally substituted.
[0128] In certain embodiments, each R3 is independently phenyl, naphthyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctyl, [4.3.0]bicyclononyl, [4.4.0]bicyclodecyl, [2.2.2]bicyclooctyl, fluorenyl, indanyl, tetrahydronaphthyl, acridinyl, acridinyl, benzimidazolyl, benzofuranyl, benzothiophenyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzotriazolyl, benzotetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, NH- carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolene, indolinyl, indolizinyl, indolyl, 3H-indolyl, isoindolinyl, isoindolene, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3 -oxadiazolyl, 1,2,4-oxadiazolyl; -1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, o-diazophenanthrenyl, phenazinyl, phenothiazinyl, phenoxathiyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinoline oxetanyl, azetidinyl, 1,2,3-thiazolyl, 1,2,4-thiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thienyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, oxetanyl, azetidinyl or xanthenyl; each of which is optionally substituted.
[0129] In certain embodiments, each R3 is independently halogen, -haloalkyl, -OR, -SR, -CN, -NO2, -S02R, -SOR, -C(O)R, -C02R, -C(O)N(R)2, -NRC(O)R, -NRC(O)N(R)2, -NRSO2R or -N(R)2.
[0130] In certain embodiments, each R 4 Independently -H.
[0131] In certain embodiments, each R 4 Independently C 1-6 Aliphatic, halogen, -haloalkyl, -OR, -SR, -CN, -NO2, -S02R, -SOR, -C(O)R, -C02R, -C(O)N(R)2, -NRC(O)R, -NRC(O)N(R)2, -NRC(O)OR, -NRC(O)OR, -NRSO2R, or -N(R)2.
[0132] In certain embodiments, each R 4 Independently C 1-6 aliphatic, -OR, -C(O)R, -CO2R, -C(O)N(R)2, -NRC(O)R, -NRC(O)OR, -NRC(O)N(R)2, -NRSO2R, or -N(R)2; each of which is optionally substituted.
[0133] In certain embodiments, each R 4 Independently C 1-6 aliphatic, -C(O)N(R)2, -NRC(O)R, or -N(R)2; each of which is optionally substituted.
[0134] In certain embodiments, each R 4 Independently
[0135]
[0136]
[0137] In certain embodiments, each R 5 Independently -H.
[0138] In certain embodiments, each R 5 are independently halogen, C 1-6 Aliphatic group, C 3-10 Aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur; each of which is optionally substituted.
[0139] In certain embodiments, each R 5 is independently methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, straight or branched pentyl, or straight or branched hexyl; each of which is optionally substituted; or each R 5 is independently -F, -Cl, -Br, or -I.
[0140] In certain embodiments, each R5 is independently methyl, ethyl, -F, -Cl or -Br.
[0141] In certain embodiments, each R 5 Independently
[0142]
[0143] In certain embodiments, Ring A, Ring B, R 1 , R 2 , R 3 , R 4 , R 5 Each of k, n, p, r and t is as defined above and described above and in the embodiments, classes and subclasses herein, alone or in combination.
[0144] In certain embodiments, the present invention provides a compound of formula Ia,
[0145]
[0146] or a pharmaceutically acceptable salt thereof, wherein R, R 1 , R 4 , R 5 Each of , r, and t is as defined above and described above and herein, alone or in combination in the embodiments, classes and subclasses.
[0147] In certain embodiments, the present invention provides a compound of Formula Ib,
[0148]
[0149] or a pharmaceutically acceptable salt thereof, wherein R 2 , R 3 , R 4 , R 5 Each of , n, p, r, and t is as defined above and described above and in the embodiments, classes, and subclasses herein, alone or in combination.
[0150] In certain embodiments, the present invention provides a compound of Formula Ic,
[0151]
[0152] or a pharmaceutically acceptable salt thereof, wherein R 2 , R 3 , R 4 , R 5 Each of , n, p, r, and t is as defined above and described above and in the embodiments, classes, and subclasses herein, alone or in combination.
[0153] In certain embodiments, the present invention provides a compound of Formula Ic,
[0154]
[0155] or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 Each of k, n, p, r and t is as defined above and described above and in the embodiments, classes and subclasses herein, alone or in combination.
[0156] In certain embodiments, the present invention provides a compound of Formula Id,
[0157]
[0158] or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 Each of k, n, p, r and t is as defined above and described above and in the embodiments, classes and subclasses herein, alone or in combination.
[0159] In certain embodiments, the present invention provides a compound of Formula Ie,
[0160]
[0161] or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 Each of k, n, p, r and t is as defined above and described above and in the embodiments, classes and subclasses herein, alone or in combination.
[0162] In certain embodiments, the present invention provides a compound selected from Table 1:
[0163] Table 1
[0164]
[0165]
[0166]
[0167]
[0168]
[0169]
[0170]
[0171]
[0172]
[0173]
[0174]
[0175]
[0176] In some embodiments, the present invention provides a compound selected from those described above, or a pharmaceutically acceptable salt thereof.
[0177] Various structural descriptions may show heteroatoms without a linker group, radical, charge, or counterion. One of ordinary skill in the art will appreciate that such descriptions are intended to indicate that the heteroatom is attached to a hydrogen (e.g., Understood as ).
[0178] In certain embodiments, compounds of the invention are synthesized according to the schemes provided in the following examples.
[0179] 4. Use, preparation and administration
[0180] Pharmaceutically acceptable compositions
[0181] According to another embodiment, the present invention provides a composition comprising a compound of the present invention or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier, adjuvant or vehicle. The amount of the compound in the composition of the present invention is effective for measurably inhibiting TLR7 / 8 or its mutant in a biological sample or patient. In certain embodiments, the amount of the compound in the composition of the present invention is effective for measurably inhibiting TLR7 / 8 or its mutant in a biological sample or patient. In certain embodiments, the composition of the present invention is formulated for administration to a patient in need of such a composition.
[0182] As used herein, the term "patient" or "subject" refers to an animal, preferably a mammal, and most preferably a human.
[0183] The term "pharmaceutically acceptable carrier, adjuvant or vehicle" refers to a non-toxic carrier, adjuvant or vehicle that does not destroy the pharmacological activity of the compound formulated therewith. Pharmaceutically acceptable carriers, adjuvants or vehicles for the compositions of the present invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silicon dioxide, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene block polymers, polyethylene glycol and lanolin.
[0184] "Pharmaceutically acceptable derivative" refers to any non-toxic salt, ester, ester salt or other derivative of a compound of the invention which, upon administration to a recipient, is capable of providing, directly or indirectly, a compound of the invention or an inhibitory active metabolite or residue thereof.
[0185] The composition of the present invention is administered orally, parenterally, by inhalation spray, topically, rectally, nasally, orally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the composition is administered orally, intraperitoneally or intravenously. The sterile injectable form of the composition of the present invention includes aqueous or oily suspensions. According to technology known in the art, these suspensions are prepared using suitable dispersing or wetting agents and suspending agents. Sterile injectable preparations can also be sterile injectable solutions or suspensions in nontoxic parenteral acceptable diluents or solvents, such as solutions in 1,3-butanediol. The acceptable medium and solvent employed include water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils are typically used as solvents or suspension media.
[0186] For this purpose, any gentle fixed oil adopted comprises synthetic monoglyceride or diglyceride.Oleic acid and glyceride derivative thereof for example can be used for preparing injection, and natural pharmaceutically acceptable oil, for example olive oil or castor oil, especially their polyoxyethylated form also can be used for preparing injection.These oil solutions or suspensions also contain long-chain alcohol diluent or dispersant, for example carboxymethyl cellulose or similar dispersant, and it is generally used for preparing pharmaceutically acceptable dosage form comprising emulsion and suspension.Other conventional surfactants, such as Tweens, Spans and other emulsifiers or bioavailability enhancers that are generally used for making pharmaceutically acceptable solid, liquid or other dosage forms are also used for preparation purpose.
[0187] The pharmaceutically acceptable compositions of the present invention are orally administered in any orally acceptable dosage form. Exemplary oral dosage forms are capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, commonly used carriers include lactose and corn starch. Lubricants such as magnesium stearate are also usually added. For oral administration in capsule form, useful diluents include lactose and dry corn starch. When an aqueous suspension is required for oral use, the active ingredient is combined with an emulsifier and a suspending agent. If desired, certain sweeteners, flavoring agents or coloring agents are optionally added.
[0188] Alternatively, the pharmaceutically acceptable compositions of the present invention are administered in the form of suppositories for rectal administration. These can be prepared by mixing the medicament with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and will therefore melt in the rectum to release the drug. These materials include cocoa butter, beeswax, and polyethylene glycol.
[0189] The pharmaceutically acceptable compositions of this invention are also administered topically, particularly when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
[0190] Topical application to the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation.Topical transdermal patches are also in use.
[0191] For topical application, the pharmaceutically acceptable composition provided is formulated into a suitable ointment containing an active component suspended or dissolved in one or more carriers. Exemplary carriers for topical application of the compound are mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying wax and water. Alternatively, the pharmaceutically acceptable composition provided can be formulated into a suitable lotion or emulsifiable paste containing an active component suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
[0192] The pharmaceutically acceptable compositions of the present invention are optionally administered by nasal aerosol or inhalation. These compositions are prepared according to techniques well known in the art of pharmaceutical formulation and are prepared as saline solutions, using benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons and / or other conventional solubilizing or dispersing agents.
[0193] The pharmaceutically acceptable compositions of the present invention are formulated for oral administration. These formulations may be administered with or without food. In some embodiments, the pharmaceutically acceptable compositions of the present invention are not administered with food. In other embodiments, the pharmaceutically acceptable compositions of the present invention are administered with food.
[0194] The amount of the compound of the invention optionally combined with a carrier material to produce a single dosage form of the composition will vary depending on the host being treated, the specific mode of administration. Preferably, the provided compositions should be formulated so that a dosage of 0.01-100 mg / kg body weight / day of the compound can be administered to a patient receiving these compositions.
[0195] It should also be understood that the specific dosage and treatment regimen for any particular patient will depend on a variety of factors, including the activity of the specific compound used, age, body weight, general health, sex, diet, time of administration, excretion rate, drug combination, and the judgment of the treating physician and the severity of the specific disease being treated. The amount of the compound of the invention in the composition will also depend on the specific compound in the composition.
[0196] Uses of compounds and pharmaceutically acceptable compositions
[0197] The present invention also relates to methods of treating a subject suffering from a TLR7 / 8-related disorder, comprising administering to the subject an effective amount of a compound of Formula I and related formulae.
[0198] The compounds of the present invention can be used as anticancer agents for cancers that respond to TLR7 activation. In certain embodiments, cancers include, but are not limited to: cancers of the breast, bladder, bone, brain, central and peripheral nervous system, colon, endocrine glands, esophagus, endometrium, germ cells, head and neck, kidney, liver, lung, larynx and hypopharynx, mesothelioma, sarcoma, ovary, pancreas, prostate, rectum, kidney, small intestine, soft tissue, testis, stomach, skin, ureter, vagina and vulva; hereditary cancers, retinoblastoma and Wilms tumor; leukemia, lymphoma, non-Hodgkin's disease, chronic and acute myeloid leukemia, acute lymphoblastic leukemia, Hodgkin's disease, multiple myeloma and T-cell lymphoma; myelodysplastic syndrome, plasmacytoma formation, tumor-associated syndrome, cancer of unknown primary site and AIDS-related malignancies.
[0199] In certain embodiments, the compounds of the invention are used to treat cancer of the skin or kidney. The sensitivity of a given cancer to TLR7 activation can be assessed by, but not limited to, the following measurements: reduction in primary or metastatic tumor burden (slight, partial or complete regression), changes in blood counts, changes in hormone or cytokine concentrations in the blood, inhibition of further increase in tumor burden, stabilization of the disease in the patient, assessment of biomarkers or surrogate markers associated with the disease, prolongation of overall survival of the patient, prolongation of time to disease progression in the patient, prolongation of progression-free survival in the patient, prolongation of disease-free survival in the patient, improvement of quality of life in the patient, or modulation of comorbidities of the disease (e.g., but not limited to pain, cachexia, mobilization, hospitalization, changes in blood counts, weight loss, wound healing, fever).
[0200] The compounds according to the invention may further be used as immune response modulators, which may modulate the immune response in a number of different ways, making them useful in the treatment of a variety of disorders.
[0201] Provided herein is a method for suppressing an immune response in an individual, comprising administering an effective amount of an inhibitor of TLR7 and / or TLR8 (e.g., a TLR inhibitor) to an individual using a compound as described herein. In some variations, the TLR inhibitor suppresses TLR7-dependent immune response. In some variations, the TLR inhibitor suppresses TLR8-dependent immune response. In some variations, the TLR inhibitor suppresses TLR7-dependent and TLR8-dependent immune responses. In some variations, the TLR inhibitor suppresses TLR7-dependent, TLR8-dependent and another TLR-dependent immune response. Unless otherwise noted, the term TLR inhibitor refers to any TLR inhibitor disclosed herein. In some preferred embodiments, the individual is a human patient.
[0202] Immunomodulatory methods are provided by the present disclosure, and include those methods of suppressing and / or inhibiting immune responses (including but not limited to immune responses). The present disclosure also provides methods for improving symptoms associated with undesirable immune activation (including but not limited to symptoms associated with autoimmunity). Immune suppression and / or inhibition according to the methods described herein can be implemented on individuals, including those individuals suffering from obstacles associated with undesirable activation of immune responses. The present disclosure also provides methods for suppressing responses (for example, in vitro or in vivo) induced by TLR7 and / or TLR8. In some variations, cells are contacted with a TLR inhibitor of the amount of the response that effectively suppresses the cells that contribute to the immune response.
[0203] The inhibition of TLR7 and / or TLR8 can be used to treat and / or prevent a variety of diseases or disorders that respond to cytokines. TLR7 and / or TLR8 inhibitors can be used as treatment for conditions including, but not limited to, autoimmune diseases and inflammatory disorders. Provided herein is a method for treating or preventing a disease or disorder in an individual, comprising administering an effective amount of TLR7 and / or TLR8 inhibitors to the individual. In addition, a method for improving symptoms associated with a disease or disorder is provided, comprising administering an effective amount of TLR7 and / or TLR8 inhibitors to an individual with the disease or disorder. Also provided herein is a method for preventing or delaying the development of a disease or disorder, comprising administering an effective amount of one or more inhibitors of TLR7 and / or TLR8 to an individual with the disease or disorder. In certain embodiments, the inhibitor is a compound as described herein.
[0204] Provided herein is a method for suppressing an immune response in an individual, the method comprising administering to an individual at least one TLR inhibitor as disclosed herein in an amount effective to suppress an immune response in the individual. In some variations, the immune response is associated with an autoimmune disease. In other aspects, wherein suppressing the immune response improves one or more symptoms of an autoimmune disease. In other aspects, wherein suppressing the immune response treats an autoimmune disease. In other aspects, wherein suppressing the immune response prevents or delays the development of an autoimmune disease. In some variations, the TLR inhibitor suppresses a TLR7-dependent immune response. In some variations, the TLR inhibitor suppresses a TLR8-dependent immune response. In some variations, the TLR inhibitor suppresses TLR7-dependent and TLR8-dependent immune responses. In some aspects, at least one TLR inhibitor is administered in an amount effective to suppress an immune response in an individual.
[0205] Also provided herein is a method for treating or preventing an autoimmune disease in an individual, comprising administering an effective amount of a TLR7 and / or TLR8 inhibitor to an individual. In some respects, the autoimmune disease is characterized by joint pain, antinuclear antibody positivity, malar rash or discoid rash. In some respects, the autoimmune disease is associated with skin, muscle tissue and / or connective tissue. In some embodiments, the autoimmune disease is not indicated by skin, muscle tissue and / or connective tissue symptoms in an individual. In some embodiments, the autoimmune disease is systemic. Autoimmune diseases include, but are not limited to, rheumatoid arthritis (RA), autoimmune pancreatitis (AIP), systemic lupus erythematosus (SLE), type I diabetes, multiple sclerosis (MS), antiphospholipid syndrome (APS), sclerosing cholangitis, systemic onset arthritis, irritable bowel disease (IBD), scleroderma, Sjogren's disease, vitiligo, polymyositis, pemphigus vulgaris, pemphigus foliaceus, inflammatory bowel diseases including Crohn's disease and ulcerative colitis, autoimmune hepatitis, hypopituitarism, graft versus host disease (GvHD), autoimmune skin diseases, uveitis, pernicious anemia, and hypoparathyroidism. Autoimmune diseases may also include, but are not limited to, polyangiitis overlap syndrome, Kawasaki disease, sarcoidosis, glomerulonephritis, and cold illness.
[0206] In some aspects, the autoimmune disease is selected from arthritis, pancreatitis, mixed connective tissue disease (MCTD), lupus, antiphospholipid syndrome (APS), systemic onset arthritis, and irritable bowel syndrome.
[0207] In other aspects, the autoimmune disease is selected from systemic lupus erythematosus (SLE), rheumatoid arthritis, autoimmune skin disease and multiple sclerosis.
[0208] In other aspects, the autoimmune disease is selected from pancreatitis, glomerulonephritis, pyelitis, sclerosing cholangitis and type I diabetes. In some aspects, the autoimmune disease is rheumatoid arthritis. In some aspects, the autoimmune disease is autoimmune pancreatitis (AIP). In some aspects, the autoimmune disease is glomerulonephritis. In some aspects, the autoimmune disease is pyelitis. In some aspects, the autoimmune disease is sclerosing cholangitis. In some aspects, the autoimmune disorder is psoriasis. In some aspects, the autoimmune disease is rheumatoid disease or disorder. In some aspects, the rheumatoid disease or disorder is rheumatoid arthritis. In some aspects, the disease is diabetes and / or diabetes-related diseases or disorders. In some aspects, wherein the autoimmune disease is associated with an immune complex containing RNA. In some aspects, the autoimmune disease is Sjogren's disease.
[0209] Provided herein is a method for suppressing an immune response in an individual, the method comprising administering to an individual at least one TLR inhibitor disclosed herein in an amount that effectively suppresses the immune response in the individual. In some variations, the immune response is associated with an inflammatory disorder. As used herein, the term "inflammatory disorder" includes autoimmune diseases, and inflammatory conditions (e.g., atherosclerosis, asthma, etc.) without known autoimmune components. In other aspects, suppressing the immune response improves one or more symptoms of inflammatory disorders. In other aspects, suppressing the immune response treats inflammatory disorders. In other aspects, suppressing the immune response prevents or delays the development of inflammatory disorders. In some aspects, inflammatory disorders are selected from non-rheumatoid arthritis, renal fibrosis, and liver fibrosis. In some aspects, inflammatory disorders are interface dermatitis. In some other aspects, interface dermatitis is selected from lichen planus, lichenoid eruption, lichen planus keratosis, lichen stripes, chronic lichenoid keratosis, erythema multiforme, fixed drug eruption, pityriasis lichenoides, phototoxic dermatitis, radiation dermatitis, viral eruption, dermatomyositis, secondary syphilis, atrophic lichen sclerosus, mycosis fungoides, bullous pemphigoid, golden lichen, porokeratosis, acrodermatitis chronica atrophica and degenerative melanoma. In some aspects, inflammatory conditions are skin disorders, such as atopic dermatitis (eczema). In some aspects, inflammatory disorders are sterile inflammatory conditions, such as drug-induced liver and / or pancreatic inflammation. In some other aspects, inflammatory diseases are inflammatory liver disorders. In some other aspects, inflammatory diseases are inflammatory pancreatic disorders.
[0210] Provided herein is a method for suppressing an immune response in an individual, the method comprising administering to an individual at least one TLR inhibitor disclosed herein in an amount that effectively suppresses an immune response in the individual. In some variations, the immune response is associated with chronic pathogen stimulation. In some variations, the immune response is associated with infection by HIV. In other aspects, wherein the immune response is suppressed to improve one or more symptoms of a viral disease or disorder caused by HIV infection. In other aspects, wherein the immune response is suppressed to treat a viral disease or disorder caused by HIV infection. In other aspects, wherein the immune response is suppressed to prevent or delay the development of a viral disease or disorder caused by HIV infection. Other variations provided herein relate to immunosuppressive therapy for individuals who have been exposed to HIV or infected with HIV. Applying a TLR inhibitor to an individual exposed to HIV or infected with HIV results in suppression of HIV-induced cytokine production. In some aspects, at least one TLR inhibitor is administered in an amount that effectively suppresses HIV-induced cytokine production in an individual exposed to HIV or infected with HIV.
[0211] Provided herein is a method for suppressing a TLR7 and / or TLR8-dependent immune response in an individual, the method comprising administering a TLR inhibitor to an individual in an amount that effectively suppresses an immune response in the individual. In some variations, the immune response is associated with an autoimmune disease. In some aspects, the autoimmune disease is rheumatoid arthritis. In some aspects, the TLR inhibitor effectively suppresses one or more symptoms of rheumatoid arthritis. In some aspects, the autoimmune disease is multiple sclerosis. In some aspects, the TLR inhibitor effectively suppresses one or more symptoms of multiple sclerosis. In some aspects, the autoimmune disease is lupus. In some aspects, the TLR inhibitor effectively suppresses one or more symptoms of lupus. In some aspects, the autoimmune disease is pancreatitis. In some aspects, the TLR inhibitor effectively suppresses one or more symptoms of pancreatitis. In some aspects, the autoimmune disease is diabetes. In some aspects, the TLR inhibitor effectively suppresses one or more symptoms of diabetes. In some aspects, the disease is Sjogren's disease. In some aspects, the TLR inhibitor effectively suppresses one or more symptoms of Sjogren's disease. In some variations, the immune response is associated with an inflammatory disorder. In some aspects, TLR inhibitors effectively suppress one or more symptoms of inflammatory disorders. In some variations, immune response is associated with chronic pathogen stimulation. In some aspects, TLR inhibitors effectively suppress one or more symptoms of chronic pathogen stimulation. In some variations, immune response is associated with viral diseases caused by HIV infection. In some aspects, TLR inhibitors effectively suppress one or more symptoms of viral diseases caused by HIV infection. In any variation, TLR inhibitors are polynucleotides comprising one or more inhibition motifs of TLR7, TLR8 and TLR9.
[0212] In some embodiments of any method involving administering a TLR inhibitor to an individual (e.g., a method for suppressing an immune response, treating or preventing an autoimmune disease or inflammatory disorder, etc.), the TLR inhibitor has a therapeutically acceptable safety profile. The TLR inhibitor may, for example, have a therapeutically acceptable histological profile, including acceptable low toxicity (if toxic) to the liver, kidney, pancreas or other organs. Sometimes, polynucleotides are associated with toxicity to certain organs such as the liver, kidney and pancreas. In some embodiments, the TLR inhibitor has an unexpected and favorable safety profile. In some embodiments, the safety profile includes assessing toxicity, histological features and / or necrosis (e.g., liver, kidney and / or heart). In some embodiments, the TLR inhibitor has a therapeutically acceptable level of toxicity. In some embodiments, the TLR inhibitor has a reduced level of toxicity compared to another TLR inhibitor. In some embodiments, the TLR inhibitor induces a therapeutically acceptable reduction in body weight compared to the initial body weight of the treated individual. In some embodiments, the TLR inhibitor induces a total body weight reduction of less than 5%, 7.5%, 10%, 12.5 or 15%. In some embodiments, the TLR inhibitor has a therapeutically acceptable histological profile. In some embodiments, for example, compared with a reference TLR inhibitor, the TLR inhibitor has better (e.g., lower severity score) histological features. In some embodiments, for example, when assessing liver, kidney and / or heart, the TLR inhibitor has better (e.g., lower severity score) histological features. In some embodiments, the TLR inhibitor has a therapeutically acceptable necrosis score. In some embodiments, for example, compared with a reference TLR inhibitor, the TLR inhibitor has reduced necrosis and / or better (e.g., lower) necrosis score. In some embodiments, for example, compared with a reference TLR inhibitor, the TLR inhibitor has reduced kidney and / or hepatocyte necrosis and / or better kidney and / or hepatocyte necrosis score.
[0213] Therefore, the present invention provides a method for activating TLR7 in an animal (particularly a mammal, preferably a human), comprising administering an effective amount of a compound of formula I to the animal. As with all compositions for suppressing immune responses, the effective amount and method of administration of a specific TLR inhibitor preparation can vary based on the individual, the condition to be treated, and other factors apparent to those skilled in the art. The effective amount of the compound will vary according to factors known in the art, but is expected to be about 0.1 to 10 mg / kg, 0.5 to 10 mg / kg, 1 to 10 mg / kg, 0.1 to 20 mg / kg, 0.1 to 20 mg / kg, or 1 to 20 mg / kg.
[0214] The present invention also provides a method for treating viral infection in animals, comprising administering an effective amount of a compound of formula I to an animal. The amount of effective treatment or inhibition of viral infection is an amount that results in a reduction in one or more manifestations of viral infection (e.g., viral damage, viral load, viral production rate, and mortality) compared to untreated control animals. The exact amount will vary according to factors known in the art, but is expected to be a dosage as indicated above for TLR7 activation, or about 100 ng / kg to about 50 mg / kg, preferably about 10 μg / kg to about 5 mg / kg.
[0215] In various embodiments, compounds of Formula (I) and related formulae exhibit an IC50 for binding to TLR7 / 8 of less than about 5 μM, preferably less than about 1 μM and even more preferably less than about 0.100 μM.
[0216] The method of the present invention can be carried out in vitro or in vivo. Whether in the research process or in clinical applications, the susceptibility of specific cells to treatment with compounds according to the present invention can be particularly determined by in vitro tests. Typically, cell cultures are combined with compounds according to the present invention at various concentrations for a period of time sufficient for the active agent to inhibit TLR7 / 8 activity, typically between about 1 hour and 1 week. In vitro treatment can be performed using cultured cells from biopsy samples or cell lines.
[0217] The host or patient may be of any mammalian species, such as primate species, particularly humans; rodents, including mice, rats and hamsters; rabbits; horses, cows, dogs, cats, etc. Animal models are of interest for experimental research and provide models for the treatment of human diseases.
[0218] In order to identify the interaction between signal transduction pathways and detect various signal transduction pathways, different scientists have developed suitable models or model systems, such as cell culture models and transgenic animal models. In order to determine certain stages in the signal transduction cascade, interactive compounds can be used to regulate the signal. The compound according to the present invention can also be used as a reagent for the TLR7 / 8 dependent signal transduction pathway in the clinical disease mentioned in the test animal and / or cell culture model or in the application.
[0219] Furthermore, the subsequent teachings of the specification regarding the use of compounds according to formula (I) and their derivatives for the manufacture of medicaments for prophylactic or therapeutic treatment and / or monitoring are considered valid and applicable, without being limited to the use of the compounds for inhibiting TLR7 / 8 activity, if convenient.
[0220] The present invention further relates to the use of compounds according to formula (I) and / or their physiologically acceptable salts for preventive or therapeutic treatment and / or monitoring of diseases caused, mediated and / or propagated by TLR7 / 8 activity. In addition, the present invention relates to the use of compounds according to formula (I) and / or their physiologically acceptable salts for the manufacture of drugs for preventive or therapeutic treatment and / or monitoring of diseases caused, mediated and / or propagated by TLR7 / 8 activity. In certain embodiments, the present invention provides the use of compounds according to formula I or their physiologically acceptable salts for the manufacture of drugs for preventive or therapeutic treatment of TLR7 / 8-mediated disorders.
[0221] In addition, the compound of formula (I) and / or its physiologically acceptable salt can be used as an intermediate for the preparation of other pharmaceutical active ingredients. The medicine is preferably prepared in a non-chemical manner, for example by combining the active ingredient with at least one solid, fluid and / or semi-fluid carrier or excipient, and optionally combined with a single or multiple other active substances that are suitable dosage forms.
[0222] The compound of formula (I) according to the present invention can be applied once or several times before or after the onset of the disease, serving as therapy. The above-mentioned compound and pharmaceutical product of the present invention are particularly used for therapeutic treatment. The treatment-related effect alleviates one or more symptoms of the disorder to a certain extent, or partially or completely restores one or more physiological or biochemical parameters related to or causing the disease or pathological condition to normal. Monitoring is considered to be a treatment, as long as the compound is applied at different intervals, for example, in order to enhance the response and completely eradicate the pathogen and / or symptoms of the disease. The same compound or different compounds can be applied. The method of the present invention can also be used to reduce the possibility of disorder development or even prevent the onset of the disorder associated with TLR7 / 8 activity in advance or treat the symptoms that appear and last.
[0223] In the meaning of the present invention, a preventive treatment is recommended if the subject has any preconditions for the above mentioned physiological or pathological conditions, such as a familial predisposition, a genetic defect or a previously suffered disease.
[0224] The present invention also relates to a medicament comprising at least one compound according to the present invention and / or its pharmaceutically useful derivatives, salts, solvates and stereoisomers, including mixtures in all ratios thereof. In certain embodiments, the present invention relates to a medicament comprising at least one compound according to the present invention and / or its physiologically acceptable salts.
[0225] A "drug" within the meaning of the present invention is any medicament in the field of medicine, which comprises one or more compounds of formula (I) or a preparation thereof (e.g. a pharmaceutical composition or a pharmaceutical preparation) and which can be used for the prevention, therapy, follow-up or subsequent care of patients suffering from a disease associated with TLR7 / 8 activity in such a way that a pathogenic change in their overall condition or in the condition of a specific area of the organism can be established at least temporarily.
[0226] In various embodiments, the active ingredient can be administered alone or in combination with other treatments. A synergistic effect can be achieved by using more than one compound in a pharmaceutical composition, i.e., a compound of formula (I) combined with at least one other agent as an active ingredient, the other agent being another compound of formula (I) or a compound of a different structural skeleton. The active ingredients can be used simultaneously or sequentially.
[0227] The TLR inhibitors of the present disclosure can be administered in combination with one or more additional therapeutic agents. As described herein, the TLR inhibitors can be combined with a physiologically acceptable carrier. The methods described herein can be implemented in combination with other therapies that constitute the standard of care for the disorder (e.g., administration of anti-inflammatory agents).
[0228] In some embodiments, a TLR inhibitor as described herein is administered in combination with a corticosteroid. In some embodiments, the corticosteroid is a glucocorticoid. In some embodiments, the corticosteroid is a mineralocorticoid. Corticosteroids include, but are not limited to, corticosterone and its derivatives, prodrugs, isomers and analogs, cortisone and its derivatives, prodrugs, isomers and analogs (i.e., Cortone), aldosterone and its derivatives, prodrugs, isomers and analogs, dexamethasone and its derivatives, prodrugs, isomers and analogs (i.e., Decadron), prednisone and its derivatives, prodrugs, isomers and analogs (i.e., Prelone), fludrocortisone and its derivatives, prodrugs, isomers and analogs, hydrocortisone and its derivatives, prodrugs, isomers and analogs (i.e., Cortisol or Cortef), hydroxycortisone and its derivatives, prodrugs, isomers and analogs, betamethasone and its derivatives, prodrugs, isomers and analogs (i.e., Celestone), budesonide and its derivatives, prodrugs, isomers and analogs (i.e., Entocort EC), methylprednisolone and its derivatives, prodrugs, isomers and analogs (i.e., Medrol), prednisolone and its derivatives, prodrugs, isomers and analogs (i.e., Deltasone, Crtan, Meticorten, Orasone or Sterapred), triamcinolone and its derivatives, prodrugs, isomers and analogs (i.e., Kenacort or Kenalog), etc. In some embodiments, the corticosteroid is fludrocortisone or its derivatives, prodrugs, isomers or analogs. In some embodiments, the corticosteroid is fludrocortisone. In some embodiments, the corticosteroid is hydroxycortisone or its derivatives, prodrugs, isomers or analogs. In some embodiments, the corticosteroid is hydroxycortisone.
[0229] In some embodiments, the corticosteroid is administered at about any of 0.001 mg to 1 mg, 0.5 mg to 1 mg, 1 mg to 2 mg, 2 mg to 20 mg, 20 mg to 40 mg, 40 to 80 mg, 80 to 120 mg, 120 mg to 200 mg, 200 mg to 500 mg, or 500 mg to 1000 mg per day. In some embodiments, the corticosteroid is administered at about any of 0.1 mg / kg to 0.5 mg / kg, 0.5 mg / kg to 1 mg / kg, 1 mg / kg to 2 mg / kg, 2 mg / kg to 5 mg / kg, 5 mg / kg to 10 mg / kg, 10 mg / kg to 15 mg / kg, 15 mg / kg to 20 mg / kg, 20 mg / kg to 25 mg / kg, 25 mg / kg to 35 mg / kg, or 35 mg / kg to 50 mg / kg per day.
[0230] In some embodiments, the TLR inhibitor used in the combination therapy administered in an amount of TLR inhibitor delivered can be, for example, about any of 0.1 to 10 mg / kg, 0.5 to 10 mg / kg, 1 to 10 mg / kg, 0.1 to 20 mg / kg, 0.1 to 20 mg / kg, or 1 to 20 mg / kg.
[0231] In some embodiments, the TLR inhibitor is administered simultaneously with one or more additional therapeutic agents, including but not limited to corticosteroids (administered simultaneously). In some embodiments, the TLR inhibitor is administered sequentially with additional therapeutic agents, including but not limited to corticosteroids (administered sequentially). In some embodiments, sequential administration includes administering the TLR inhibitor or an additional therapeutic agent followed within about 1 minute, 5 minutes, 30 minutes, 1 hour, 5 hours, 24 hours, 48 hours or any one of a week. In some embodiments, the TLR inhibitor is administered by the same route of administration as the additional therapeutic agent. In some embodiments, the TLR inhibitor is administered by a route of administration different from that of the additional therapeutic agent. In some embodiments, additional therapeutic agents are administered parenterally (e.g., central venous catheter, intra-arterial, intravenous, intramuscular, intraperitoneal, intradermal or subcutaneous injection), orally, gastrointestinal, topically, nasopharyngeally and pulmonary (e.g., inhaled or intranasally). In some embodiments, the additional therapeutic agent is a corticosteroid.
[0232] The disclosed compounds of Formula I can be administered in combination with other known therapeutic agents, including anticancer agents.As used herein, the term "anticancer agent" relates to any agent that is administered to a patient with cancer for the purpose of treating the cancer.
[0233] The anticancer treatment defined above may be applied as a monotherapy or may include conventional surgery or radiotherapy or drug therapy in addition to the compounds of Formula I disclosed herein. Such drug therapy (e.g., chemotherapy or targeted therapy) may include one or more, but preferably one, of the following anti-tumor agents:
[0234] Alkylating agents: such as altretamine, bendamustine, busulfan, carmustine, chlorambucil, nitrogen mustard, cyclophosphamide, dacarbazine, ifosfamide, improsulfan, p-toluenesulfonate, lomustine, guanfalan, dibromomannitol, dibromodulan, nimustine, ranimustine, temozolomide, thiotepa, trooxsulfan, mechloretamine, carboquinone; apaziquone, fotemustine, glufosfamide, palivamid, pipobroman, trofosfamide, uramustine, TH-302 4 , VAL-083 4 ;
[0235] Platinum compounds: such as carboplatin, cisplatin, epazoteplatin, imiplatin hydrate, oxaliplatin, lobaplatin, nedaplatin, picoplatin, satraplatin; lobaplatin, nedaplatin, picoplatin, satraplatin;
[0236] DNA-altering agents: amrubicin, bisantrene, decitabine, mitoxantrone, procarbazine, trabectedin, clofarabine; amsacrine, brostallicin, pilsentron, laromustine 1,3 ;
[0237] Topoisomerase inhibitors: etoposide, irinotecan, razoxane, sobuzoxane, teniposide, topotecan; amifide, belotecan, elixirsium acetate, voreloxin;
[0238] Microtubule modifiers: such as cabazitaxel, docetaxel, eribulin, ixabepilone, paclitaxel, vinblastine, vincristine, vinorelbine, vindesine, and vinflunine;
[0239] fosbretabulin, tesetaxel;
[0240] Antimetabolites: such as asparaginase 3 , azacitidine, leucovorin, capecitabine, cladribine, cytarabine, enocitabine, floxuridine, fludarabine, fluorouracil, gemcitabine, mercaptopurine, methotrexate, nelarabine, peginterferon, pralatrexate, azathioprine, thioguanine, carmofur; doxifluridine, elcitabine, raltitrexed, sapacitabine, fludoxor 2,3 , trimetrexate;
[0241] Anticancer antibiotics: such as bleomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, levamisole, miltefosine, mitomycin C, romidepsin, streptozotocin, valrubicin, netastatin, daunorubicin, plicamycin; aclarubicin, peclorubicin, pirarubicin;
[0242] Hormones / antagonists: such as abarelix, abiraterone, bicalutamide, buserelin, calusterone, chlorotrianisene, degarelix, dexamethasone, estradiol, fluocortolone, fluoxymesterone, flutamide, fulvestrant, goserelin, histrelin, leuprolide, megestrol acetate, mitotane, nafarelin, nandrolone, nilutamide, octreotide, prednisolone, raloxifene, tamoxifen, thyroxine alfa, toremifene, trilostane, triptorelin, diethylstilbestrol; acolbifene, danazol, deserelin, cyclosporine, orteronel, enzalutamide1,3 ;
[0243] Aromatase inhibitors: such as aminoglutethimide, anastrozole, escitalopram, fadrozole, letrozole, testolactone; fuguantan;
[0244] Small molecule kinase inhibitors: such as crizotinib, dasatinib, erlotinib, imatinib, lapatinib, nilotinib, pazopanib, regorafenib, ruxolitinib, sorafenib, sunitinib, vandetanib, vemurafenib, bosutinib, gefitinib, axitinib; afatinib, alisertib, dabrafenib, dacomitinib, dinaciclib, dovitinib, enzastaurin, nintedanib, lenvatinib, linifanib, linsitinib, masitinib, midostaurin, motesanib, neratinib, orantinib, perifosine, ponatinib, radotinib, rigosertib, tipifarnib, tivantinib, tivozanib, traguantinib, pimasertib, brivanib, cediranib, apatinib 4 , Cabozantinib S-malate 1,3 , ibrutinib 1,3 , icotinib 4 , buparlisib 2 cipatinib 4 , cobimetinib 1,3 , idelalisib 1,3 , fedratinib 1 ,XL-647 4 ;
[0245] Photosensitizers: such as methoxsalen 3 ; Porfimer sodium, talaporfin, temoporphin;
[0246] Antibodies: such as alemtuzumab, bevacizumab, brentuximab vedotin, cetuximab, denosumab, ipilimumab, ofatumumab, panitumumab, rituximab, tositumomab, trastuzumab, bevacizumab, pertuzumab 2,3; catumaxomab, elotuzumab, epratuzumab, farletuzumab, mogamulizumab, necitumumab, nimotuzumab, obinutuzumab, ocaratuzumab, ogavuzumab, ramucirumab, rilotumumab, siltuximab, tocilizumab, zalutumumab, zanolimumab, matuzumab, dalotuzumab 1,2,3 , onartuzumab 1,3 , racotumomab 1 , tabalumab 1,3 ,EMD-525797 4 , nivolumab 1,3 ;
[0247] Cytokines: such as aldesleukin, interferon alpha 2 , interferon α2a 3 , interferon α2b 2,3 ; simoleukin, tasonamine, tesileukin, oprelleukin 1,3 , recombinant interferon beta-1a 4 ;
[0248] Drug conjugates: such as denileukin diftitox, ibritumomab tiuxetan, iodobenzylguanidine I123, prednimustine, trastuzumab emtansine, estramustine, gemtuzumab, ozogamicin, aflibercept; cintredekin besudotox, edotreotide, inotuzumab ozogamicin, naptumomab estafenatox, oportuzumab monatox, technetium (99mTc) arcitumomab 1,3 ,vintafolide 1,3 ;
[0249] Vaccines: such as sipuleucel 3 ;vitespen 3 , emepepimut-S 3 ,oncoVAX 4 ,rindopepimut 3 ,troVax 4 ,MGN-1601 4 ,MGN-1703 4 ;and
[0250] Others: alitretinoin, bexarotene, bortezomib, everolimus, ibandronic acid, imiquimod, lenalidomide, lentinan, metyrosine, mifatide, pamidronate, pegaspargase, pentostatin, sipuleucel 3, sizoran, tamibarotene, sirolimus, thalidomide, tretinoin, vismodegib, zoledronic acid, vorinostat; celecoxib, cilengitide, entinostat, etanidazole, ga netespib, idronoxil, iniparib, ixazomib, lonidamine, nimorazole, panobinostat, peretinoin, plitidepsin, pomalidomide, procodazol, dafosil, taquimod, telotristat, thymalfasin, tirapazamine, torsedot, trabedersen, ubenguansine, pentaspodar, gendicine 4 , picibanil 4 , reolysin 4 , Retamycin hydrochloride 1,3 , trebananib 2,3 , Virulkin 4 , Carfilzomib 1,3 , endostatin 4 , immucothel 4 Belinostat 3 ,MGN-1703 4 . ( 1 Prop. INN (Proposed International Nonproprietary Name); 2 Rec.INN (Recommended International Nonproprietary Name); 3 USAN (name adopted by the United States); 4 No INN).
[0251] In some embodiments, the combination of a TLR inhibitor and one or more additional therapeutic agents reduces the effective amount of the TLR inhibitor and / or the one or more additional therapeutic agents (including but not limited to the dose volume, dose concentration and / or total drug dose administered) administered to obtain the same result compared to the effective amount administered when the TLR inhibitor or additional therapeutic agent is administered alone. In some embodiments, compared to a corticosteroid administered alone, the combination of a TLR inhibitor and a corticosteroid reduces the effective amount of the corticosteroid administered. In some embodiments, compared to an additional therapeutic agent administered alone, the combination of a TLR inhibitor and an additional therapeutic agent reduces the frequency of administration of the therapeutic agent. In some embodiments, compared to an additional therapeutic agent administered alone, the combination of a TLR inhibitor and an additional therapeutic agent reduces the total duration of treatment. In some embodiments, the combination of a TLR inhibitor and an additional therapeutic agent reduces the side effects associated with the administration of an additional therapeutic agent alone. In some embodiments, an additional therapeutic agent is a corticosteroid. In some embodiments, a corticosteroid is fludrocortisone or a derivative, prodrug, isomer or analog thereof. In some embodiments, a corticosteroid is fludrocortisone. In some embodiments, an effective amount of a TLR inhibitor in combination with an additional therapeutic agent is more effective than an effective amount of either the TLR inhibitor or the additional therapeutic agent alone.
[0252] TLR inhibitors can also be used as vaccine adjuvants for use in combination with any material that modulates humoral and / or cell-mediated immune responses, such as live viruses, bacteria or parasitic immunogens; inactivated viruses, tumor-derived, protozoan, organism-derived, fungal or bacterial immunogens, toxoids, toxins; autoantigens; polysaccharides; proteins; glycoproteins; peptides; cell vaccines; DNA vaccines; recombinant proteins; glycoproteins; peptides; etc. In some aspects, combination therapies including but not limited to the combination of TLR inhibitors and vaccines are used to treat autoimmune diseases or inflammatory disorders. In some aspects, combination therapies including but not limited to the combination of TLR inhibitors and vaccines are used to treat infectious diseases.
[0253] In some embodiments, combination therapy including but not limited to a combination of a TLR inhibitor and a corticosteroid is used to treat an autoimmune disease or an inflammatory disorder. In some embodiments, the autoimmune disease is selected from but not limited to rheumatoid arthritis, systemic lupus erythematosus, autoimmune skin diseases, multiple sclerosis, pancreatitis, glomerulonephritis, pyelitis, sclerosing cholangitis, and type I diabetes. In some embodiments, the autoimmune disease is Sjögren's disease.
[0254] Also provided herein are kits comprising a TLR inhibitor as provided herein, and instructions for use in methods of inhibiting a TLR7 and / or TLR8-dependent immune response.
[0255] The kit may include one or more containers, which include a TLR inhibitor as described herein (or a preparation comprising a TLR inhibitor) and a set of instructions, usually written instructions, but electronic storage media (e.g., disks or optical disks) containing instructions are also acceptable, and the instructions relate to the use and dosage of the TLR inhibitor or preparation for intended treatment (e.g., suppressing the response to TLR7 and / or TLR8 agonists, suppressing TLR7 and / or TLR8-dependent immune responses, improving one or more symptoms of autoimmune diseases, improving the symptoms of chronic inflammatory diseases, reducing cytokine production in response to viruses, and / or treating and / or preventing one or more symptoms of diseases or disorders mediated by TLR7 and / or TLR8). The instructions included in the kit generally include information about the dosage, dosing schedule, and route of administration for the intended treatment. The container for the TLR inhibitor (or a preparation comprising a TLR inhibitor) can be a unit dose, a large package (e.g., a multi-dose package), or a subunit dose. The kit may also include a container containing an adjuvant.
[0256] On the other hand, the present invention provides a test kit consisting of an effective amount of a compound according to the present invention and / or its pharmaceutically acceptable salt, derivative, solvate and stereoisomer (including mixtures of all ratios thereof) and optionally an effective amount of other active ingredients in a separate package. The test kit includes a suitable container, such as a box, a single bottle, a bag or an ampoule. The test kit can, for example, comprise a separate ampoule, each ampoule containing an effective amount of a compound according to the present invention and / or its pharmaceutically acceptable salt, derivative, solvate and stereoisomer, including mixtures of all ratios thereof, and an effective amount of other active ingredients, in dissolved or lyophilized form.
[0257] As used herein, the terms "treatment", "treat" and "treating" refer to reversing, alleviating, delaying the onset of, or inhibiting the progression of a disease or disorder or one or more symptoms thereof, as described herein. In some embodiments, treatment is administered after one or more symptoms have developed. In other embodiments, treatment is administered in the absence of symptoms. For example, treatment is administered to a susceptible individual before the onset of symptoms (e.g., based on a history of symptoms and / or based on genetic or other predisposing factors). Treatment is also continued after symptoms subside, for example to prevent or delay their recurrence.
[0258] According to the method of the present invention, the compounds and compositions are administered using any amount and any route of administration effective for treating or alleviating the severity of the disorder provided above. The exact amount required will vary from subject to subject, depending on the species, age and overall condition of the subject, the severity of the infection, the specific agent, its mode of administration, etc. The compounds of the present invention are preferably formulated in dosage unit form for ease of administration and dosage consistency. The expression "dosage unit form" as used herein refers to physically discrete dosage units suitable for the patient to be treated. However, it should be understood that the total daily dosage of the compounds and compositions of the present invention will be determined by the attending physician within the scope of reasonable medical judgment. The specific effective dose level for any particular patient or organism will depend on a variety of factors, including the disorder being treated and the severity of the disorder; the activity of the specific compound used; the specific composition used; the patient's age, weight, overall health, sex and diet; the administration time, route of administration and excretion rate of the specific compound used; the duration of treatment; the drugs used in combination or simultaneously with the specific compound used, and similar factors well known in the medical field.
[0259] The pharmaceutically acceptable compositions of the present invention, depending on the severity of the infection being treated, can be administered to humans and other animals orally, rectally, parenterally, intracisternal, intravaginal, intraperitoneally, topically (such as by powders, ointments or drops), orally, as an oral or nasal spray, etc. In certain embodiments, the compounds of the present invention are administered orally or parenterally at a dosage level of about 0.01 mg / kg to about 100 mg / kg and preferably about 1 mg / kg to about 50 mg / kg of subject body weight per day, once or more per day to obtain the desired therapeutic effect.
[0260] In certain embodiments, the therapeutically effective amount of the compound of formula (I) and related formulae and the therapeutically effective amount of other active ingredients depend on many factors, including, for example, the age and weight of the animal, the exact disease condition to be treated and its severity, the nature of the preparation and the method of administration, and are ultimately determined by the treating physician or veterinarian. However, the effective amount of the compound is generally in the range of 0.1 to 100 mg / kg of recipient (mammal) body weight per day and in particular generally in the range of 1 to 10 mg / kg of body weight per day. Therefore, the actual amount per day for an adult mammal weighing 70 kg is generally between 70 and 700 mg, wherein the amount can be administered as a single dose per day or generally in a series of partial doses (e.g., twice, three times, four times, five times or six times) per day to make the total daily dose the same. The effective amount of a salt or solvate or a physiologically functional derivative thereof can be determined as a fraction of the effective amount of the compound itself.
[0261] In certain embodiments, pharmaceutical preparations can be used in the form of dosage units, which include active ingredients of a predetermined amount per dosage unit.Depending on the disease condition treated, the age, weight and condition of the application method and the patient, such a unit can include, for example, 0.5mg to 1g, preferably 1mg to 700mg, particularly preferably 5mg to 100mg of the compound according to the present invention, or pharmaceutical preparations can be used in the form of dosage units, and each dosage unit includes an active ingredient of a predetermined amount.Preferred dosage unit preparations are those comprising daily doses or partial doses as indicated above, or the active ingredients of their corresponding fractions.In addition, pharmaceutical preparations of this type can be prepared using methods generally known in the pharmaceutical field.
[0262] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compound, the liquid dosage form optionally contains an inert diluent commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oil (particularly cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol and fatty acid esters of sorbitan and mixtures thereof. In addition to the inert diluent, the oral composition may also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweeteners, flavoring agents and aromatics.
[0263] Injectable preparations are prepared according to known techniques using suitable dispersion or wetting agents and suspending agents, such as sterile injectable aqueous or oily suspensions. Sterile injectable preparations are also sterile injectable solutions, suspensions or emulsions in nontoxic parenteral acceptable diluents or solvents, such as solutions in 1,3-butylene glycol. Acceptable vehicles and solvents that can be adopted include water, Ringer's solution USP and isotonic sodium chloride solution. In addition, sterile fixed oils are generally used as solvents or suspension media. For this purpose, any gentle fixed oil can be used, including synthetic monoglycerides or diglycerides. In addition, fatty acids such as oleic acid are used to prepare injectables.
[0264] The injectable formulations can be sterilized, for example, by filtration through a bacteria-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
[0265] In order to prolong the effect of the compound of the present invention, it is generally desired to slow down the absorption of the compound from subcutaneous or intramuscular injection. This is achieved by using a liquid suspension of a crystalline or amorphous material with poor water solubility. Then, the absorption rate of the compound depends on its dissolution rate, and the dissolution rate can depend on the crystal size and crystalline form. Alternatively, the delayed absorption of the compound form for parenteral administration is achieved by dissolving or suspending the compound in an oil medium. The injectable reservoir form is prepared by forming a microcapsule matrix of the compound in a biodegradable polymer such as polylactide-polyglycolide. Depending on the ratio of the compound to the polymer and the properties of the specific polymer used, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly (orthoesters) and poly (anhydrides). Depot injectable preparations are also prepared by embedding the compound in a liposome or microemulsion compatible with body tissues.
[0266] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
[0267] Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is mixed with at least one inert pharmaceutically acceptable excipient or carrier, such as sodium citrate or dicalcium phosphate and / or a) fillers or extenders such as starch, lactose, sucrose, glucose, mannitol and silicic acid, b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia, c) humectants such as glycerol, d) disintegrants such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate, e) solution retardants such as paraffin, f) absorption promoters such as quaternary ammonium compounds, g) wetting agents such as cetyl alcohol and glyceryl monostearate, h) absorbents such as kaolin and bentonite, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also optionally comprise buffering agents.
[0268] Solid compositions of similar types are also used as fillers in soft and hard filled gelatin capsules, using such excipients as lactose or milk sugar and high molecular weight polyethylene glycols, etc. Solid dosage forms of tablets, dragees, capsules, pills and granules can be prepared with coatings and shells, such as other coatings known in the field of enteric coatings and pharmaceutical formulations. They optionally contain opacifiers, and can also be the following compositions, which only or preferably release the active ingredient in a certain part of the intestinal tract in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of similar types are also used as fillers in soft and hard filled gelatin capsules, using such excipients as lactose or milk sugar and high molecular weight polyethylene glycols, etc.
[0269] Active compound can also be in the form of microencapsulation with one or more excipients as indicated above. The solid dosage forms of tablets, dragees, capsules, pills and granules can be prepared with coatings and shells, such as enteric coatings, release control coatings and other coatings known in the field of pharmaceutical formulation. In this solid dosage form, the active compound can be mixed with at least one inert diluent such as sucrose, lactose or starch. As normal practice, these dosage forms also include other materials except inert diluents, such as tableting lubricants and other tableting aids such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage form optionally also includes a buffer. They optionally contain an emulsifier, and can also be the following composition, which only or preferably releases the active ingredient in a delayed manner in a certain part of the intestinal tract. The example of the embedding composition that can be used includes polymeric substances and waxes.
[0270] The dosage form for topical or transdermal administration of the compound of the present invention includes ointment, paste, cream, lotion, gel, powder, solution, spray, inhalant or patch. Active ingredient is mixed as required with pharmaceutically acceptable carrier and any required preservative or buffer under aseptic conditions. Ophthalmic preparations, ear drops and eye drops are also expected to be within the scope of the present invention. In addition, the present invention is expected to use transdermal patches, which have the additional advantage of providing controlled delivery of compounds to health. This dosage form can be prepared by dissolving or distributing the compound in a suitable medium. Absorption enhancers can also be used to increase the flux of the compound through the skin. Rate control can be carried out by providing a rate control membrane or by dispersing the compound in a polymer matrix or a gel.
[0271] According to one embodiment, the present invention relates to a method for inhibiting TLR7 / 8 activity in a biological sample, comprising the step of contacting the biological sample with a compound of the present invention or a composition comprising the compound.
[0272] According to another embodiment, the present invention relates to a method for inhibiting the activity of TLR7 / 8 or a mutant thereof in a biological sample in an active manner, comprising the step of contacting the biological sample with a compound of the present invention or a composition comprising the compound.
[0273] The compounds of the present invention can be used as a unique tool for understanding the biological effects of TLR7 / 8 in vitro, including assessing many factors that are believed to affect the generation of TLR7 / 8 and the interaction of TLR7 / 8 and the generation of TLR7 / 8 and the interaction of TLR7 / 8. The compounds of the present invention can also be used to develop other compounds that interact with TLR7 / 8, because the compounds of the present invention provide important structure-activity relationship (SAR) information that promotes the development. The compounds of the present invention that are bound to TLR7 / 8 can be used as reagents for detecting TLR7 / 8 in living cells, fixed cells, biological fluids, tissue homogenates, purified natural biological materials, etc. For example, by marking these compounds, cells expressing TLR7 / 8 can be identified. In addition, based on their ability to bind TLR7 / 8, the compounds of the present invention can be used for in situ staining, FACS (fluorescence activated cell sorting), sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), ELISA (enzyme-linked immunosorbent assay), etc., enzyme purification, or for purifying cells expressing TLR7 / 8 in permeabilized cells. The compounds of the present invention can also be used as commercial research reagents for various medical research and diagnostic purposes. Such uses may include, but are not limited to: use as calibration standards for quantifying the activity of candidate TLR7 / 8 inhibitors in various functional assays; use as blocking reagents in random compound screening, i.e., in the search for new families of TLR7 / 8 ligands, where the compounds can be used to block the recovery of currently claimed TLR7 / 8 compounds; use for co-crystallization with TLR7 / 8, i.e., the compounds of the invention will allow the formation of crystals of compounds bound to TLR7 / 8, thereby enabling enzyme / compound structure determination by x-ray crystallography; other research and diagnostic applications, where activation of TLR7 / 8 is preferred or such activation is conveniently calibrated against known amounts of TLR7 / 8 inhibitors, etc.; use as probes in assays for measuring TLR7 / 8 expression in cells; and development of assays for detecting compounds that bind to the same site as TLR7 / 8 binding ligands.
[0274] The compounds of the invention can be used by themselves and / or in combination with physical measurements for diagnosing the effectiveness of treatment. Pharmaceutical compositions containing the compounds and the use of the compounds to treat TLR7 / 8-mediated conditions are promising new approaches for broad-spectrum therapy that result in direct and immediate improvement in health status, whether in humans or animals. The orally bioavailable and active new chemical entities of the invention improve patient convenience and compliance with physicians.
[0275] The compounds of formula (I), their salts, isomers, tautomers, enantiomeric forms, diastereomers, racemates, derivatives, prodrugs and / or metabolites are characterized by high specificity and stability, low manufacturing costs and convenient handling. These features form the basis for reproducible action (among others, lack of cross-reactivity) and reliable and safe interaction with target structures.
[0276] As used herein, the term "biological sample" includes, but is not limited to, cell cultures or extracts thereof; biopsy material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears or other body fluids or extracts thereof.
[0277] Modulation of TLR7 / 8 or its mutant activity in biological samples can be used for a variety of purposes known to those skilled in the art. Examples of such purposes include, but are not limited to, blood transfusion, organ transplantation, biological sample storage, and bioassays.
[0278] example
[0279] As described in the Examples below, in certain exemplary embodiments, compounds are prepared according to the following general procedures. It should be understood that although the general methods describe the synthesis of certain compounds of the present invention, the following general methods and other methods known to those of ordinary skill in the art can be applied to all compounds as described herein and subclasses and species of each of these compounds.
[0280] The symbols and conventions used in the description of the following procedures, schemes, and examples are consistent with those used in the contemporary scientific literature, for example, the Journal of the American Chemical Society or the Journal of Biological Chemistry.
[0281] Unless otherwise indicated, all temperatures are expressed in °C (degrees Celsius).
[0282] All solvents used were commercially available and used without further purification. Reactions were generally carried out under an inert atmosphere of nitrogen using anhydrous solvents. Flash column chromatography was generally performed using silica gel 60 (0.035-0.070 mm particle size).
[0283] All NMR experiments were recorded on a Bruker Mercury Plus 400 NMR spectrometer equipped with a Bruker 400 BBFO probe at 400 MHz for proton NMR, or a Bruker Mercury Plus 300 NMR spectrometer equipped with a Bruker 300BBFO probe at 300 MHz for proton NMR, or a Bruker Avance III 400 NMR spectrometer equipped with a Bruker PABBO BB-1H / DZ GRD probe at 400 MHz for proton NMR. All deuterated solvents typically contained 0.03% to 0.05% v / v tetramethylsilane, which was used as a reference signal (for 1 H and 13 C were all set at δ 0.00). In the case where the deuterated solvent did not contain tetramethylsilane, the residual non-deuterated solvent peak was used as a reference signal according to published guidelines (J. Org. Chem., Vol. 62, No. 21, 1997).
[0284] LC-MS analysis was performed on either of the following two instruments:
[0285] SHIMADZU LC-MS machine, the machine is composed of UFLC 20-AD system and LCMS 2020 MS detector. The column used is Shim-pack XR-ODS, 2.2μm, 3.0×50mm. A linear gradient was applied, starting from 95% A (A: 0.05% TFA aqueous solution) and ending at 100% B (B: 0.05% TFA acetonitrile solution) over 2.2min, with a total run time of 3.6min. The column temperature was 40°C and the flow rate was 1.0mL / min. The diode array detector scanned from 200-400nm. The mass spectrometer was equipped with an electrospray ion source (ES) operating in positive or negative mode. The mass spectrometer scanned between m / z 90-900 with a scan time of 0.6s.
[0286] Agilent Technologies' Agilent 1200 series mass spectrometer, using atmospheric chemical ionization (APCI) or electrospray ionization (ESI). The diode array detector scanned from 200-400 nm. The mass spectrometer was scanned between m / z 90-900 with a scan time of 0.6 s. Column: XBridge C8, 3.5 μm, 4.6×50 mm; solvent A: water + 0.1% TFA; solvent B: ACN + 0.1% TFA; flow rate: 2 ml / min; gradient: 0 min: 5% B, 8 min: 100% B, 8.1 min: 100% B, 8.5 min: 5% B, 10 min 5% B or LC / MS Waters ZMD (ESI).
[0287] HPLC data were obtained from a SHIMAZU LC-MS machine or using an Agilent 1100 series HPLC from Agilent technologies using a column (XBridge C8, 3.5 μm, 4.6 x 50 mm) and two mobile phases (mobile phase A: water + 0.1% TFA; mobile phase B: ACN + 0.1% TFA). The flow rate was 2 ml / min. The gradient method was: 0 min: 5% B; 8 min: 100% B; 8.1 min: 100% B; 8.5 min: 5% B; 10 min 5% B, unless otherwise stated.
[0288] Generally, compounds according to formula (I) and related formulas of the present invention can be prepared from readily available raw materials. If these raw materials are not commercially available, they can be prepared by standard synthesis techniques. Generally, the synthetic route of any individual compound of formula (I) and related formulas will depend on the specific substituents of each molecule, and these factors are understood by those of ordinary skill in the art. The following general methods and procedures described in the examples below can be used to prepare compounds of formula (I) and related formulas. The reaction conditions described in the following schemes, such as temperature, solvent or co-reagent, are given as examples only and are not restrictive. It should be understood that, in the case of typical or preferred experimental conditions (i.e., reaction temperature, time, mole number of reagents, solvent, etc.), unless otherwise stated, other experimental conditions may also be used. The optimal reaction conditions may vary with the specific reactants or solvents used, but these conditions may be determined by those skilled in the art using conventional optimization procedures. For all protection and deprotection methods, see Philip J. Kocienski, "Protecting Groups", Georg Thieme Verlag Stuttgart, New York, 1994 and Theodora W. Greene and Peter GM Wuts, "Protective Groups in Organic Synthesis", Wiley Interscience, 3rd edition, 1999.
[0289] Intermediate 1: 8-bromoquinoxaline-5-carbonitrile
[0290]
[0291] 5-Bromo-8-methylquinoxaline: To a solution of 5-methylquinoxaline (9.50 g, 66.0 mmol) in acetonitrile (80 mL) was added 1-bromopyrrolidine-2,5-dione (27.0 g, 151.7 mmol) at room temperature. The resulting solution was stirred at 60 °C for 16 h. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure, and the residue was diluted with ethyl acetate (500 mL). The insoluble solids in the mixture were filtered out, and the filtrate was washed with brine and dried over Na2SO4. The solvent was removed under reduced pressure to obtain 5-bromo-8-methylquinoxaline as a brown solid (6.00 g, 41%). MS: m / z=222.9 [M+H] + .
[0292] 5-Bromo-8-(dibromomethyl)quinoxaline: To a solution of 5-bromo-8-methylquinoxaline (6.00 g, 27.0 mmol) in CCl4 (200 mL) was added NBS (19.2 g, 108.1 mmol) and AIBN (0.71 g, 4.3 mmol) at room temperature. The resulting solution was then stirred at 80 °C for 16 h. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure, and the residue was diluted with ethyl acetate (500 mL). The insoluble solids in the mixture were filtered out, and the filtrate was then washed with brine and dried over Na2SO4. The solvent was removed under reduced pressure, and the residue was purified by flash chromatography eluting with EtOAc / petroleum ether (0% to 5% gradient) to give 5-bromo-8-(dibromomethyl)quinoxaline as a light yellow solid (7.15 g, 70%). MS: m / z=378.7 [M+H] + .
[0293] 8-Bromoquinoxaline-5-carboxaldehyde: To a solution of 5-bromo-8-(dibromomethyl)quinoxaline (13.5 g, 35.7 mmol) in ethanol (290 mL) was added dropwise a solution of AgNO3 (24.3 g, 142.9 mmol) in water (90 mL) at room temperature. The resulting mixture was then stirred at room temperature for 1 h. When the reaction was complete, the reaction mixture was diluted with acetonitrile (300 mL) and precipitation occurred. The precipitate was filtered off, and the filtrate was concentrated under reduced pressure to obtain 8-bromoquinoxaline-5-carboxaldehyde as a yellow solid (10.0 g, crude). MS: m / z=236.8[M+H] + .
[0294] (E)-8-Bromoquinoxaline-5-carbaldehyde oxime: To a solution of 8-bromoquinoxaline-5-carbaldehyde (10 g, crude) in ethanol (100 mL) was added NaOAc (6.34 g, 73.4 mmol) and NH2OH·HCl (3.12 g, 42.7 mmol) at room temperature. The resulting mixture was stirred at 70°C for 3 h. When the reaction was complete, the insoluble solid in the reaction mixture was filtered out at 70°C, and then the filtrate was cooled to 0°C and precipitation occurred. The precipitate was collected by filtration and dried in an oven to give (E)-N-[(8-bromoquinoxaline-5-yl)methylene]hydroxylamine as a yellow solid (2.96 g, 33% for 2 steps). MS: m / z=253.9[M+H] + .
[0295] 8-Bromoquinoxaline-5-carbonitrile: To a solution of (E)-N-[(8-bromoquinoxaline-5-yl)methylene]hydroxylamine (3.47 g, 13.8 mmol) in acetonitrile (20 mL) was added Cu(OAc)2 (577 mg, 3.18 mmol) and acetic acid (1.24 g, 20.7 mmol) at room temperature. The resulting mixture was stirred at 88 °C for 15 h. After cooling to room temperature, the reaction mixture was diluted with acetonitrile (10 mL). The insoluble solids in the mixture were filtered out, and the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography eluting with EtOAc / petroleum ether (0% to 15% gradient) to give 8-bromoquinoxaline-5-carbonitrile as a yellow solid (1.22 g, 38%). MS: m / z=235.8[M+H] + .
[0296] Intermediate 2: 5-bromo-8-methyl-[1,7]naphthyridine
[0297]
[0298] 5-Bromo-8-methyl-[1,7]naphthyridine: 5-Bromo-2-methyl-pyridin-3-ylamine (3.00 g; 16.0 mmol), glycerol (4.7 mL; 64.1 mmol), iron (II) sulfate heptahydrate (892 mg;
[0299] To a mixture of 5-bromo-8-methyl-[1,7]naphthyridine (470 mg, 13%) was added sulfuric acid (5.6 mL; 96.2 mmol). The resulting mixture was heated at 120°C overnight. The reaction mixture was treated with ice, 2N sodium hydroxide solution, ethyl acetate and dichloromethane. After filtering to remove the dark brown solid, the organic layer was separated and washed with brine, dried and concentrated. The crude product was purified by silica gel chromatography eluting with ethyl acetate and hexanes to give 5-bromo-8-methyl-[1,7]naphthyridine (470 mg, 13%). MS: m / z=224[M+H] + .
[0300] Intermediate 3: 8-Chloropyrido[2,3-b]pyrazine
[0301]
[0302] 8-Chloropyrido[2,3-b]pyrazine: To a solution of 4-chloropyridine-2,3-diamine (1.90 g, 13.20 mmol) in THF (100 mL) was added oxalaldehyde (1.00 g, 17.20 mmol) at room temperature. The resulting solution was then stirred at room temperature for 6 hours. When the reaction was complete, the reaction mixture was concentrated under reduced pressure and the residue was purified by flash chromatography, eluting with EtOAc / petroleum ether (0% to 50% gradient) to give 8-chloropyrido[2,3-b]pyrazine as a yellow solid (2.10 g, 91%). MS: m / z=166.1[M+H] + .
[0303] Intermediate 4: 4-bromo-1,2-dimethyl-1H-pyrrolo[2,3-b]pyridine
[0304]
[0305] 4-Bromo-1,2-dimethyl-1H-pyrrolo[2,3-b]pyridine: To a solution of 4-bromo-2-methyl-1H-pyrrolo[2,3-b]pyridine (6.00 g, 27.0 mmol) in N,N-dimethylformamide (60 mL) was added sodium hydride (1.62 g, 40.5 mmol) at 0°C. The reaction was stirred at 0°C for 15 minutes, then iodomethane (2.1 mL, 32.4 mmol) was added and the resulting mixture was stirred at room temperature for 8 h. When the reaction was complete, the reaction mixture was quenched with water (250 mL) and the resulting mixture was extracted with ethyl acetate (3×100 mL). The combined organic phases were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residual gum was triturated with hexanes (40 mL) and dried to give 4-bromo-1,2-dimethyl-1H-pyrrolo[2,3-b]pyridine as a brown semisolid (3.80 g, 62%). MS: m / z = 227 [M+H] + .
[0306] Example 1: Synthesis of Compound 1 (8-[(3R, 4R)-3-amino-4-methylpyrrolidin-1-yl]quinoxaline-5-carbonitrile)
[0307]
[0308] N-[(3R, 4R)-1-(8-cyanoquinoxaline-5-yl)-4-methylpyrrolidin-3-yl]carbamic acid tert-butyl ester: To a solution of 8-bromoquinoxaline-5-carbonitrile (900 mg, 3.85 mmol) and N-[(3R, 4R)-4-methylpyrrolidin-3-yl]carbamic acid tert-butyl ester (808 mg, 4.03 mmol) in N, N-dimethylformamide (7 mL) was added DIEA (1.58 g, 12.20 mmol) at room temperature. The reaction solution was stirred at 130°C for 3 hours. When the reaction was complete, it was quenched by adding water (30 mL). The resulting mixture was extracted with ethyl acetate (50 mL×3). The organic phases were combined, washed with brine and dried over Na2SO4. The solvent was removed under reduced pressure to give tert-butyl N-[(3R,4R)-1-(8-cyanoquinoxalin-5-yl)-4-methylpyrrolidin-3-yl]carbamate as a yellow solid (1.19 g, 44%). MS: m / z = 354.1 [M+H] + .
[0309] 8-[(3R,4R)-3-amino-4-methylpyrrolidin-1-yl]quinoxaline-5-: To a solution of tert-butyl N-[(3R,4R)-1-(8-cyanoquinoxaline-5-yl)-4-methylpyrrolidin-3-yl]carbamate (720 mg, 2.04 mmol) in MeOH was added hydrogen chloride solution (12N, 6 mL, 72 mmol) at room temperature. The resulting mixture was stirred at room temperature for 6 hours. When the reaction was complete, the reaction mixture was concentrated under reduced pressure and the residue was purified by preparative HPLC under the following conditions: column, XBridgePrep C18 OBD column, 250 mm, 5 um, 13 nm; mobile phase, acetonitrile / water (with 0.05% NH3.H2O), 29% to 42% gradient in 8 minutes; detector, UV 254 nm. 8-[(3R,4R)-3-Amino-4-methylpyrrolidin-1-yl]quinoxaline-5-carbonitrile was obtained as a white solid (490 mg, 95%).
[0310] Compound 1: HPLC: 98.1% purity, RT = 1.05 min. MS: m / z = 254.3 [M+H] + . 1H NMR (400MHz, methanol-d4, ppm) δ8.79 (d, J=1.8Hz, 1H), 8.73 (d, J=1.8Hz, 1H), 7.97-7.89 (m, 1H), 6.72 (d, J=8.8Hz, 1H), 4.21-4.12 ( m, 1H), 4.05-3.95 (m, 1H), 3.93-3.85 (m, 1H), 3.79-3.69 (m, 1H), 3.63-3.52 (m, 1H), 2.53-2.38 (m, 1H), 1.16 (d, J=7.0Hz, 3H).
[0311] The following compounds were synthesized in a similar manner:
[0312] Compound 56 8-(3-amino-4-methyl-pyrrolidin-1-yl)-quinoxaline-5-carbonitrile hydrochloride: synthesized from 8-bromoquinoxaline-5-carbonitrile and (4-methyl-pyrrolidin-3-yl)-carbamic acid tert-butyl ester. HPLC: 92% purity, RT = 1.50 min. MS: m / z = 254 [M+H] + .
[0313] Example 2: Synthesis of Compound 2 (N-[(3R, 4R)-1-(8-cyanoquinoxaline-5-yl)-4-methylpyrrolidin-3-yl]-2-(1-methylpiperidin-4-yl)acetamide)
[0314]
[0315] N-[(3R,4R)-1-(8-cyanoquinoxalin-5-yl)-4-methylpyrrolidin-3-yl]-2-(1-methylpiperidin-4-yl)acetamide: To a solution of 8-[(3R,4R)-3-amino-4-methylpyrrolidin-1-yl]quinoxaline-5-carbonitrile (48 mg, 0.19 mmol) in N,N-dimethylformamide (10 mL) was added 2-(1-methylpiperidin-4-yl)acetic acid (59 mg, 0.38 mmol), DIEA (145 mg, 1.13 mmol) and HATU (143 mg, 0.38 mmol) at room temperature. The resulting solution was stirred at room temperature for 14 hours. When the reaction was complete, the solvent was removed under reduced pressure and the residue was purified by preparative HPLC under the following conditions: column, XBridge Shield RP18OBD column, 150 mm, 5 um, 13 nm; mobile phase, acetonitrile / water (with 10 mM NH4HCO3), 13% to 40% gradient in 8 minutes; detector, UV 254 nm. N-[(3R, 4R)-1-(8-cyanoquinoxaline-5-yl)-4-methylpyrrolidin-3-yl]-2-(1-methylpiperidin-4-yl)acetamide was obtained as a yellow solid (18 mg, 25%).
[0316] Compound 2: HPLC: 92.4% purity, RT = 3.85 min. MS: m / z = 393.4 [M+H] + . 1 H NMR (400MHz, methanol-d4, ppm) δ8.81 (d, J=1.8Hz, 1H), 8.75 (d, J=1.8Hz, 1H), 7.95 (d, J= 8.7Hz, 1H), 6.75 (d, J=8.7Hz, 1H), 4.64-4.56 (m, 1H), 4.31-4.21 (m, 1H), 4.08-3.9 2(m, 2H), 3.74-3.64(m, 1H), 2.89-2.78(m, 2H), 2.69-2.54(m, 1H), 2.29-2.09(m, 5 H), 2.06-1.94 (m, 2H), 1.83-1.62 (m, 3H), 1.37-1.20 (m, 2H), 1.10 (d, J=6.8Hz, 3H).
[0317] The following compounds were synthesized in a similar manner:
[0318] Compound 7 (N-[(3R, 4R)-1-(8-cyanoquinoxalin-5-yl)-4-methylpyrrolidin-3-yl]-2-(morpholin-4-yl)acetamide): synthesized from 8-[(3R, 4R)-3-amino-4-methylpyrrolidin-1-yl]quinoxaline-5-carbonitrile and 2-(morpholin-4-yl)acetic acid, purified by preparative HPLC under the following conditions: column, XBridge Prep C18 OBD column, 150 mm, 5 um, 13 nm; mobile phase, acetonitrile / water (with 10 mM NH4HCO3 and 0.1% NH3.H2O), 5% to 75% gradient in 7 minutes; detector, UV 254 nm (18 mg, 25%, yellow solid). HPLC: 91.7% purity, RT = 2.14 min. MS: m / z = 381.3 [M+H] + . 1 H NMR (400MHz, methanol-d4, ppm) δ8.83 (d, J=1.8Hz, 1H), 8.76 (d, J=1.8Hz, 1H), 7.97 (d, J=8.7Hz, 1H), 6.78 (d, J=8.7Hz, 1H), 4.64-4.54 (m, 1H), 4.31-4.21 (m, 1H), 4.12-3.96 (m, 2H), 3.76-3.62 (m, 5H), 3.09-3.04 (m, 2H), 2.71-2.59 (m, 1H), 2.57-2.45 (m, 4H), 1.12 (d, J=6.8Hz, 3H).
[0319] Compound 8 (N-[(3R, 4R)-1-(8-cyanoquinoxaline-5-yl)-4-methylpyrrolidin-3-yl]-2-(1,4-dimethylpiperidin-4-yl)acetamide): synthesized from 8-[(3R, 4R)-3-amino-4-methylpyrrolidin-1-yl]quinoxaline-5-carbonitrile (43 mg, 0.17 mmol) and 2-(1,4-dimethylpiperidin-4-yl)acetic acid, and purified by preparative HPLC under the following conditions: column, XBridge Prep C18 OBD column, 150 mm, 5 um, 13 nm; mobile phase, acetonitrile / water (with 10 mM NH4HCO3), gradient from 22% to 35% in 7 minutes; detector, UV 254 nm (12 mg, 17%, yellow solid). HPLC: 94.5% purity, RT = 4.31 min. MS: m / z = 407.3 [M+H] + . 1 H NMR (300MHz, DMSO-d6, ppm) δ8.91 (d, J=1.8Hz, 1H), 8.80 (d, J=1.8Hz, 1H), 8.01 (d, J=8.7Hz, 1H), 7.89 (d, J=8.3Hz, 1H), 6.71 (d, J=8.8Hz, 1H), 4.52- 4.39 (m, 1H), 4.19-4.09 (m, 1H), 3.97-3.90 (m, 1H), 3.79-3.55 (m, 2H), 2.4 7-1.93 (m, 10H), 1.55-1.39 (m, 2H), 1.31-1.25 (m, 2H), 1.08-0.88 (m, 6H).
[0320] Compound 15 ((2S)-N-[(3R,4R)-1-(8-cyanoquinoxaline-5-yl)-4-methylpyrrolidin-3-yl]-2-hydroxy-3-methylbutanamide): synthesized from 8-[(3R,4R)-3-amino-4-methylpyrrolidin-1-yl]quinoxaline-5-carbonitrile and (2S)-2-hydroxy-3-methylbutanoic acid, and purified by preparative HPLC under the following conditions: column, XBridge Shield PrepC18 OBD column, 150mm, 5um, 13nm; mobile phase, acetonitrile / water (with 10mmol / L NH4HCO3 and 0.1% NH3.H2O), gradient from 30% to 35% in 7 minutes; detector, UV 254nm (29mg, 27%, yellow solid). HPLC: 95.0% purity, RT = 3.35 min. MS: m / z = 354.3 [M+H] + . 1H NMR (400MHz, DMSO-d6, ppm) δ8.93 (d, J=1.9Hz, 1H), 8.81 (d, J=1.8Hz, 1H), 8.03 (d, J=8 .7Hz, 1H), 7.79 (d, J=8.5Hz, 1H), 6.73 (d, J=8.8Hz, 1H), 5.09 (d, J=6.1Hz, 1H), 4.55-4. 45(m, 1H), 4.21-4.12(m, 1H), 4.05-3.74(m, 2H), 3.71-3.58(m, 2H), 2.58-2.49(m, 1H), 1.98-1.85 (m, 1H), 0.98 (d, J=6.8Hz, 3H), 0.86 (d, J=6.8Hz, 3H), 0.73 (d, J=6.8Hz, 3H).
[0321] Compound 16 ((2R)-N-[(3R, 4R)-1-(8-cyanoquinoxaline-5-yl)-4-methylpyrrolidin-3-yl]-2-hydroxy-3-methylbutanamide): synthesized from 8-[(3R, 4R)-3-amino-4-methylpyrrolidin-1-yl]quinoxaline-5-carbonitrile and (2R)-2-hydroxy-3-methylbutanoic acid, and purified by preparative HPLC under the following conditions: column, XBridge Shield PrepC18OBD column, 150mm, 5um, 13nm; mobile phase, acetonitrile / water (with 10mmol / L NH4HCO3 and 0.1% NH3.H2O), gradient from 35% to 39% in 7 minutes; detector, UV 254nm (14mg, 26%, yellow solid). HPLC: 96.1% purity, RT = 2.16 min. MS: m / z = 354.4 [M+H] + . 1 H NMR (300MHz, methanol-d4, ppm) δ8.79 (d, J=1.8Hz, 1H), 8.73 (d, J=1.8Hz, 1H), 7.94 (d , J=8.7Hz, 1H), 6.75 (d, J=8.7Hz, 1H), 4.61-4.54 (m, 1H), 4.30-4.18 (m, 1H), 4.1 1-3.91(m, 2H), 3.86-3.78(m, 1H), 3.76-3.63(m, 1H), 2.66-2.57(m, 1H), 2.11-1 .96 (m, 1H), 1.10 (d, J=6.8Hz, 3H), 0.96 (d, J=6.9Hz, 3H), 0.86 (d, J=6.8Hz, 3H).
[0322] Example 3: Synthesis of Compounds 3 and 4 (N-[(3R, 4R)-1-(8-cyanoquinoxalin-5-yl)-4-methylpyrrolidin-3-yl]-2-[(3S)-1-methylpiperidin-3-yl]acetamide and N-[(3R, 4R)-1-(8-cyanoquinoxalin-5-yl)-4-methylpyrrolidin-3-yl]-2-[(3R)-1-methylpiperidin-3-yl]acetamide)
[0323]
[0324] N-[(3R,4R)-1-(8-Cyanoquinoxalin-5-yl)-4-methylpyrrolidin-3-yl]-2-[(3S)-1-methylpiperidin-3-yl]acetamide and N-[(3R,4R)-1-(8-Cyanoquinoxalin-5-yl)-4-methylpyrrolidin-3-yl]-2-[(3R)-1-methylpiperidin-3-yl]acetamide: To a solution of 8-[(3R,4R)-3-amino-4-methylpyrrolidin-1-yl]quinoxaline-5-carbonitrile (48 mg, 0.19 mmol) in N,N-dimethylformamide (4 mL) were added 2-(1-methylpiperidin-3-yl)acetic acid (59 mg, 0.38 mmol), HATU (144 mg, 0.38 mmol) and DIEA (147 mg, 1.14 mmol) at room temperature. The resulting solution was stirred at room temperature for 14 hours. When the reaction was complete, it was quenched by adding water (15mL). The resulting mixture was extracted with DCM (30mL×3). The organic phase was combined, washed with brine and dried over Na2SO4. The solvent was removed under reduced pressure, and the residue was first purified by preparative HPLC under the following conditions: column, XBridge C18OBD Prep column, 150mm, 5um; mobile phase, acetonitrile / water (with 10mMNH4HCO3), 25% to 31% gradient in 8 minutes; detector, UV 254nm. Then two diastereomers were obtained by separation on chiral preparative HPLC under the following conditions: column, CHIRALPAK IG, 2x15cm, 3um; mobile phase, 100% MeOH (with 0.1% DEA), within 20min; detector, UV 254nm.
[0325] Isomer 1: (18 mg, 25%, yellow solid) HPLC: 90.3% purity, RT = 3.55 min. MS: m / z = 393.4 [M+H] + . 1HNMR (400MHz, methanol-d4, ppm) δ8.82 (d, J=1.7Hz, 1H), 8.76 (d, J=1.8Hz, 1H), 7.96 (d, J=8.7Hz, 1H), 6.77 (d, J=8.7Hz, 1H), 4.62-4.57 (m, 1H), 4.32-4.22 (m, 1H), 4.09-3.94 (m, 2H), 3.75- 3.65(m, 1H), 2.92-2.78(m, 2H), 2.68-2.56(m, 1H), 2.27(s, 3H), 2.18-2.11(m, 2H), 2.04-1 .99 (m, 2H), 1.84-1.64 (m, 3H), 1.64-1.53 (m, 1H), 1.11 (d, J=6.8Hz, 3H), 1.03-0.90 (m, 1H).
[0326] Isomer 2: (11 mg, 13%, yellow solid) HPLC: 95.3% purity, RT = 5.07 min. MS: m / z = 393.1 [M+H] + . 1 H NMR (300MHz, methanol-d4, ppm) δ8.83-8.69 (m, 2H), 7.94 (d, J=8.7Hz, 1H), 6.74 (d, J=8.8Hz, 1H), 4.60-4.53 (m, 1H), 4.30-4.18 (m, 1H), 4.08-3.89 (m, 2H) , 3.74-3.60(m, 1H), 3.04-2.97(m, 2H), 2.67-2.51(m, 1H), 2.40(s, 3H), 2. 32-1.96 (m, 6H), 1.82-1.72 (m, 2H), 1.67-1.56 (m, 1H), 1.30-0.85 (m, 4H).
[0327] The following compounds were synthesized in a similar manner:
[0328] Compounds 5 and 6 (N-[(3R,4R)-1-(8-cyanoquinoxalin-5-yl)-4-methylpyrrolidin-3-yl]-2-[(3S)-1-methylpyrrolidin-3-yl]acetamide and N-[(3R,4R)-1-(8-cyanoquinoxalin-5-yl)-4-methylpyrrolidin-3-yl]-2-[(3R)-1-methylpyrrolidin-3-yl]acetamide): synthesized from 8-[(3R,4R)-3-amino-4-methylpyrrolidin-1-yl]quinoxaline-5-carbonitrile and 2-(1-methylpyrrolidin-3-yl)acetic acid and purified by preparative HPLC under the following conditions: column, XBridge C18 OBD Prep column, 150 mm, 5 um; mobile phase, acetonitrile / water (with 10 mM NH4HCO3 and 0.1% NH3.H2O), 15% to 45% gradient in 8 minutes; detector, UV 254 nm. The two diastereomers were obtained by separation on chiral preparative HPLC under the following conditions: column, CHIRALPAK IC-3, 0.46 x 10 cm, 3 um; mobile phase, MtBE (with 0.1% DEA) / MeOH, 70% isocratic in 30 min; detector, UV 254 nm. Isomer 1: (13 mg, 15%, yellow solid) HPLC: 97.3% purity, RT = 3.00 min. MS: m / z = 379.3 [M+H] + . 1 H NMR (300MHz, DMSO-d6, ppm) δ8.91 (d, J=1.8Hz, 1H), 8.80 (d, J=1.8Hz, 1H), 8.00 (d, J=8.4Hz, 2H), 6.71 (d, J=8.8Hz, 1H), 4.51-4.40 (m, 1H), 4.15-4.08 (m, 1H), 3.96-3.89 (m, 1H), 3.80-3.73 (m, 1H) ), 3.61-3.54 (m, 1H), 2.37-2.26 (m, 5H), 2.23-1.98 (m, 6H), 1.91-1.75 (m, 1H), 1.36-1.21 (m, 1H), 0.94 (d, J = 6.8 Hz, 3H). Isomer 2: (15 mg, 16%, yellow solid) HPLC: 94.1% purity, RT = 4.39 min. MS: m / z = 379.3 [M+H] + . 1H NMR (300MHz, methanol-d4, ppm) δ 8.82-8.69 (m, 2H), 7.93 (d, J = 8.7Hz, 1H), 6.73 (d, J = 8.7Hz, 1H), 4.59-4.52 (m, 1H), 4.29-4.17 (m, 1H), 4.08-3.88 (m , 2H), 3.73-3.60 (m, 1H), 2.80-2.68 (m, 1H), 2.66-2.52 (m, 4H), 2.33-2. 17 (m, 6H), 2.14-1.95 (m, 1H), 1.57-1.39 (m, 1H), 1.07 (d, J=6.8Hz, 3H).
[0329] Compounds 13 and 14 ((2S)-N-[(3R,4R)-1-(8-cyanoquinoxalin-5-yl)-4-methylpyrrolidin-3-yl]-2-cyclopropyl-2-hydroxyacetamide and (2R)-N-[(3R,4R)-1-(8-cyanoquinoxalin-5-yl)-4-methylpyrrolidin-3-yl]-2-cyclopropyl-2-hydroxyacetamide): synthesized from 8-[(3R,4R)-3-amino-4-methylpyrrolidin-1-yl]quinoxaline-5-carbonitrile (52 mg, 0.20 mmol) and 2-cyclopropyl-2-hydroxyacetic acid, and purified by preparative HPLC under the following conditions: column, XBridge Prep C18 OBD column, 150 mm, 5 um; mobile phase, acetonitrile / water (with 10 mmol / L NH4HCO3 and 0.1% NH3.H2O), 5% to 62% gradient in 7 minutes; detector, UV 254nm. The two diastereomers were obtained by separation on chiral preparative HPLC under the following conditions: column, CHIRALPAK IA-3, 0.46x5cm, 3um; mobile phase, hexane (with 0.1% DEA) / EtOH, 50% isocratic, in 15min; detector, UV 254nm. Isomer 1: (20mg, 27%, yellow solid) HPLC: 96.1% purity, RT = 1.17min.MS: m / z = 352.2 [M+H] + . 1HNMR (400MHz, DMSO-d6, ppm) δ8.93 (d, J=1.8Hz, 1H), 8.82 (d, J=1.8Hz, 1H), 8.04 (d, J=8.7Hz, 1H), 7.78 (d, J=8.5Hz, 1H), 6.74 (d, J=8.8Hz, 1H), 5.09 (d, J=6.1Hz, 1H), 4.52-4.47 (m, 1H), 4.21-4.16 (m, 1H), 4. 00-3.95 (m, 1H), 3.89-3.81 (m, 1H), 3.62-3.57 (m, 1H), 3.45 (t, J = 6.4 Hz, 1H), 2.61-2.50 (m, 1H), 1.08-0.95 (m, 4H), 0.40-0.22 (m, 4H). Isomer 2: (11 mg, 13%, yellow solid) HPLC: 97.4% purity, RT = 1.19 min. MS: m / z = 352.2 [M+H] + . 1 H NMR (400MHz, DMSO-d6, ppm) δ8.94 (d, J=1.7Hz, 1H), 8.83 (d, J=1.7Hz, 1H), 8.05 (d, J= 8.6Hz, 1H), 7.70 (d, J=8.4Hz, 1H), 6.74 (d, J=8.7Hz, 1H), 5.28 (d, J=5.7Hz, 1H), 4.56 -4.46(m, 1H), 4.25-4.15(m, 1H), 4.03-3.94(m, 1H), 3.91-3.83(m, 1H), 3.67-3.53(m , 2H), 2.61-2.52(m, 1H), 1.12-1.02(m, 1H), 1.00(d, J=6.8Hz, 3H), 0.41-0.25(m, 4H).
[0330] Example 4: Synthesis of Compound 9 (N-[(3R, 4R)-1-(8-cyanoquinoxaline-5-yl)-4-methylpyrrolidin-3-yl]-2-(4-fluoropiperidin-4-yl)acetamide)
[0331]
[0332] tert-Butyl 4-([[(3R,4R)-1-(8-cyanoquinoxalin-5-yl)-4-methylpyrrolidin-3-yl]carbamoyl]methyl)-4-fluoropiperidine-1-carboxylate: To a solution of 8-[(3R,4R)-3-amino-4-methylpyrrolidin-1-yl]quinoxaline-5-carbonitrile (129 mg, 0.51 mmol) in DCM (8 mL) was added 2-[1-[(tert-butoxy)carbonyl]-4-fluoropiperidin-4-yl]acetic acid (266 mg, 1.02 mmol), HATU (388 mg, 1.02 mmol) and DIEA (394 mg, 3.06 mmol) at room temperature. The resulting solution was stirred at room temperature for 16 hours. When the reaction was complete, the reaction mixture was concentrated under reduced pressure and the residue was purified by preparative HPLC under the following conditions: column, XBridge Prep C18 OBD column, 150 mm, 5 um, 13 nm; mobile phase, acetonitrile / water (with 10 mM NH4HCO3 and 0.1% NH3.H2O), 40% to 53% gradient in 7 minutes; detector, UV 254 nm. 4-([[(3R,4R)-1-(8-cyanoquinoxalin-5-yl)-4-methylpyrrolidin-3-yl]carbamoyl]methyl)-4-fluoropiperidine-1-carboxylate was obtained as a yellow solid (76 mg, 30%). MS: m / z=497.3 [M+H] + .
[0333] N-[(3R,4R)-1-(8-cyanoquinoxalin-5-yl)-4-methylpyrrolidin-3-yl]-2-(4-fluoropiperidin-4-yl)acetamide: To a solution of tert-butyl 4-([[(3R,4R)-1-(8-cyanoquinoxalin-5-yl)-4-methylpyrrolidin-3-yl]carbamoyl]methyl)-4-fluoropiperidine-1-carboxylate (76 mg, 0.15 mmol) in MeOH (4 mL) was added hydrogen chloride solution (12N, 4 mL, 48 mmol) at room temperature. The resulting solution was stirred at room temperature for 12 hours. When the reaction was complete, the reaction mixture was concentrated under reduced pressure and the residue was purified by preparative HPLC under the following conditions: column, XBridge Prep C18 OBD column, 150 mm, 5 um, 13 nm; mobile phase, acetonitrile / water (with 10 mM NH4HCO3 and 0.1% NH3.H2O), 15% to 42% gradient in 7 minutes; detector, UV 254 nm. N-[(3R, 4R)-1-(8-cyanoquinoxalin-5-yl)-4-methylpyrrolidin-3-yl]-2-(4-fluoropiperidin-4-yl)acetamide was obtained as a yellow solid (13 mg, 19%).
[0334] Compound 9: MS: m / z = 497.3 [M+H] + .1 HNMR (300MHz, DMSP-d6, ppm) δ8.95 (d, J=1.8Hz, 1H), 8.84 (d, J=1.8Hz, 1H), 8.13-8.01 (m, 2H), 6.75 (d, J=8.8Hz, 1H), 4.52-4.43 (m, 1H), 4.26-3.86 (m, 2H), 3.84-3.74 (m, 1H), 3.62-3.52 (m, 1H), 2.74-2.61 (m, 4H), 2.50-2.36 (m, 3H), 1.76-1.55 (m, 4H), 1.00 (d, J=6.8Hz, 3H).
[0335] Example 5: Synthesis of Compound 10 (N-[(3R, 4R)-1-(8-cyanoquinoxalin-5-yl)-4-methylpyrrolidin-3-yl]-2-(4-fluoro-1-methylpiperidin-4-yl)acetamide)
[0336]
[0337] N-[(3R,4R)-1-(8-cyanoquinoxalin-5-yl)-4-methylpyrrolidin-3-yl]-2-(4-fluoro-1-methylpiperidin-4-yl)acetamide: To a solution of N-[(3R,4R)-1-(8-cyanoquinoxalin-5-yl)-4-methylpyrrolidin-3-yl]-2-(4-fluoropiperidin-4-yl)acetamide (32 mg, 0.08 mmol) in MeOH (3 mL) at room temperature were added (HCHO)n (44 mg, 0.49 mmol), NaOAC (135 mg, 1.64 mmol) and NaBH4 (15 mg, 0.41 mmol). The resulting solution was stirred at room temperature for 3 hours. When the reaction was complete, the reaction mixture was concentrated under reduced pressure and the residue was purified by preparative HPLC under the following conditions: column, XBridge Shield RP18 OBD column, 150 mm, 5 um, 13 nm; mobile phase, acetonitrile / water (with 10 mM NH4HCO3), 35% to 65% gradient in 7 minutes; detector, UV 254 nm. N-[(3R, 4R)-1-(8-cyanoquinoxaline-5-yl)-4-methylpyrrolidin-3-yl]-2-(4-fluoro-1-methylpiperidin-4-yl)acetamide was obtained as a yellow solid (7 mg, 21%).
[0338] Compound 10: HPLC: 90.3% purity, RT = 5.76 min. MS: m / z = 411.3 [M+H] + . 1H NMR (300MHz, methanol-d4, ppm) δ8.78 (d, J=1.8Hz, 1H), 8.71 (d, J=1.8Hz, 1H), 7.92 (d, J=8.7Hz, 1H), 6.73 (d, J=8.7Hz, 1H), 4.62-4.52 (m, 1H), 4.31-4.16 (m, 1H ), 4.11-3.88(m, 2H), 3.73-3.59(m, 1H), 3.38-3.31(m, 2H), 3.22-3.06(m, 2H ), 2.80 (s, 3H), 2.73-2.52 (m, 3H), 2.25-1.96 (m, 4H), 1.09 (d, J=6.8Hz, 3H).
[0339] Example 6: Synthesis of Compounds 11 and 12 (N-[(3R, 4R)-1-(8-cyanoquinoxalin-5-yl)-4-methylpyrrolidin-3-yl]-2-[(4S)-3,3-difluoro-1-methylpiperidin-4-yl]acetamide and N-[(3R, 4R)-1-(8-cyanoquinoxalin-5-yl)-4-methylpyrrolidin-3-yl]-2-[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]acetamide)
[0340]
[0341] Tert-butyl 4-(2-ethoxy-2-oxoethylidene)-3,3-dimethylpiperidine-1-carboxylate: At 0°C, sodium hydride (102 mg, 4.25 mmol) was added to a solution of ethyl (diethoxyphosphoryl)formate (950 mg, 4.52 mmol) in THF (50 mL) at 0°C. The resulting mixture was stirred for 15 minutes, and then tert-butyl 3,3-difluoro-4-oxopiperidine-1-carboxylate (798 mg, 3.39 mmol) was added at 0°C. The reaction mixture was stirred at 0°C for 0.5 h, warmed to room temperature, and stirred at room temperature for 3 h. When the reaction was complete, it was quenched by adding water (20 mL). The resulting mixture was extracted with ethyl acetate (40 mL×3). The organic phases were combined, washed with brine and dried over Na2SO4. The solvent was removed under reduced pressure and the residue was purified by flash chromatography eluting with EtOAc / petroleum ether (0% to 50% gradient) to give tert-butyl 4-(2-ethoxy-2-oxoethylidene)-3,3-dimethylpiperidine-1-carboxylate as a colorless oil (560 mg, 35%). MS: m / z = 205.9 [M-100+1] + .
[0342] 4-(2-ethoxy-2-oxoethyl)-3,3-difluoropiperidine-1-carboxylic acid tert-butyl ester: To a solution of 4-(2-ethoxy-2-oxoethylidene)-3,3-difluoropiperidine-1-carboxylic acid tert-butyl ester (1.11 g, 3.62 mmol) in EtOH (30 mL) under a nitrogen atmosphere, palladium carbon (138 mg, 0.13 mmol) was added. The reaction tank was evacuated and flushed with hydrogen. The reaction mixture was then hydrogenated for 3 hours at room temperature using a hydrogen balloon under a hydrogen atmosphere. When the reaction was complete, the reaction mixture was filtered through a celite pad, and the filtrate was concentrated under reduced pressure to give 4-(2-ethoxy-2-oxoethyl)-3,3-difluoropiperidine-1-carboxylic acid tert-butyl ester as a colorless oil (1.01 g, 92%). MS: m / z=207.9[M-100+1] + .
[0343] 2-[1-[(tert-butoxy)carbonyl]-3,3-difluoropiperidin-4-yl]acetic acid: To a solution of tert-butyl 4-(2-ethoxy-2-oxoethyl)-3,3-difluoropiperidin-1-carboxylate (1.01 g, 3.29 mmol) in tetrahydrofuran (25 mL) was added sodium hydroxide solution (500 mg / 25 mL water, 12.5 mmol) at room temperature. The resulting mixture was stirred at 60 ° C for 16 h. When the reaction was complete, the reaction mixture was concentrated under vacuum. The pH value of the residual mixture was adjusted to 5 with hydrogen chloride solution (4N), and the resulting mixture was extracted with ethyl acetate (50 mL×3). The organic phases were combined, washed with brine and dried over Na2SO4. The solvent was removed under reduced pressure to give 2-[1-[(tert-butoxy)carbonyl]-3,3-difluoropiperidin-4-yl]acetic acid as a colorless oil (504 mg, 42%). MS: m / z = 280.1 [M+H] + .
[0344] 2-4-([[(3R,4R)-1-(8-cyanoquinoxalin-5-yl)-4-methylpyrrolidin-3-yl]carbamoyl]methyl)-3,3-difluoropiperidine-1-carboxylate: To a solution of 8-[(3R,4R)-3-amino-4-methylpyrrolidin-1-yl]quinoxaline-5-carbonitrile (208 mg, 0.82 mmol) in DCM (14 mL) was added 2-[1-[(tert-butoxy)carbonyl]-3,3-difluoropiperidin-4-yl]acetic acid (581 mg, 2.08 mmol), HATU (620 mg, 1.63 mmol) and DIEA (633 mg, 4.90 mmol) at room temperature. The resulting solution was stirred at room temperature for 1 h. When the reaction was complete, it was quenched by the addition of water (15 mL). The resulting mixture was extracted with ethyl acetate (50 mL×3). The organic phases were combined, washed with brine and dried over Na2SO4. The solvent was removed under reduced pressure to give tert-butyl 4-([[(3R,4R)-1-(8-cyanoquinoxalin-5-yl)-4-methylpyrrolidin-3-yl]carbamoyl]methyl)-3,3-difluoropiperidine-1-carboxylate as a yellow solid (320 mg, crude). MS: m / z = 515.3 [M+H] + .
[0345] N-[(3R,4R)-1-(8-Cyanoquinoxalin-5-yl)-4-methylpyrrolidin-3-yl]-2-[(4S)-3,3-difluoro-1-methylpiperidin-4-yl]acetamide and N-[(3R,4R)-1-(8-Cyanoquinoxalin-5-yl)-4-methylpyrrolidin-3-yl]-2-[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]acetamide: To a solution of tert-butyl 4-([[(3R,4R)-1-(8-Cyanoquinoxalin-5-yl)-4-methylpyrrolidin-3-yl]carbamoyl]methyl)-3,3-difluoropiperidine-1-carboxylate (320 mg, crude) in HCOOH (26 mL) was added formalin (10%, 15 mL, 54 mmol) at room temperature. The resulting mixture was stirred at 140°C for 1 h. When the reaction was complete, the reaction mixture was concentrated under reduced pressure and the residue was purified by preparative HPLC under the following conditions: column, XBridge C18 OBD Prep column, 150 mm, 5 um; mobile phase, acetonitrile / water (with 10 mM NH4HCO3 and 0.1% NH3.H2O), 30% to 44% gradient in 8 minutes; detector, UV 254 nm. The two diastereomers were then separated on chiral preparative HPLC under the following conditions: column, CHIRALPAK IA-3, 0.46 x 5 cm, 3 um; mobile phase, hexane (with 0.1% DEA) / EtOH, 50% isocratic, in 15 min; detector, UV 254 nm.
[0346] Isomer 1: (93 mg, 59%, yellow solid) HPLC: 93.2% purity, RT = 2.67 min. MS: m / z = 429.4 [M+H] + . 1 H NMR (300MHz, methanol-d4, ppm) δ8.78 (d, J=1.8Hz, 1H), 8.72 (d, J=1.8Hz, 1H), 7.93 (d, J= 8.7Hz, 1H), 6.73 (d, J=8.7Hz, 1H), 4.62-4.53 (m, 1H), 4.30-4.17 (m, 1H), 4.07-3.8 8(m, 2H), 3.73-3.60(m, 1H), 3.03-2.97(m, 1H), 2.86-2.75(m, 1H), 2.69-2.50(m, 2 H), 2.34-2.01 (m, 7H), 1.85-1.72 (m, 1H), 1.60-1.42 (m, 1H), 1.07 (d, J=6.9Hz, 3H).
[0347] Isomer 2: (11 mg, 13%, yellow solid) HPLC: 93.1% purity, RT = 2.74 min. MS: m / z = 429.4 [M+H] + . 1 H NMR (300MHz, methanol-d4, ppm) δ8.82-8.69 (m, 2H), 7.93 (d, J=8.7Hz, 1H), 6.73 (d , J=8.7Hz, 1H), 4.60-4.53 (m, 1H), 4.31-4.18 (m, 1H), 4.07-3.89 (m, 2H), 3.7 3-3.60 (m, 1H), 3.04-2.94 (m, 1H), 2.81-2.70 (m, 1H), 2.69-2.50 (m, 2H), 2.3 8-1.89 (m, 7H), 1.79-1.68 (m, 1H), 1.56-1.41 (m, 1H), 1.07 (d, J=6.9Hz, 3H).
[0348] Example 7: Synthesis of Compound 17 ((3R, 4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-amine)
[0349]
[0350] Tert-butyl N-[(3R, 4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]carbamate: To a solution of 5-bromo-8-(trifluoromethyl)quinoline (245 mg, 0.89 mmol) in N,N-dimethylformamide (5 mL) was added tert-butyl N-[(3R, 4R)-4-methylpyrrolidin-3-yl]carbamate (241 mg, 1.20 mmol), Pd2(dba)3.CHCl3 (124 mg, 0.12 mmol), K3PO4 (768 mg, 3.62 mmol) and DavePhos (93 mg, 0.23 mmol) at room temperature. The resulting mixture was stirred at 130°C for 3 hours. When the reaction was complete, the solid in the reaction mixture was filtered out and the filtrate was diluted with water (20 mL). The resulting mixture was extracted with DCM (50 mL×3). The organic phases were combined, washed with brine and dried over Na2SO4. The solution was removed under reduced pressure and the residue was purified by flash chromatography eluting with EtOAc / hexanes (0% to 20% gradient) to give tert-butyl N-[(3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]carbamate as a brown solid (298 mg, 85%). MS: m / z=396.2 [M+H] + .
[0351] (3R, 4R) -4-methyl-1- [8- (trifluoromethyl) quinolin-5-yl] pyrrolidin-3-amine: To a solution of tert-butyl N- [(3R, 4R) -4-methyl-1- [8- (trifluoromethyl) quinolin-5-yl] pyrrolidin-3-yl] carbamate (50 mg, 0.13 mmol) in methanol (3 mL) was added hydrogen chloride solution (6M / dioxane, 2 mL, 12 mmol) at room temperature. The resulting solution was stirred at room temperature for 2 h. When the reaction was complete, the reaction mixture was concentrated under reduced pressure and the residue was purified by preparative HPLC under the following conditions: column, XBridge Shield Prep C18 OBD column, 150 mm, 5 um, 13 nm; mobile phase, acetonitrile / water (with 10 mmol / L NH4HCO3 and 0.1% NH3.H2O), 30% to 51% gradient in 7 minutes; detector, UV 254 nm. (3R,4R)-4-Methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-amine was obtained as a yellow solid (25 mg, 64%).
[0352] Compound 17: HPLC: 93.4% purity, RT = 2.08 min. MS: m / z = 296.0 [M+H] + . 1H NMR (300MHz, DMSO-d6, ppm) δ8.89 (d, J=3.9Hz, 1H), 8.70 (d, J=8.8Hz, 1H), 7.86 (d, J=8.4Hz, 1H), 7.51-7.40 (m, 1H), 6. 67 (d, J=8.5Hz, 1H), 3.92-3.80 (m, 1H), 3.58-3.43 (m, 3H), 3.38-3.27 (m, 1H), 2.37-2.22 (m, 1H), 1.03 (d, J=6.8Hz, 3H).
[0353] Example 8: Synthesis of Compound 18 (N-[(3R, 4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]-2-(1-methylpiperidin-4-yl)acetamide)
[0354]
[0355] N-[(3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]-2-(1-methylpiperidin-4-yl)acetamide: To a solution of (3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-amine (38 mg, 0.13 mmol) in N,N-dimethylformamide (3 mL) was added 2-(1-methylpiperidin-4-yl)acetic acid (63 mg, 0.40 mmol), DIEA (31 mg, 0.24 mmol) and HATU (307 mg, 0.81 mmol, 6.36 equiv, 95%) at room temperature. The resulting solution was stirred at room temperature for 3 hours. When the reaction was completed, the reaction mixture was concentrated under reduced pressure, and the residue was purified by preparative HPLC under the following conditions: column, XBridge Shield Prep C18 OBD column, 150 mm, 5 um, 13 nm; mobile phase, acetonitrile / water (with 10 mmol / L NH4HCO3 and 0.1% NH3.H2O), 35% to 42% gradient in 7 minutes; detector, UV254 nm. N-[(3R, 4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]-2-(1-methylpiperidin-4-yl)acetamide was obtained as a yellow solid (25 mg, 44%).
[0356] Compound 18: HPLC: 98.4% purity, RT = 0.90 min. MS: m / z = 435.2 [M+H] + . 1H NMR (300MHz, DMSO-d6, ppm) δ8.95-8.86 (m, 1H), 8.69 (d, J=8.8, 1.7Hz, 1H), 7.98-7.84 (m , 2H), 7.54-7.43 (m, 1H), 6.72 (d, J=8.5Hz, 1H), 4.54-4.40 (m, 1H), 4.04-3.92 (m, 1H), 3. 68-3.56(m, 1H), 3.58-3.45(m, 1H), 3.37-3.25(m, 2H), 2.74-2.60(m, 2H), 2.14-1.99(m, 5H), 1.78 (d, J=9.4Hz, 2H), 1.61-1.44 (m, 3H), 1.19-1.02 (m, 2H), 0.97 (d, J=6.8Hz, 3H).
[0357] The following compounds were synthesized in a similar manner:
[0358] Compound 23 (N-[(3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]-2-(morpholin-4-yl)acetamide): synthesized from (3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-amine and 2-(morpholin-4-yl)acetic acid and purified by preparative HPLC under the following conditions: column, XBridge Shield Prep C18 OBD column, 150 mm, 5 um, 13 nm; mobile phase, acetonitrile / water (with 0.05% NH3.H2O), 39% to 59% gradient in 8 minutes; detector, UV 254 nm (35 mg, 39%, yellow solid). HPLC: 96.3% purity, RT = 2.80 min. MS: m / z = 423.1 [M+H] + . 1 H NMR (300MHz, DMSO-d6, ppm) δ8.96-8.87 (m, 1H), 8.70 (d, J=8.8, 1.7Hz, 1H), 7.95-7.80 (m, 2H), 7.55-7.44 (m, 1H), 6.76 (d, J=8.5Hz, 1H), 4.52-4.43 (m, 1H), 4.01-3.89 (m, 1H), 3.72-3.37 (m, 7H), 3.06-2.88 (m, 2H), 2.59-2.51 (m, 1H), 2.47-2.37 (m, 4H), 0.98 (d, J=6.8Hz, 3H).
[0359] Compound 24 (2-(1,4-dimethylpiperidin-4-yl)-N-[(3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]acetamide): synthesized from (3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-amine (60 mg, 0.20 mmol) and 2-(1,4-dimethylpiperidin-4-yl)acetic acid, and purified by preparative HPLC under the following conditions: column, XBridge Shield Prep C18 OBD column, 150 mm, 5 um, 13 nm; mobile phase, acetonitrile / water (with 10 mmol / L NH4HCO3 and 0.1% NH3.H2O), gradient from 40% to 52% in 10 minutes; detector, UV 254 nm (45 mg, 49%, yellow solid). HPLC: 98.4% purity, RT = 4.24 min. MS: m / z = 449.4 [M+H] + . 1 H NMR (300MHz, DMSO-d6, ppm) δ8.95-8.87 (m, 1H), 8.70 (d, J=8.8, 1.7Hz, 1H), 7 .94-7.84(m, 2H), 7.55-7.44(m, 1H), 6.72(d, J=8.5Hz, 1H), 4.50-4.41(m, 1H) , 4.04-3.92(m, 1H), 3.66-3.46(m, 2H), 3.40-3.30(m, 1H), 2.36-2.30(m, 2H) , 2.22-1.99(m, 8H), 1.58-1.44(m, 2H), 1.34-1.27(m, 2H), 1.03-0.91(m, 6H).
[0360] Compound 31 ((2S)-2-hydroxy-3-methyl-N-[(3R, 4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]butanamide): synthesized from (3R, 4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-amine and (2S)-2-hydroxy-3-methylbutanoic acid, and purified by preparative HPLC under the following conditions: column, XBridge ShieldPrep C18 OBD column, 150mm, 5um; mobile phase, acetonitrile / water (with 10mmol / LNH4HCO3 and 0.1% NH3.H2O), gradient from 40% to 56% in 7 minutes; detector, UV 254nm (42mg, 53%, yellow solid). HPLC: 98.2% purity, RT = 4.89 min. MS: m / z = 396.1 [M+H] + . 1H NMR (300MHz, DMSO-d6, ppm) δ8.94-8.86 (m, 1H), 8.72 (d, J=8.8, 1.7Hz, 1H), 7.88 (d, J= 8.4Hz, 1H), 7.67 (d, J=8.5Hz, 1H), 7.53-7.42 (m, 1H), 6.74 (d, J=8.5Hz, 1H), 4.58-4.3 6(m, 1H), 3.96-3.84(m, 1H), 3.72-3.60(m, 2H), 3.59-3.42(m, 2H), 2.60-2.49(m, 1H), 2.06-1.91 (m, 1H), 0.97 (d, J=6.8Hz, 3H), 0.88 (d, J=6.9Hz, 3H), 0.79 (d, J=6.7Hz, 3H).
[0361] Compound 32 ((2R)-2-hydroxy-3-methyl-N-[(3R, 4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]butanamide): synthesized from (3R, 4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-amine (60 mg, 0.20 mmol) and (2S)-2-hydroxy-3-methylbutanoic acid, and purified by preparative HPLC under the following conditions: column, XBridge Shield Prep C18 OBD column, 150 mm, 5 um; mobile phase, acetonitrile / water (with 10 mmol / L NH4HCO3 and 0.1% NH3.H2O), gradient from 40% to 56% in 7 minutes; detector, UV 254 nm (42 mg, 52%, yellow solid). HPLC: 97.6% purity, RT = 1.68 min. MS: m / z = 396.2 [M+H] + . 1 H NMR (300MHz, methanol-d4, ppm) δ8.89-8.80 (m, 1H), 8.73 (d, J=8.8, 1.7Hz, 1H), 7.91 (d , J=8.5Hz, 1H), 7.53-7.42 (m, 1H), 6.87 (d, J=8.5Hz, 1H), 4.64-4.55 (m, 1H), 4.0 3-3.86(m, 2H), 3.77-3.64(m, 1H), 3.61-3.43(m, 2H), 2.75-2.59(m, 1H), 2.14-1 .97 (m, 1H), 1.11 (d, J=6.9Hz, 3H), 0.98 (d, J=6.9Hz, 3H), 0.80 (d, J=6.8Hz, 3H).
[0362] Example 9: Synthesis of Compounds 19 and 20 (N-[(3R, 4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]-2-[(3S)-1-methylpiperidin-3-yl]acetamide and N-[(3R, 4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]-2-[(3R)-1-methylpiperidin-3-yl]acetamide)
[0363]
[0364] N-[(3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]-2-[(3S)-1-methylpiperidin-3-yl]acetamide and N-[(3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]-2-[(3R)-1-methylpiperidin-3-yl]acetamide: To a solution of (3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-amine (119 mg, 0.40 mmol) in N,N-dimethylformamide (5 mL) were added 2-(1-methylpiperidin-3-yl)acetic acid (152 mg, 0.97 mmol), DIEA (76 mg, 0.59 mmol) and HATU (735 mg, 1.93 mmol) at room temperature. The resulting mixture was stirred at room temperature for 3 h. When the reaction was complete, the reaction mixture was concentrated under reduced pressure, and the residue was first purified by preparative HPLC under the following conditions: column, XBridge Prep C18 OBD column, 150 mm, 5 um; mobile phase, acetonitrile / water (with 10 mmol / L NH4HCO3 and 0.1% NH3.H2O), 40% to 70% gradient in 7 minutes; detector, UV 254 nm. The two diastereomers were then separated on chiral preparative HPLC under the following conditions: column, CHIRALPAK IG,
[0365] 0.46x15cm, 3um; mobile phase, hexane (with 0.1% DEA) / EtOH, 88% isocratic, within 30min; detector, UV254nm.
[0366] Isomer 1: (20 mg, 11%, yellow solid) HPLC: 97.8% purity, RT = 2.39 min. MS: m / z = 435.3 [M+H] + . 1H NMR (300MHz, DMSO-d6, ppm) δ8.95-8.87 (m, 1H), 8.70 (d, J=8.8, 1.7Hz, 1H), 8.00-7.85 (m, 2H ), 7.55-7.44 (m, 1H), 6.73 (d, J=8.5Hz, 1H), 4.58-4.37 (m, 1H), 4.04-3.92 (m, 1H), 3.69-3.5 7(m, 1H), 3.59-3.46(m, 1H), 3.38-3.27(m, 1H), 2.62-2.51(m, 3H), 2.14-1.94(m, 5H), 1.88- 1.73 (m, 2H), 1.65-1.48 (m, 3H), 1.44-1.33 (m, 1H), 0.97 (d, J=6.7Hz, 3H), 0.91-0.74 (m, 1H).
[0367] Isomer 2: (25 mg, 14%, yellow solid) HPLC: 99.5% purity, RT = 1.25 min. MS: m / z = 435.3 [M+H] + . 1 H NMR (300MHz, DMSO-d6, ppm) δ8.94-8.86 (m, 1H), 8.69 (d, 1H), 7.99-7.83 (m, 2H), 7.54-7. 43(m, 1H), 6.72(d, J=8.6Hz, 1H), 4.50-4.41(m, 1H), 4.04-3.92(m, 1H), 3.67-3.55(m, 1H ), 3.58-3.45(m, 1H), 3.37-3.25(m, 2H), 2.62-2.52(m, 2H), 2.12-1.97(m, 5H), 1.92-1.7 3 (m, 2H), 1.60-1.49 (m, 3H), 1.45-1.34 (m, 1H), 0.96 (d, J=6.8Hz, 3H), 0.88-0.78 (m, 1H).
[0368] The following compounds were synthesized in a similar manner:
[0369] Compounds 21 and 22 (N-[(3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]-2-[(3S)-1-methylpyrrolidin-3-yl]acetamide and N-[(3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]-2-[(3R)-1-methylpyrrolidin-3-yl]acetamide): synthesized from (3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-amine (109 mg, 0.37 mmol) and 2-(1-methylpyrrolidin-3-yl)acetic acid and purified by preparative HPLC under the following conditions: column, XBridge Prep C18 OBD column, 150 mm, 5 um; mobile phase, acetonitrile / water (with 0.05% NH3.H2O), 39% to 54% gradient in 8 minutes; detector, UV 254 nm. The two diastereomers were obtained by separation on chiral preparative HPLC under the following conditions: column, CHIRALPAK IC-3, 0.46x15 cm, 3 um; mobile phase, hexane (with 0.1% DEA) / IPA, 50% isocratic in 30 min; detector, UV 254 nm. Isomer 1: (20 mg, 11%, yellow solid) HPLC: 99.5% purity, RT = 2.87 min. MS: m / z = 421.2 [M+H] + . 1 H NMR (300MHz, DMSO-d6, ppm) δ8.95-8.86 (m, 1H), 8.69 (d, J=8.7, 1.7Hz, 1H), 7.98 (d, J=8.3Hz, 1H), 7.88 (d, J=8.5Hz, 1H), 7.54-7.43 (m, 1H), 6.72 (d, J=8.5Hz, 1H), 4.50-4.41 (m, 1H), 4.03-3.91 (m, 1H), 3.67 -3.45 (m, 2H), 3.37-3.27 (m, 1H), 2.58-2.30 (m, 5H), 2.26-2.01 (m, 6H), 1.91-1.73 (m, 1H), 1.39-1.21 (m, 1H), 0.96 (d, J = 6.7 Hz, 3H). Isomer 2: (20 mg, 11%, yellow solid) HPLC: 98.8% purity, RT = 2.88 min. MS: m / z = 421.1 [M+H] + . 1H NMR (300MHz, DMSO-d6, ppm) δ8.94-8.86 (m, 1H), 8.74-8.64 (m, 1H), 7.99 (d, J=8.3H z, 1H), 7.88 (d, J=8.5Hz, 1H), 7.54-7.43 (m, 1H), 6.72 (d, J=8.5Hz, 1H), 4.49-4.42 (m, 1H), 4.04-3.92 (m, 1H), 3.67-3.45 (m, 2H), 3.36-3.29 (m, 1H), 2.59-2.33 (m, 5H ), 2.28-2.05 (m, 6H), 1.97-1.79 (m, 1H), 1.44-1.26 (m, 1H), 0.96 (d, J=6.8Hz, 3H).
[0370] Compounds 29 and 30 ((2S)-2-cyclopropyl-2-hydroxy-N-[(3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]acetamide and (2R)-2-cyclopropyl-2-hydroxy-N-[(3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]acetamide): synthesized from (3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-amine and 2-cyclopropyl-2-hydroxyacetic acid, and purified by preparative HPLC under the following conditions: column, XBridge Prep C18 OBD column, 150 mm, 5 um; mobile phase, acetonitrile / water (with 10 mmol / L NH4HCO3 and 0.1% NH3.H2O), 35% to 52% gradient in 7 minutes; detector, UV 254nm. The two diastereomers were obtained by separation on chiral preparative HPLC under the following conditions: column, CHIRALPAK IA-3, 0.46x15cm, 3um; mobile phase, hexane (with 0.1% DEA) / EtOH, 90% isocratic, in 30min; detector, UV 254nm. Isomer 1: (25mg, 19%, yellow solid) HPLC: 99.8% purity, RT = 1.59min.MS: m / z = 394.1 [M+H] + . 1H NMR (300MHz, DMSO-d6, ppm) δ8.94-8.86 (m, 1H), 8.71 (d, J=8.7, 1.7Hz, 1H), 7.89 (d, J=8.5Hz , 1H), 7.74 (d, J=8.4Hz, 1H), 7.54-7.43 (m, 1H), 6.73 (d, J=8.5Hz, 1H), 4.53-4.46 (m, 1H), 4. 02-3.89 (m, 1H), 3.72-3.60 (m, 1H), 3.55-3.40 (m, 3H), 2.60-2.51 (m, 1H), 1.09-0.93 (m, 4H), 0.43-0.21 (m, 4H). Isomer 2: (18 mg, 10%, yellow solid) HPLC: 99.7% purity, RT = 2.30 min. MS: m / z = 394.1 [M+H] + . 1 HNMR (300MHz, methanol-d4, ppm) δ8.89-8.80 (m, 1H), 8.75 (d, J=8.8, 1.7Hz, 1H), 7.91 (d, J=8.4Hz, 1H), 7.53-7.42 (m, 1H), 6.88 (d, J=8.4Hz, 1H ), 4.66-4.59(m, 1H), 4.03-3.91(m, 1H), 3.76-3.63(m, 2H), 3.60-3.43(m, 2H), 2.75-2.59(m, 1H), 1.24-1.07(m, 4H), 0.57-0.37(m, 4H).
[0371] Example 10: Synthesis of Compound 25 (2-(4-fluoropiperidin-4-yl)-N-[(3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]acetamide)
[0372]
[0373] tert-Butyl 4-fluoro-4-([[(3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]carbamoyl]methyl)piperidine-1-carboxylate: To a solution of (3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-amine (48 mg, 0.16 mmol) in N,N-dimethylformamide (1 mL) was added 2-[1-[(tert-butoxy)carbonyl]-4-fluoropiperidin-4-yl]acetic acid (82 mg, 0.31 mmol), DIEA (31 mg, 0.24 mmol) and HATU (307 mg, 0.81 mmol) at room temperature. The resulting solution was stirred at room temperature for 3 hours. When the reaction was complete, the reaction mixture was diluted with water (10 mL), and the resulting mixture was extracted with ethyl acetate (30 mL×3). The organic phases were combined, washed with brine and dried over Na2SO4. The solvent was removed under reduced pressure to give tert-butyl 4-fluoro-4-([[(3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]carbamoyl]methyl)piperidine-1-carboxylate as a yellow solid (80 mg, crude).
[0374] 2-(4-Fluoropiperidin-4-yl)-N-[(3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]acetamide: To a solution of tert-butyl 4-fluoro-4-([[(3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]carbamoyl]methyl)piperidine-1-carboxylate (80 mg, crude) in methanol (3 mL) was added hydrogen chloride solution (6N / dioxane, 2 mL, 12 mmol) at room temperature. The resulting mixture was stirred at room temperature for 2 h. When the reaction was complete, the reaction mixture was concentrated under reduced pressure, and the residue was purified by preparative HPLC under the following conditions: column, XBridge Shield PrepC18 OBD column, 150 mm, 5 um, 13 nm; mobile phase, acetonitrile / water (with 10 mmol / L NH4HCO3 and 0.1% NH3.H2O), 32% to 38% gradient in 7 minutes; detector, UV 254 nm. 2-(4-fluoropiperidin-4-yl)-N-[(3R, 4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]acetamide was obtained as a yellow solid (12 mg, 1.3%, 2 steps).
[0375] Compound 25: HPLC: 95.2% purity, RT = 2.93 min. MS: m / z = 439.4 [M+H] + . 1H NMR (300MHz, DMSO-d6, ppm) δ 8.86-8.78 (m, 1H), 8.61 (d, J = 8.8Hz, 1H), 7.80 (d, J = 8.5Hz, 1H), 7.67 (d, J = 7.5Hz, 1H), 7.45-7.34 (m, 1H), 6.70 (d, J = 8.4Hz, 1H), 4.52-4.43 (m, 1H), 4.10-3.90 (m, 1H), 3.63-3.45 (m, 3H), 2.8 1-2.60 (m, 4H), 2.40-2.20 (m, 4H), 1.85-1.55 (m, 4H), 1.05-0.85 (m, 3H).
[0376] Example 11: Synthesis of Compound 26 (2-(4-fluoro-1-methylpiperidin-4-yl)-N-[(3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]acetamide)
[0377]
[0378] 2-(4-Fluoro-1-methylpiperidin-4-yl)-N-[(3R, 4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]acetamide: To a solution of 2-(4-fluoropiperidin-4-yl)-N-[(3R, 4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]acetamide (48 mg, 0.11 mmol) in methanol (3 mL) was added (CH2O)n (95 mg, 1.05 mmol), NaOAC (190 mg, 2.32 mmol) and NaBH4 (66 mg, 1.76 mmol) at room temperature. The resulting mixture was stirred at room temperature for 12 hours. When the reaction was complete, it was quenched by the addition of water (5 mL). The resulting mixture was extracted with ethyl acetate (30 mL×3). The organic phases were combined, washed with brine and dried over Na2SO4. The solvent was removed under reduced pressure, and the residue was purified by preparative HPLC under the following conditions: column, XBridge Shield Prep C18 OBD column, 150 mm, 5 um, 13 nm; mobile phase, acetonitrile / water (with 10 mmol / L NH4HCO3 and 0.1% NH3.H2O), 30% to 55% gradient in 7 minutes; detector, UV 254 nm. 2-(4-fluoro-1-methylpiperidin-4-yl)-N-[(3R, 4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]acetamide was obtained as a yellow solid (20 mg, 40%).
[0379] Compound 26: HPLC: 98.3% purity, RT = 3.39 min. MS: m / z = 453.5 [M+H] + . 1 H NMR (300MHz, methanol-d4, ppm) δ8.88-8.79 (m, 1H), 8.74 (d, J=8.8, 1.7Hz, 1H), 7.90 (d, J =8.5Hz, 1H), 7.51-7.40 (m, 1H), 6.83 (d, J = 8.5Hz, 1H), 4.65-4.54 (m, 1H), 4.05-3.9 3(m, 1H), 3.72-3.60(m, 1H), 3.62-3.49(m, 1H), 3.47-3.36(m, 1H), 2.74-2.45(m, 5 H), 2.40-2.26 (m, 5H), 1.95-1.89 (m, 3H), 1.98-1.75 (m, 1H), 1.09 (d, J=6.8Hz, 3H).
[0380] Example 12: Synthesis of Compounds 27 and 28 (2-[(4S)-3,3-difluoro-1-methylpiperidin-4-yl]-N-[(3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]acetamide and 2-[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]-N-[(3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]acetamide)
[0381]
[0382] tert-Butyl 3,3-difluoro-4-([[(3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]carbamoyl]methyl)piperidine-1-carboxylate: To a solution of (3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-amine (50 mg, 0.17 mmol) in dichloromethane (3 mL) was added 2-[1-[(tert-butoxy)carbonyl]-3,3-difluoropiperidin-4-yl]acetic acid (62 mg, 0.22 mmol), DIEA (32 mg, 0.24 mmol) and HATU (307 mg, 0.81 mmol) at room temperature. The resulting solution was stirred at room temperature for 3 hours. When the reaction was complete, it was quenched by adding water (10 mL). The resulting mixture was extracted with ethyl acetate (50 mL×3). The organic phases were combined, washed with brine and dried over Na2SO4. The solution was concentrated under reduced pressure to give 3,3-difluoro-4-([[(3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]carbamoyl]methyl)piperidine-1-carboxylate as a yellow solid (80 mg, crude). MS: m / z = 557.5 [M+H] + .
[0383] 3,3-difluoro-4-([[(3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]carbamoyl]methyl)piperidine-1-carboxylic acid tert-butyl ester: To a solution of 3,3-difluoro-4-([[(3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]carbamoyl]methyl)piperidine-1-carboxylic acid tert-butyl ester (80 mg, crude) in methanol (3 mL) was added hydrogen chloride solution (6N / dioxane, 2 mL, 12 mmol) at room temperature. The resulting mixture was stirred at room temperature for 3 h. When the reaction was complete, it was quenched by adding water (10 mL). The pH value of the resulting mixture was adjusted to 8 with saturated NaHCO3 solution. The resulting mixture was extracted with ethyl acetate (50 mL×3). The organic phases were combined, washed with brine and dried over Na2SO4. The solvent was removed under reduced pressure to give 2-(3,3-difluoropiperidin-4-yl)-N-[(3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]acetamide as a yellow solid (60 mg, crude product). MS: m / z = 557.5 [M+H] + .
[0384] 2-[(4S)-3,3-difluoro-1-methylpiperidin-4-yl]-N-[(3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]acetamide and 2-[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]-N-[(3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]acetamide: 2-(3 To a solution of (4-(3-(trifluoromethyl)quinolin-5-yl)-N-[(3R,4R)-4-methyl-1-[8-(trifluoromethyl)quinolin-5-yl]pyrrolidin-3-yl]acetamide (60 mg, crude) in methanol (4 mL) was added (CH2O)n (110 mg, 2.45 mmol), NaOAC (200 mg, 4.86 mmol) and NaBH4 (72 mg, 3.79 mmol) at room temperature. The resulting mixture was stirred at room temperature for 16 hours. When the reaction was complete, the reaction mixture was concentrated under reduced pressure, and the residue was first purified by preparative HPLC under the following conditions: column, XBridge Prep C18 OBD column, 150 mm, 5 um; mobile phase, acetonitrile / water (with 10 mmol / L NH4HCO3 and 0.1% NH3.H2O), 35% to 50% gradient in 8 minutes; detector, UV 254 nm. The two diastereomers were then obtained by separation on chiral preparative HPLC under the following conditions: column, CHIRALPAK IC-3, 0.46x15cm, 3um; mobile phase, hexane (with 0.1% DEA) / IPA, 50% isocratic in 20min; detector, UV 254nm.
[0385] Isomer 1: (12 mg, 15%, 3 steps, off-white solid) HPLC: 99.0% purity, RT = 3.06 min. MS: m / z = 471.5 [M+H] + . 1H NMR (300MHz, DMSP-d6, ppm) δ8.96-8.87 (m, 1H), 8.75-8.65 (m, 1H), 8.12 (d, J=8.4Hz, 1H), 7. 90 (d, J=8.4Hz, 1H), 7.55-7.44 (m, 1H), 6.73 (d, J=8.5Hz, 1H), 4.51-4.42 (m, 1H), 4.06-3.94 (m, 1H), 3.68-3.46 (m, 2H), 2.98-2.86 (m, 1H), 2.67-2.56 (m, 1H), 2.50-2.44 (m, 2H), 2.29-2 .02 (m, 7H), 1.98-1.84 (m, 1H), 1.64-1.52 (m, 1H), 1.38-1.20 (m, 1H), 0.98 (d, J=6.7Hz, 3H).
[0386] Isomer 2: (12 mg, 15%, 3 steps, yellow solid) HPLC: 99.5% purity, RT = 3.01 min. MS: m / z = 471.5 [M+H] + . 1 HNMR (300MHz, DMSO-d6, ppm) δ9.01-8.93 (m, 1H), 8.83-8.71 (m, 1H), 8.20 (d, J=8.4Hz, 1H), 7 .95 (d, J=8.5Hz, 1H), 7.61-7.50 (m, 1H), 6.79 (d, J=8.6Hz, 1H), 4.64-4.40 (m, 1H), 4.10-3.9 8(m, 1H), 3.74-3.62(m, 1H), 3.65-3.52(m, 1H), 3.14-2.83(m, 2H), 2.82-2.71(m, 1H), 2.53- 2.47 (m, 1H), 2.38-1.88 (m, 8H), 1.81-1.70 (m, 1H), 1.52-1.34 (m, 1H), 1.02 (d, J=6.7Hz, 3H).
[0387] Example 13: Synthesis of Compound 33 ((3R, 4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-amine)
[0388]
[0389] 5-Bromo-8-methylquinoline: To a mixture of 5-bromo-2-methylaniline (980 mg, 5.27 mmol) in HCl solution (2M, 30 mL) was added 3,3-diethoxyprop-1-ene (1.67 g, 12.80 mmol) at room temperature. The resulting mixture was stirred at 110°C for 16 hours. When the reaction was complete, the pH value of the reaction mixture was adjusted to 7-8 with sodium bicarbonate solution (4 M). The resulting mixture was extracted with DCM (100 mL×3). The organic phases were combined, washed with brine and dried over Na2SO4. The organic phases were combined, washed with brine and dried over Na2SO4. The solvent was removed under reduced pressure, and the residue was purified by flash chromatography, eluted with EtOAc / hexane (0% to 70% gradient) to give 5-bromo-8-methylquinoline as a yellow solid (360 mg, 30%). MS: m / z=223.9[M+H] + .
[0390] N-[(3R, 4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]carbamic acid tert-butyl ester: To a solution of 5-bromo-8-methylquinoline (360 mg, 1.62 mmol) in N, N-dimethylformamide (10 mL) was added N-[(3R, 4R)-4-methylpyrrolidin-3-yl]carbamic acid tert-butyl ester (342 mg, 1.71 mmol), Pd2(dba)3CHCl3 (177 mg, 0.17 mmol), K3PO4 (1088 mg, 5.12 mmol) and Davephos (135 mg, 0.34 mmol) at room temperature. The resulting mixture was stirred at 130°C for 3 hours. When the reaction was complete, it was quenched by adding water (20 mL). The resulting mixture was extracted with DCM (100 mL×3). The organic phases were combined, washed with brine and dried over Na2SO4. The organic phases were combined, washed with brine and dried over Na2SO4. The solvent was removed under reduced pressure and the residue was purified by flash chromatography eluting with EtOAc / hexane (0% to 25% gradient) to give tert-butyl N-[(3R, 4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]carbamate as a yellow oil (400 mg, 72%). MS: m / z=342.2 [M+H] + .
[0391] (3R, 4R) -4-methyl-1- (8-methylquinolin-5-yl) pyrrolidin-3-amine: To a solution of tert-butyl N- [(3R, 4R) -4-methyl-1- (8-methylquinolin-5-yl) pyrrolidin-3-yl] carbamate (200 mg, 0.59 mmol) in methanol (5 mL) was added a solution of hydrogen chloride (4M / dioxane, 3 mL, 12 mmol) at room temperature. The resulting mixture was stirred at room temperature for 1 h. When the reaction was complete, the reaction mixture was concentrated under reduced pressure and the residue was purified by preparative HPLC under the following conditions: column, XBridge Shield Prep C18 OBD column, 150 mm, 5 um; mobile phase, acetonitrile / water (with 10 mmol / L NH4HCO3 and 0.1% NH3.H2O), 5% to 60% gradient in 7 minutes; detector, UV 254nm. (3R,4R)-4-Methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-amine was obtained as a yellow solid (60 mg, 42%).
[0392] Compound 33: HPLC: 99.5% purity, RT = 1.07 min. MS: m / z = 242.3 [M+H] + . 1 H NMR (300MHz, methanol-d4, ppm) δ 8.82-8.74 (m, 1H), 8.71-8.61 (m, 1H), 7.48-7.37 (m, 2H), 6.92 (d, J=7.9Hz, 1H), 3.77-3.65 (m, 1H), 3. 62-3.51 (m, 1H), 3.50-3.38 (m, 1H), 3.37-3.25 (m, 1H), 3.23-3.12 (m, 1H), 2.63 (s, 3H), 2.56-2.40 (m, 1H), 1.14 (d, J=7.0Hz, 3H).
[0393] Example 14: Synthesis of Compound 34 (N-[(3R, 4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]-2-(1-methylpiperidin-4-yl)acetamide)
[0394]
[0395] N-[(3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]-2-(1-methylpiperidin-4-yl)acetamide: To a solution of (3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-amine (40 mg, 0.16 mmol) in N-dimethylformamide (2 mL) was added 2-(1-methylpiperidin-4-yl)acetic acid (38 mg, 0.24 mmol), HATU (91 mg, 0.24 mmol) and DIEA (101 mg, 0.78 mmol) at room temperature. The resulting solution was stirred at room temperature for 14 hours. When the reaction was completed, the reaction mixture was concentrated under reduced pressure, and the residue was purified by preparative HPLC under the following conditions: column, XBridgeShield Prep C18 OBD column, 150 mm, 5 um; mobile phase, acetonitrile / water (with 10 mmol / L NH4HCO3 and 0.1% NH3.H2O), 5% to 61% gradient in 7 minutes; detector, UV 254 nm. N-[(3R, 4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]-2-(1-methylpiperidin-4-yl)acetamide was obtained as a yellow solid (20 mg, 31%).
[0396] Compound 34: HPLC: 97.4% purity, RT = 2.79 min. MS: m / z = 381.4 [M+H] + . 1 H NMR (300 MHz, methanol-d4, ppm) δ 8.84-8.75 (m, 1H), 8.73-8.59 (m, 1H), 7.50-7.39 (m, 2H), 6.96 (d, J = 7.8 Hz, 1H), 4.68-4.56 (m, 1H), 3.80-3.68 (m, 1H), 3.51-3.39 (m, 1H), 3.32- 3.19(m, 1H), 3.21-3.10(m, 1H), 2.90-2.78(m, 2H), 2.71-2.52(m, 4H), 2.30-2.12(m, 5H), 2.09-1.93 (m, 2H), 1.88-1.62 (m, 3H), 1.42-1.17 (m, 2H), 1.06 (d, J=7.0Hz, 3H).
[0397] The following compounds were synthesized in a similar manner:
[0398] Compound 39 (N-[(3R, 4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]-2-(morpholin-4-yl)acetamide): synthesized from (3R, 4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-amine and 2-(morpholin-4-yl)acetic acid and purified by preparative HPLC under the following conditions: column, XBridge Shield Prep C18 OBD column, 150 mm, 5 um; mobile phase, acetonitrile / water (with 10 mmol / L NH4HCO3 and 0.1% NH3.H2O), 20% to 50% gradient in 8 minutes; detector, UV 254 nm (20 mg, 24%, yellow solid). HPLC: 99.1% purity, RT = 1.29 min. MS: m / z = 369.4 [M+H] + . 1 H NMR (300MHz, methanol-d4, ppm) δ8.85-8.76 (m, 1H), 8.69-8.59 (m, 1H), 7.52-7.41 (m, 2H), 7.00 (d, J=7.8Hz, 1H), 4.66-4.54 (m, 1H), 3.81- 3.64 (m, 5H), 3.50-3.37 (m, 1H), 3.31-3.11 (m, 3H), 3.12-2.99 (m, 2H), 2.78-2.57 (m, 4H), 2.62-2.45 (m, 4H), 1.08 (d, J=7.0Hz, 3H).
[0399] Compound 40 (2-(1,4-dimethylpiperidin-4-yl)-N-[(3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]acetamide): synthesized from (3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-amine and 2-(1,4-dimethylpiperidin-4-yl)acetic acid, and purified by preparative HPLC under the following conditions: column, XBridge ShieldPrep C18 OBD column, 150 mm, 5 um; mobile phase, acetonitrile / water (with 10 mmol / L NH4HCO3 and 0.1% NH3.H2O), gradient from 30% to 60% in 8 minutes; detector, UV 254 nm (10 mg, 15%, light yellow solid). HPLC: 97.3% purity, RT = 2.30 min. MS: m / z = 395.4 [M+H] + . 1H NMR (300MHz, DMSO-d6, ppm) δ8.83-8.74 (m, 1H), 8.54-8.44 (m, 1H), 7.83 (d, J=8.3Hz, 1H), 7.4 2-7.31 (m, 2H), 6.77 (d, J=7.7Hz, 1H), 4.49-4.34 (m, 1H), 3.68-3.57 (m, 1H), 3.40-3.31 (m, 2H ), 3.23-3.11(m, 1H), 3.07-2.96(m, 1H), 2.55-2.49(m, 4H), 2.45-2.31(m, 2H), 2.23(s, 3H), 2 .15-1.98(m, 2H), 1.60-1.47(m, 2H), 1.39-1.25(m, 2H), 1.20-1.13(m, 1H), 0.92-0.88(m, 6H).
[0400] Compound 47 ((2S)-2-hydroxy-3-methyl-N-[(3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]butanamide): synthesized from (3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-amine and (2S)-2-hydroxy-3-methylbutyric acid and purified by preparative HPLC under the following conditions: column, XBridge Shield Prep C18 OBD column, 150 mm, 5 um; mobile phase, acetonitrile / water (with 10 mmol / L NH4HCO3 and 0.1% NH3.H2O), 35% to 45% gradient in 7 minutes; detector, UV 254 nm (20 mg, 24%, orange solid). HPLC: 99.6% purity, RT = 1.40 min. MS: m / z = 342.4 [M+H] + . 1 H NMR (300 MHz, methanol-d4, ppm) δ 8.85-8.77 (m, 1H), 8.71-8.61 (m, 1H), 7.53-7.42 (m, 2H), 7.00 (d, J = 7.8 Hz, 1H), 4.70-4.58 (m, 1H), 3.94-3.86 (m, 1H), 3.80-3.6 8(m, 1H), 3.53-3.40(m, 1H), 3.32-3.16(m, 2H), 2.76-2.60(m, 4H), 2.22-2.0 5 (m, 1H), 1.10 (d, J=7.0Hz, 3H), 1.03 (d, J=7.0Hz, 3H), 0.92 (d, J=6.8Hz, 3H).
[0401] Compound 48 ((2R)-2-hydroxy-3-methyl-N-[(3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]butanamide): synthesized from (3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-amine and (2R)-2-hydroxy-3-methylbutyric acid and purified by preparative HPLC under the following conditions: column, XBridge Shield Prep C18 OBD column, 150 mm, 5 um; mobile phase, acetonitrile / water (with 10 mmol / L NH4HCO3 and 0.1% NH3.H2O), 35% to 45% gradient in 7 minutes; detector, UV 254 nm (23 mg, 29%, orange solid). HPLC: 99.7% purity, RT = 1.39 min. MS: m / z = 342.4 [M+H] + . 1 H NMR (300 MHz, methanol-d4, ppm) δ 8.85-8.77 (m, 1H), 8.70-8.60 (m, 1H), 7.52-7.41 (m, 2H), 7.01 (d, J = 7.8 Hz, 1H), 4.69-4.56 (m, 1H), 3.94 (d, J = 3.6 Hz, 1H), 3.79-3 .67(m, 1H), 3.53-3.41(m, 1H), 3.31-3.15(m, 2H), 2.77-2.62(m, 4H), 2.18-2. 00 (m, 1H), 1.10 (d, J=7.0Hz, 3H), 1.01 (d, J=6.9Hz, 3H), 0.84 (d, J=6.8Hz, 3H).
[0402] Example 15: Synthesis of Compounds 35 and 36 (N-[(3R, 4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]-2-[(3S)-1-methylpiperidin-3-yl]acetamide and N-[(3R, 4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]-2-[(3R)-1-methylpiperidin-3-yl]acetamide)
[0403]
[0404] N-[(3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]-2-[(3S)-1-methylpiperidin-3-yl]acetamide and N-[(3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]-2-[(3R)-1-methylpiperidin-3-yl]acetamide: To a solution of (3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-amine (49 mg, 0.20 mmol) in N,N-dimethylformamide (3 mL) was added 2-(1-methylpiperidin-3-yl)acetic acid (46 mg, 0.30 mmol), HATU (120 mg, 0.30 mmol) and DIEA (126 mg, 0.98 mmol) at room temperature. The resulting solution was stirred at room temperature for 14 hours. When the reaction was complete, the reaction mixture was concentrated under reduced pressure, and the residue was first purified by preparative HPLC under the following conditions: column, XBridge Prep C18 OBD column, 150 mm, 5 um; mobile phase, acetonitrile / water (with 10 mmol / L NH4HCO3 and 0.1% NH3.H2O), 20% to 57% gradient in 7 minutes; detector, UV 254 nm. Then two diastereomers were obtained by separation on chiral preparative HPLC under the following conditions: column, CHIRALPAK IG-3, 0.46 x 10 cm, 3 um; mobile phase, hexane (with 0.1% DEA) / EtOH, 80% isocratic, in 30 min; detector, UV 254 nm.
[0405] Isomer 1: (15 mg, 19%, red solid) HPLC: 99.8% purity, RT = 1.31 min. MS: m / z = 381.2 [M+H] + . 1 H NMR (300MHz, methanol-d4, ppm) δ8.84-8.75 (m, 1H), 8.72-8.62 (m, 1H), 7.50-7.39 (m, 2H), 6.96 (d, J=7.8Hz, 1H), 4.68-4.56 (m, 1H), 3.81-3.69 (m, 1H), 3.51- 3.39(m, 1H), 3.30-3.09(m, 4H), 2.72-2.51(m, 8H), 2.51-2.37(m, 1H), 2.31 -2.09 (m, 3H), 1.91-1.65 (m, 3H), 1.24-1.10 (m, 1H), 1.07 (d, J=6.9Hz, 3H).
[0406] Isomer 2: (18 mg, 10%, yellow solid) HPLC: 99.5% purity, RT = 1.30 min. MS: m / z = 381.2 [M+H]+ . 1 H NMR (300 MHz, methanol-d4, ppm) δ 8.84-8.75 (m, 1H), 8.73-8.63 (m, 1H), 7.51-7.40 (m, 2H), 6.96 (d, J = 7.8 Hz, 1H), 4.69-4.56 (m, 1H), 3.82-3.70 (m, 1H), 3.51-3.35 (m, 2H), 3.38-3.31 (m, 1 H), 3.30-3.21(m, 1H), 3.21-3.10(m, 1H), 2.83-2.69(m, 4H), 2.72-2.54(m, 5H), 2.38-2.2 1 (m, 3H), 2.00-1.83 (m, 2H), 1.86-1.65 (m, 1H), 1.31-1.13 (m, 1H), 1.07 (d, J=6.9Hz, 3H).
[0407] The following compounds were synthesized in a similar manner:
[0408] Compounds 37 and 38 (N-[(3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]-2-[(3S)-1-methylpyrrolidin-3-yl]acetamide and N-[(3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]-2-[(3R)-1-methylpyrrolidin-3-yl]acetamide): synthesized from (3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-amine and 2-(1-methylpyrrolidin-3-yl)acetic acid, purified by preparative HPLC under the following conditions: column, XBridge Prep C18 OBD column, 150 mm, 5 um; mobile phase, acetonitrile / water (with 10 mmol / L NH4HCO3 and 0.1% NH3.H2O), 20% to 47% gradient in 8 minutes; detector, UV 254nm. The two isomers were obtained by separation on chiral preparative HPLC under the following conditions: column, CHIRALPAK IG-3, 0.46x10cm, 3um; mobile phase, MtBE (with 0.1% DEA) / EtOH, 70% isocratic in 30min; detector, UV 254nm. Isomer 1: (25mg, 26%, red solid) HPLC: 97.7% purity, RT = 2.14min.MS: m / z = 367.4 [M+H] + . 1H NMR (400MHz, DMSO-d6, ppm) δ8.89-8.83 (m, 1H), 8.60-8.48 (m, 1H), 7.95 (d, J=8.5Hz, 1H), 7.48-7.4 0 (m, 2H), 6.84 (d, J=7.8Hz, 1H), 4.54-4.43 (m, 1H), 3.74-3.65 (m, 1H), 3.50-3.35 (m, 1H), 3.28-3.18 (m, 1H), 3.13-3.02 (m, 1H), 2.65-2.30 (m, 8H), 2.27-2.05 (m, 6H), 1.94-1.80 (m, 1H), 1.41-1.28 (m, 1H), 0.95 (d, J = 6.9 Hz, 3H). Isomer 2: (25 mg, 26%, yellow solid) HPLC: 95.2% purity, RT = 2.16 min. MS: m / z = 367.4 [M+H] + . 1 H NMR (400MHz, DMSO-d6, ppm) δ8.89-8.83 (m, 1H), 8.60-8.53 (m, 1H), 7.96 (d, J=8.5Hz, 1H), 7.48-7 .40 (m, 2H), 6.84 (d, J=7.8Hz, 1H), 4.54-4.43 (m, 1H), 3.74-3.65 (m, 1H), 3.44-3.35 (m, 1H), 3.28 -3.19(m, 1H), 3.12-3.04(m, 1H), 2.62-2.57(m, 3H), 2.57-2.50(m, 1H), 2.49-2.37(m, 4H), 2.20( d, J=9.5Hz, 5H), 2.15-2.06 (m, 1H), 1.97-1.83 (m, 1H), 1.44-1.31 (m, 1H), 0.95 (d, J=6.8Hz, 3H).
[0409] Compounds 45 and 46 ((2S)-2-cyclopropyl-2-hydroxy-N-[(3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]acetamide and (2R)-2-cyclopropyl-2-hydroxy-N-[(3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]acetamide): synthesized from (3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-amine and 2-cyclopropyl-2-hydroxyacetamide, purified by preparative HPLC under the following conditions: column, XBridge RP18OBD column, 150mm, 5um; mobile phase, acetonitrile / water (with 10mmol / L NH4HCO3 and 0.1% NH3.H2O), gradient from 20% to 50% in 7 minutes; detector, UV 254 nm. Two diastereomers were obtained by separation on chiral preparative HPLC under the following conditions: column, CHIRALPAK IA-3, 0.46x5 cm, 3 um; mobile phase, hexane (with 0.1% DEA) / EtOH, 70% isocratic, over 15 min; detector, UV 254 nm. Isomer 1: (25 mg, 22%, red solid) HPLC: 97.6% purity, RT = 1.26 min. MS: m / z = 340.3 [M+H] + . 1 H NMR (300 MHz, methanol-d4, ppm) δ 9.18-9.08 (m, 1H), 8.92-8.83 (m, 1H), 7.82-7.61 (m, 2H), 7.04 (d, J = 8.1 Hz, 1H), 4.68-4.56 (m, 1H), 3.93-3.81 (m, 1H), 3.67-3.54 (m, 2H), 3.46-3.31 (m, 2H), 2.77-2.61 (m, 4H), 1.11-1.04 (m, 4H), 0.56-0.29 (m, 4H). Isomer 2: (25 mg, 22%, red solid) HPLC: 98.1% purity, RT = 1.26 min. MS: m / z = 340.4 [M+H] + . 1 H NMR (300MHz, methanol-d4, ppm) δ8.87-8.74(m, 2H), 7.59-7.48(m, 2H), 7.02(d, J=7.9Hz, 1H), 4.70-4.58(m, 1H), 3.83-3.72(m , 1H), 3.74-3.65(m, 1H), 3.57-3.44(m, 1H), 3.32-3.20(m, 2H), 2.77-2.62(m, 4H), 1.26-1.05(m, 4H), 0.60-0.37(m, 4H).
[0410] Example 16: Synthesis of Compound 41 (2-(4-fluoropiperidin-4-yl)-N-[(3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]acetamide)
[0411]
[0412] tert-Butyl 4-fluoro-4-([[(3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]carbamoyl]methyl)piperidine-1-carboxylate: To a solution of (3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-amine (59 mg, 0.24 mmol) in N,N-dimethylformamide (3 mL) was added 2-[1-[(tert-butoxy)carbonyl]-4-fluoropiperidin-4-yl]acetic acid (101 mg, 0.39 mmol), HATU (138 mg, 0.36 mmol) and DIEA (153 mg, 1.18 mmol) at room temperature. The resulting solution was stirred at room temperature for 16 hours. When the reaction was complete, the reaction mixture was concentrated under reduced pressure, and the residue was purified by preparative HPLC under the following conditions: column, XBridge Shield Prep C18 OBD column, 150 mm, 5 um; mobile phase, acetonitrile / water (with 10 mmol / L NH4HCO3 and 0.1% NH3.H2O), 32% to 35% gradient in 7 minutes; detector, UV 254 nm. 4-Fluoro-4-([[(3R, 4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]carbamoyl]methyl)piperidine-1-carboxylic acid tert-butyl ester was obtained as a yellow solid (19 mg, 16%). MS: m / z = 485.3 [M+H] + .
[0413] 2-(4-Fluoropiperidin-4-yl)-N-[(3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]acetamide: To a solution of tert-butyl 4-fluoro-4-([[(3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]carbamoyl]methyl)piperidine-1-carboxylate (17 mg, 0.04 mmol) in methanol (3 mL) was added a solution of hydrogen chloride (4M / dioxane, 1 mL, 4 mmol) at room temperature. The resulting mixture was stirred at room temperature for 1 h. When the reaction was complete, the reaction mixture was concentrated under reduced pressure, and the residue was purified by preparative HPLC under the following conditions: column, XBridge Shield Prep C18 OBD column, 150 mm, 5 um; mobile phase, acetonitrile / water (with 10 mmol / L NH4HCO3 and 0.1% NH3.H2O), 32% to 35% gradient in 7 minutes; detector, UV 254 nm. 2-(4-fluoropiperidin-4-yl)-N-[(3R, 4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]acetamide was obtained as a light yellow solid (10 mg, 71%).
[0414] Compound 41: HPLC: 96.3% purity, RT = 0.85 min. MS: m / z = 385.2 [M+H] + . 1 H NMR (300MHz, methanol-d4, ppm) δ8.84-8.76 (m, 1H), 8.74-8.63 (m, 1H), 7.53-7.40 (m, 2H), 7.01-6.92 (m, 1H), 4.69-4.57 (m, 1H) ), 3.82-3.70 (m, 1H), 3.52-3.39 (m, 1H), 3.36-3.00 (m, 6H), 2.82-2.56 (m, 6H), 2.23-1.85 (m, 4H), 1.08 (d, J=7.0Hz, 3H).
[0415] Example 17: Synthesis of Compound 42 (2-(4-fluoro-1-methylpiperidin-4-yl)-N-[(3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]acetamide)
[0416]
[0417] 2-(4-Fluoro-1-methylpiperidin-4-yl)-N-[(3R, 4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]acetamide: To a solution of 2-(4-fluoropiperidin-4-yl)-N-[(3R, 4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]acetamide (176 mg, 0.46 mmol) in MeOH (30 mL) was added (CHO)n (423 mg, 4.69 mmol) and NaOAc (790 mg, 9.64 mmol) at room temperature. The resulting mixture was stirred at room temperature for 2 h, and then NaBH (275 mg, 7.27 mmol) was added in portions. The reaction mixture was stirred at room temperature for another 16 hours. When the reaction was complete, it was quenched by the addition of water (20 mL). The resulting mixture was extracted with DCM (50 mL×3). The organic phases were combined, washed with brine and dried over Na2SO4. The solvent was removed under reduced pressure and the residue was purified by preparative HPLC under the following conditions: column, XBridgeShield Prep C18 OBD column, 150 mm, 5 um; mobile phase, acetonitrile / water (with 10 mmol / L NH4HCO3 and 0.1% NH3.H2O), 30% to 43% gradient in 7 minutes; detector, UV 254 nm. 2-(4-fluoro-1-methylpiperidin-4-yl)-N-[(3R, 4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]acetamide was obtained as a yellow solid (90 mg, 49%).
[0418] Compound 42: HPLC: 96.5% purity, RT = 7.86 min. MS: m / z = 399.4 [M+H] + . 1 H NMR (400MHz, DMSO-d6, ppm) δ8.89-8.83 (m, 1H), 8.60-8.52 (m, 1H), 8.03 (d, J =8.5Hz, 1H), 7.48-7.40 (m, 2H), 6.84 (d, J = 7.8Hz, 1H), 4.55-4.43 (m, 1H), 3. 75-3.66(m, 1H), 3.45-3.36(m, 1H), 3.28-3.19(m, 1H), 3.14-3.06(m, 1H), 2. 62-2.42 (m, 8H), 2.18-2.03 (m, 5H), 1.91-1.68 (m, 4H), 0.97 (d, J=6.8Hz, 3H).
[0419] Example 18: Synthesis of Compounds 43 and 44 (2-[(4S)-3,3-difluoro-1-methylpiperidin-4-yl]-N-[(3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]acetamide and 2-[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]-N-[(3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]acetamide)
[0420]
[0421] tert-Butyl 3,3-difluoro-4-([[(3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]carbamoyl]methyl)piperidine-1-carboxylate: To a solution of (3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-amine (121 mg, 0.50 mmol) in N,N-dimethylformamide (3 mL) was added 2-{1-[(tert-butoxy)carbonyl]-3,3-difluoropiperidin-4-yl}acetic acid (363 mg, 1.30 mmol), HATU (342 mg, 0.90 mmol) and DIEA (380 mg, 2.94 mmol) at room temperature. The resulting solution was stirred at room temperature for 2 h. When the reaction was complete, it was quenched by the addition of water (20 mL). The resulting mixture was extracted with DCM (60 mL×3). The organic phases were combined, washed with brine and dried over Na2SO4. The solvent was removed under reduced pressure to give tert-butyl 3,3-difluoro-4-([[(3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]carbamoyl]methyl)piperidine-1-carboxylate as a yellow oil (300 mg, crude). MS: m / z = 503.4 [M+H] + .
[0422] 2-(3,3-difluoropiperidin-4-yl)-N-[(3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]acetamide: To a solution of tert-butyl 3,3-difluoro-4-([[(3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]carbamoyl]methyl)piperidine-1-carboxylate (300 mg, crude) in methanol (4 mL) was added hydrogen chloride solution (4M / dioxane, 4 mL, 16 mmol) at room temperature. The resulting mixture was stirred at room temperature for 2 h. When the reaction was complete, the pH value of the reaction mixture was adjusted to 7-8 with saturated NaHCO3 solution. The resulting mixture was extracted with ethyl acetate (50 mL×3). The organic phases were combined, washed with brine and dried over Na2SO4. The solvent was removed under reduced pressure to give 2-(3,3-difluoropiperidin-4-yl)-N-[(3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]acetamide as a yellow oil (330 mg, crude product). MS: m / z = 403.4 [M+H] + .
[0423] 2-[(4S)-3,3-difluoro-1-methylpiperidin-4-yl]-N-[(3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]acetamide and 2-[(4R)-3,3-difluoro-1-methylpiperidin-4-yl]-N-[(3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]acetamide: To a solution of 2-(3,3-difluoropiperidin-4-yl)-N-[(3R,4R)-4-methyl-1-(8-methylquinolin-5-yl)pyrrolidin-3-yl]acetamide (330 mg, crude) in methanol (50 mL) were added (CHO)n (684 mg, 7.59 mmol), NaOAC (1.27 g, 15.52 mmol) at room temperature. The resulting mixture was stirred at room temperature for 2 h, and then NaBH4 (444 mg, 11.73 mmol) was added in batches. The reaction mixture was stirred at room temperature for another 16 hours. When the reaction was complete, it was quenched by adding water (20 mL). The resulting mixture was extracted with DCM (50 mL×3). The organic phases were combined, washed with brine and dried over Na2SO4. The solvent was removed under reduced pressure, and the residue was first purified by preparative HPLC under the following conditions: column, XBridge Prep C18 OBD column, 150 mm, 5 um; mobile phase, acetonitrile / water (with 10 mmol / L NH4HCO3 and 0.1% NH3.H2O), 27% to 46% gradient in 7 minutes; detector, UV 254 nm. The two diastereomers were then obtained by separation on chiral preparative HPLC under the following conditions: column, Repaired ADH, 0.46x10 cm, 3 um; mobile phase, hexane (with 0.1% DEA) / EtOH, 70% isocratic in 30 min; detector, UV 254 nm.
[0424] Isomer 1: (15 mg, 7%, 3 steps, off-white solid) HPLC: 97.9% purity, RT = 2.77 min. MS: m / z = 209.1 [M+H] + . 1H NMR (300MHz, methanol-d4, ppm) δ8.83-8.75 (m, 1H), 8.73-8.59 (m, 1H), 7.50-7.39 (m, 2H), 6.96 (d, J=7.8Hz, 1H), 4.68-4.56 (m, 1H), 3.80-3.68 (m, 1H), 3.56- 3.39(m, 1H), 3.29-2.97(m, 3H), 2.87-2.54(m, 6H), 2.40-2.18(m, 6H), 2.16 -2.01 (m, 1H), 1.81-1.69 (m, 1H), 1.61-1.42 (m, 1H), 1.06 (d, J=6.9Hz, 3H).
[0425] Isomer 2: (15 mg, 7%, 3 steps, off-white solid) HPLC: 98.6% purity, RT = 2.70 min. MS: m / z = 209.0 [M+H] + . 1 H NMR (300 MHz, methanol-d4, ppm) δ 8.84-8.75 (m, 1H), 8.74-8.64 (m, 1H), 7.51-7.40 (m, 2H), 6.97 (d, J = 7.8 Hz, 1H), 4.70-4.54 (m, 1H), 3.79-3.67 (m, 1H), 3.52-3.33 (m, 1 H), 3.31-2.98(m, 3H), 2.91-2.81(m, 1H), 2.77-2.55(m, 5H), 2.41-2.20(m, 6H), 2.20-2.06 (m, 1H), 1.91-1.80 (m, 1H), 1.66-1.52 (m, 1H), 1.06 (d, J=6.9Hz, 3H).
[0426] Example 19: Synthesis of Compounds 49 and 50 ((3S, 4R)-4-fluoro-1-(8-trifluoromethyl-quinolin-5-yl)-pyrrolidin-3-ylamine and (3R, 4S)-4-fluoro-1-(8-trifluoromethyl-quinolin-5-yl)-pyrrolidin-3-ylamine)
[0427]
[0428] [cis-4-Fluoro-1-(8-trifluoromethyl-quinolin-5-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester: To a solution of 5-bromo-8-(trifluoromethyl)quinoline (400 mg; 1.45 mmol) in tBuOH (9.0 mL) was added cis-(3-boc-amino)-4-fluoropyrrolidine (355 mg; 1.74 mmol), chloro(2-dicyclohexylphosphino-2′,6′-di-isopropoxy-1,1′-biphenyl)[2-(2-aminoethylphenyl)]palladium(ii), methyl tert-butyl ether adduct (59.2 mg; 0.072 mmol), 2-dicyclohexylphosphino-2′,6′-di-isopropoxy-1,1′-biphenyl (33.8 mg; 0.072 mmol) and cesium carbonate (944 mg; 2.90 mmol). The resulting mixture was flushed with nitrogen for 10 minutes and microwaved at 85°C for 8 hours. The reaction mixture was concentrated under reduced pressure, suspended in DCM (20 mL), sonicated for 30 seconds, and filtered over diatomaceous earth. The solvent was removed under reduced pressure, and the residue was purified by flash chromatography, eluted with EtOAc / hexanes (10% to 80% gradient) to give [cis-4-fluoro-1-(8-trifluoromethyl-quinoline-5-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester as a brown glassy solid (507 mg; 88%). MS: m / z=400[M+H] + .
[0429] (3S, 4R) -4-Fluoro-1- (8-trifluoromethyl-quinoline-5-yl) -pyrrolidin-3-ylamine and (3R, 4S) -4-Fluoro-1- (8-trifluoromethyl-quinoline-5-yl) -pyrrolidin-3-ylamine: To a solution of [cis-4-fluoro-1- (8-trifluoromethyl-quinoline-5-yl) -pyrrolidin-3-yl] -carbamic acid tert-butyl ester (485 mg; 1.21 mmol) in methanol (12 mL) at room temperature was added a solution of hydrogen chloride (4M / dioxane, 9 mL, 36 mmol). The resulting mixture was stirred at room temperature overnight. When the reaction was complete, ether (40 mL) was added to the orange solution, and the yellow suspension was stirred at room temperature for 1 hour. The solid was filtered and dissolved in 5N sodium hydroxide solution. The mixture was extracted with ethyl acetate, and the combined organic phase was washed with brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The two enantiomers were obtained by separation on chiral preparative HPLC under the following conditions: column, LuxCellulose-2, 250x21.20 mm, 5 um; mobile phase, EtOH with 0.5% DMEA, 30% isocratic in 11 min; detector, UV 254 nm.
[0430] Isomer 1: (86 mg, 23%, brown solid) HPLC: 98.9% purity, RT = 1.78 min. MS: m / z = 300 [M+H] + . 1 H NMR (400MHz, chloroform-d, ppm) δ8.86 (d, J=1.7Hz, 1H), 8.64 (d, J=5.6Hz, 1H), 8.60 (d, J=1. 7Hz, 1H), 6.49 (d, J=5.7Hz, 1H), 6.41 (s, 1H), 4.29-4.14 (m, 2H), 4.08 (dt, J=12.2, 7 .3Hz, 1H), 3.91 (q, J=9.2, 8.7Hz, 1H), 3.40-3.26 (m, 2H), 3.06 (p, J=7.6Hz, 1H), 2.5 6 (t, J=6.0Hz, 2H), 2.52 (q, J=7.1Hz, 4H), 2.41-2.24 (m, 2H), 0.99 (t, J=7.1Hz, 6H).
[0431] Isomer 2: (104 mg, 29%, cream solid) HPLC: >99.9% purity, RT = 1.75 min. MS: m / z = 300 [M+H] + . 1 H NMR (400MHz, chloroform-d, ppm) δ8.99 (dd, J=4.1, 1.7Hz, 1H), 8.47 (dd, J=8.7, 1.7Hz, 1H), 7.90 (dd, J=8.4, 0.8Hz, 1H), 7.37 (dd, J=8.7, 4. 1Hz, 1H), 6.75 (d, J=8.3Hz, 1H), 5.05 (dt, J=54.5, 3.4Hz, 1H), 4.05 (ddd, J=37.9, 12.3, 3.6Hz, 1H), 3.79-3.54 (m, 4H), 1.52 (s, 2H).
[0432] Example 20: Synthesis of Compound 51 ((3R, 4R)-4-methyl-1-(8-methyl-[1,7]naphthyridin-5-yl)-pyrrolidin-3-ylamine hydrochloride)
[0433]
[0434] [(3R,4R)-4-methyl-1-(8-methyl-[1,7]naphthyridin-5-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester: To a solution of 5-bromo-8-methyl-[1,7]naphthyridine (100 mg; 0.45 mmol)) in tBuOH (1.5 mL) was added (3R,4R)-3-(boc-amino)-4-methylpyrrolidine (104 mg; 0.49 mmol), Chloro(2-dicyclohexylphosphino-2',6'-di-isopropoxy-1,1'-biphenyl)[2-(2-aminoethylphenyl)]palladium(ii), methyl tert-butyl ether adduct (18.3 mg; 0.02 mmol), 2-dicyclohexylphosphino-2',6'-di-isopropoxy-1,1'-biphenyl (10.5 mg; 0.02 mmol), cesium carbonate (292 mg; 0.90 mmol). The resulting mixture was flushed with nitrogen for 10 minutes and microwaved at 100°C for 8 hours. The reaction mixture was concentrated under reduced pressure and the residue was purified by flash chromatography eluting with EtOAc / hexanes (20% to 80% gradient) to give [(3R,4R)-4-methyl-1-(8-methyl-[1,7]naphthyridin-5-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester as a light yellow solid (70 mg; 46%). MS: m / z = 343 [M+H] + .
[0435] (3R,4R)-4-methyl-1-(8-methyl-[1,7]naphthyridin-5-yl)-pyrrolidin-3-ylamine hydrochloride: To a solution of [(3R,4R)-4-methyl-1-(8-methyl-[1,7]naphthyridin-5-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester (120 mg, 0.35 mmol) in methanol (3 mL) was added hydrogen chloride solution (4M / dioxane, 1.3 mL, 5.3 mmol) at room temperature. The resulting mixture was stirred at room temperature overnight. When the reaction was complete, the mixture was concentrated to dryness to give (3R,4R)-4-methyl-1-(8-methyl-[1,7]naphthyridin-5-yl)-pyrrolidin-3-ylamine hydrochloride as a yellow amorphous solid (110 mg; 97%).
[0436] Compound 51: HPLC: 98.9% purity, RT = 0.93 min. MS: m / z = 243 [M+H] + .
[0437] Example 21: Synthesis of Compound 52 (N-[(3R, 4R)-4-methyl-1-(8-methyl-[1,7]naphthyridin-5-yl)-pyrrolidin-3-yl]-2-(1-methyl-piperidin-4-yl)-acetamide)
[0438]
[0439] N-[(3R,4R)-4-methyl-1-(8-methyl-[1,7]naphthyridin-5-yl)-pyrrolidin-3-yl]-2-(1-methyl-piperidin-4-yl)-acetamide: To a solution of (3R,4R)-4-methyl-1-(8-methyl-[1,7]naphthyridin-5-yl)-pyrrolidin-3-ylamine hydrochloride 30 mg, 0.1 mmol) in N,N-dimethylformamide (1 mL) was added 2-(1-methylpiperidin-4-yl)acetic acid (16.5 mg, 0.105 mmol), DIEA (63 μL, 0.948 mmol) and (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (51 mg, 0.114 mmol). The resulting solution was stirred at room temperature for 1 hour. When the reaction was complete, the solvent was removed under reduced pressure and the residue was purified by preparative HPLC under the following conditions: column, XBridge Prep C18 OBD 10 μm, column, 30×250 mm; mobile phase, acetonitrile / water (with 0.1% NH OH), 10% to 60% gradient in 15 minutes; detector, UV 254 nm. N-[(3R, 4R)-4-methyl-1-(8-methyl-[1,7]naphthyridin-5-yl)-pyrrolidin-3-yl]-2-(1-methyl-piperidin-4-yl)-acetamide was obtained as a white amorphous solid (32 mg, 88%).
[0440] Compound 52: HPLC: >99% purity, RT = 1.30 min. MS: m / z = 382 [M+H] + . 1 H NMR (400MHz, DMSO-d6, ppm) δ8.96 (dd, J=4.1, 1.6Hz, 1H), 8.60 (dd, J=8.7, 1.6Hz, 1H), 7.91 (d, J=8.4Hz, 1H), 7.86 (s, 1 H), 7.66 (dd, J=8.7, 4.1Hz, 1H), 4.48 (dtd, J=9.2, 6.0, 3.4Hz, 1H), 3.85 (dd, J=9.9, 6.0Hz, 1H), 3.51 (dd, J=9.1, 7.3Hz , 1H), 3.36 (d, J=8.9Hz, 1H), 3.20 (dd, J=9.9, 3.4Hz, 1H), 2.81 (s, 3H), 2.73-2.61 (m, 2H), 2.49-2.43 (m, 1H), 2.10 (s, 3 H), 2.08-1.99 (m, 2H), 1.77 (tdd, J=11.3, 5.8, 2.4Hz, 2H), 1.65-1.45 (m, 3H), 1.20-1.05 (m, 2H), 0.97 (d, J=6.8Hz, 3H).
[0441] The following compounds were synthesized in a similar manner:
[0442] Compound 53 (2-(1-methyl-azetidin-3-yl)-N-[(3R,4R)-4-methyl-1-(8-methyl-[1,7]naphthyridin-5-yl)-pyrrolidin-3-yl]-acetamide): synthesized from 8-[(3R,4R)-3-amino-4-methylpyrrolidin-1-yl]quinoxaline-5-carbonitrile and (1-methyl-azetidin-3-yl)-acetic acid hydrochloride, and purified by preparative HPLC under the following conditions: Preparative HPLC under the following conditions: column, XBridge Prep C18 OBD 10μm, column, 30x250mm; mobile phase, acetonitrile / water (with 0.1% NH4OH), gradient from 10% to 60% in 15 minutes; detector, UV 254nm (29 mg, 86%, white amorphous solid). HPLC: >99% purity, RT = 1.24 min. MS: m / z = 354 [M+H] + . 1 H NMR (400MHz, DMSO-d6, ppm) δ8.97 (dd, J=4.1, 1.5Hz, 1H), 8.61 (dd, J=8.7, 1.7Hz, 1H), 7.97 (d, J= 8.5Hz, 1H), 7.87 (s, 1H), 7.67 (dd, J=8.7, 4.1Hz, 1H), 4.46 (dtd, J=9.3, 6.0, 3.4Hz, 1H), 3.85 (dd , J=9.9, 6.0Hz, 1H), 3.51 (dd, J=9.1, 7.3Hz, 1H), 3.38-3.32 (m, 1H), 3.28-3.15 (m, 3H), 2.82 (s, 3 H), 2.78-2.68 (m, 2H), 2.61-2.55 (m, 1H), 2.48-2.31 (m, 3H), 2.14 (s, 3H), 0.95 (d, J=6.9Hz, 3H).
[0443] Example 22: Synthesis of Compound 54 (1-pyrido[2,3-b]pyrazine-8-yl-pyrrolidine-3-carboxylic acid (2-diethylamino-ethyl)-amide)
[0444]
[0445] 3-(2-Diethylamino-ethylcarbamoyl)-pyrrolidine-1-carboxylic acid tert-butyl ester: To a solution of 1-boc-pyrrolidine-3-carboxylic acid (1.0 g, 4.65 mmol) in anhydrous dichloromethane (25.0 mL) was added N, N-diethylethylenediamine (653 μl, 4.65 mmol), DIEA (4.0 ml, 23.2 mmol), and a 50% solution of propylphosphonic anhydride (8.2 mL, 13.9 mmol) in ethyl acetate. The resulting solution was stirred at room temperature for 1 h30 hours. When the reaction was complete, it was diluted with dichloromethane (70 mL), extracted with a saturated solution of sodium bicarbonate (3×50 mL), and washed with brine (50 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by flash chromatography using an NH2-bonded silica column and eluted with EtOAc / hexanes (10% to 60% gradient) to give 3-(2-diethylamino-ethylcarbamoyl)-pyrrolidine-1-carboxylic acid tert-butyl ester as a colorless oil (1.21 g, 83%). MS: m / z=314 [M+H] + .
[0446] Pyrrolidine-3-carboxylic acid (2-diethylamino-ethyl)-amide hydrochloride: To a solution of 3-(2-diethylamino-ethylcarbamoyl)-pyrrolidine-1-carboxylic acid tert-butyl ester (1.2 g; 3.73 mmol) in methanol (30 mL) was added a solution of hydrogen chloride (4M / dioxane, 28 mL, 112 mmol) at room temperature. The resulting mixture was stirred at room temperature overnight. When the reaction was complete, the mixture was concentrated under reduced pressure, the residue was dissolved in isopropanol (20 mL), acetonitrile (50 mL) and diethyl ether (10 mL) were added, and the colorless solution was stirred at room temperature overnight. The white suspension was filtered, and the white solid was dried in vacuo to give pyrrolidine-3-carboxylic acid (2-diethylamino-ethyl)-amide hydrochloride as a white solid (581 mg, 62%). MS: m / z=214 [M+H] + .
[0447] 1-Pyrido[2,3-b]pyrazine-8-yl-pyrrolidine-3-carboxylic acid (2-diethylamino-ethyl)-amide: A solution of 8-chloro-pyrido[2,3-b]pyrazine (60 mg, 0.362 mmol), pyrrolidine-3-carboxylic acid (2-diethylamino-ethyl)-amide hydrochloride (136 mg, 0.544 mmol) and DIEA (316 μl, 1.81 mmol) in anhydrous ethanol (3 mL) was microwaved at 100° C. for 3 hours. When the reaction was complete, the solvent was removed under reduced pressure and the residue was purified by flash chromatography using an NH2 bonded silica column and eluted with methanol / dichloromethane (0% to 7% gradient) to give 1-pyrido[2,3-b]pyrazine-8-yl-pyrrolidine-3-carboxylic acid (2-diethylamino-ethyl)-amide as a yellow solid (108 mg, 85%).
[0448] Compound 54: HPLC: 97.3% purity, RT = 1.00 min. MS: m / z = 343 [M+H] + . 1 H NMR (400MHz, chloroform-d, ppm) δ8.86 (d, J=1.7Hz, 1H), 8.64 (d, J=5.6Hz, 1H), 8.60 (d, J=1. 7Hz, 1H), 6.49 (d, J=5.7Hz, 1H), 6.41 (s, 1H), 4.29-4.14 (m, 2H), 4.08 (dt, J=12.2, 7 .3Hz, 1H), 3.91 (q, J=9.2, 8.7Hz, 1H), 3.40-3.26 (m, 2H), 3.06 (p, J=7.6Hz, 1H), 2.5 6 (t, J=6.0Hz, 2H), 2.52 (q, J=7.1Hz, 4H), 2.41-2.24 (m, 2H), 0.99 (t, J=7.1Hz, 6H).
[0449] Example 23: Synthesis of Compound 55 ([1-(1,2-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-pyrrolidin-3-ylmethyl]-(2-piperidin-1-yl-ethyl)-amine)
[0450]
[0451] 3-[(2-piperidin-1-yl-ethylamino)-methyl]-pyrrolidine-1-carboxylic acid tert-butyl ester: To a solution of 3-formyl-pyrrolidine-1-carboxylic acid tert-butyl ester (200 mg, 0.98 mmol) and 2-piperidin-1-yl-ethylamine (126 mg, 0.98 mmol) in a mixture of methanol (0.40 mL) and 1,2-dichloroethane (1.60 mL) was added acetic acid (66 mg, 1.08 mmol) and the reaction mixture was stirred at room temperature for 1 h. Sodium triacetoxyborohydride (329 mg, 1.48 mmol) was then added and the reaction mixture was stirred at room temperature for 24 h. The reaction mixture was then poured into ice-cold water (10 mL) and extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated to give 3-[(2-piperidin-1-yl-ethylamino)-methyl]-pyrrolidine-1-carboxylic acid tert-butyl ester as a light yellow gum (150 mg, 38%). MS: m / z = 312.3 [M+H] + .
[0452] 3-{[Benzyloxycarbonyl-(2-piperidin-1-yl-ethyl)-amino]-methyl}-pyrrolidine-1-carboxylic acid tert-butyl ester: To a solution of 3-[(2-piperidin-1-yl-ethylamino)-methyl]-pyrrolidine-1-carboxylic acid tert-butyl ester (150 mg, 0.38 mmol) in THF (1.2 mL) and water (0.3 mL) were added sodium hydroxide (45 mg, 1.13 mmol) and benzyl chloroformate 50% / toluene solution (0.12 mL, 0.41 mmol). The reaction mixture was stirred at room temperature for 24 h, poured onto ice-cold water (10 mL), and extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated to give 3-{[benzyloxycarbonyl-(2-piperidin-1-yl-ethyl)-amino]-methyl}-pyrrolidine-1-carboxylic acid tert-butyl ester as a light yellow gum (150 mg, 47%). MS: m / z = 446.3 [M+H] + .
[0453] (2-Piperidin-1-yl-ethyl)-pyrrolidin-3-ylmethyl-carbamic acid benzyl ester trifluoroacetate: To a solution of 3-{[benzyloxycarbonyl-(2-piperidin-1-yl-ethyl)-amino]-methyl}-pyrrolidine-1-carboxylic acid tert-butyl ester (150 mg, 0.18 mmol) in dichloromethane (0.75 mL) was added dropwise trifluoroacetic acid (0.75 mL) at 0°C for 30 min. The reaction mixture was stirred at room temperature for 5 h. The reaction mixture was then concentrated under reduced pressure and azeotroped with toluene to give (2-piperidin-1-yl-ethyl)-pyrrolidin-3-ylmethyl-carbamic acid benzyl ester trifluoroacetate as a brown gum (80 mg, 57%). MS: m / z=346.3[M+H] + .
[0454] [1-(1,2-Dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-pyrrolidin-3-ylmethyl]-(2-piperidin-1-yl-ethyl)-carbamic acid benzyl ester: To a solution of 4-bromo-1,2-dimethyl-1H-pyrrolo[2,3-b]pyridine (200 mg, 0.88 mmol) and (2-piperidin-1-yl-ethyl)-pyrrolidin-3-ylmethyl-carbamic acid benzyl ester trifluoroacetate 847 mg, 1.06 mmol) in toluene (2 mL) was added potassium tert-butoxide (307 mg, 2.65 mmol), 2,2′-bis-diphenylphosphanyl-[1,1′]binaphthyl (56 mg, 0.09 mmol). The reaction mixture was degassed for 30 minutes, then tris(dibenzylideneacetone)dipalladium(0) (42 mg, 0.04 mmol) was added. The reaction mixture was heated at 100° C. for 24 hours in a sealed tube, poured onto ice-cold water (30 mL), and extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to give [1-(1,2-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-pyrrolidin-3-ylmethyl]-(2-piperidin-1-yl-ethyl)-carbamic acid benzyl ester as a black gum (220 mg, 15%). MS: m / z=490.2[M+H] + .
[0455] [1-(1,2-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-pyrrolidin-3-ylmethyl]-(2-piperidin-1-yl-ethyl)-amine: To a solution of [1-(1,2-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-pyrrolidin-3-ylmethyl]-(2-piperidin-1-yl-ethyl)-carbamic acid benzyl ester (200 mg, 0.12 mmol) in dioxane (1 mL) was added a 4 M solution of hydrogen chloride in dioxane (0.15 mL, 0.60 mmol). The resulting pink reaction mixture was heated at 65 °C for 5 h and concentrated under reduced pressure. The resulting mixture was dissolved in water, basified with aqueous sodium bicarbonate solution and extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate, filtered and concentrated to give the crude product, which was purified by flash chromatography to give [1-(1,2-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-pyrrolidin-3-ylmethyl]-(2-piperidin-1-yl-ethyl)-amine as a brown gum (10 mg, 23%).
[0456] Compound 55: HPLC: 97.3% purity, RT = 1.00 min. MS: m / z = 343 [M+H] + . 1HNMR (400 MHz, chloroform-d, ppm) δ 8.86 (d, J = 1.7 Hz, 1H), 8.64 (d, J = 5.6 Hz, 1H), 8.60 (d, J = 1.7 Hz, 1H), 6.49 (d, J = 5.7 Hz, 1H), 6.41 (s, 1H), 4.29-4.14 (m, 2H), 4.08 (dt, J = 12.2, 7.3Hz, 1H), 3.91 (q, J=9.2, 8.7Hz, 1H), 3.40-3.26 (m, 2H), 3.06 (p, J=7.6Hz, 1H), 2. 56 (t, J=6.0Hz, 2H), 2.52 (q, J=7.1Hz, 4H), 2.41-2.24 (m, 2H), 0.99 (t, J=7.1Hz, 6H).
[0457] Example 24: HEK TLR7 cell assay
[0458] 5000c / w of TLR7 / NFKb HEK cells and 10% FCS-HI, 2mM L-glutamine, 1% Pen / Strept in 30uL DMEM (gibco#31053) without phenol red were placed in 384 Culture Plates (Corning 3707). The cells were cultured at 37 degrees Celsius and 10% carbon dioxide for 24 hours. 3uL of controls, standards and compounds were distributed into the wells, cultured for 30 minutes, and then 3uL of R848 (10uM final concentration) agonist in 20mM Hepes was added. Cultivate for 5 hours and then let it stand at room temperature for 15 minutes. Add 10uL of Steady-Glo substrate reagent and shake the assay plate at 1500rpm for 5 minutes. Let the assay plate stand at room temperature for 30 minutes and then read the plate on EnVision.
[0459] Example 25: HEK TLR8 cell assay
[0460] 5000c / w of TLR8 / NFKb HEK cells and 10% FCS-HI, 2mM L-glutamine, 1% Pen / Strept in 30uL DMEM (gibco#31053) without phenol red were placed in 384 Culture Plates (Corning 3707). The cells were cultured at 37 degrees Celsius and 10% carbon dioxide for 24 hours. 3uL of controls, standards and compounds were distributed into the wells, cultured for 30 minutes, and then 3uL of R848 (30uM final concentration) agonist in 20mM Hepes was added. Cultivate for 5 hours and then let it stand at room temperature for 15 minutes. Add 10uL of Steady-Glo substrate reagent and shake the assay plate at 1500rpm for 5 minutes. Let the assay plate stand at room temperature for 30 minutes and then read the plate on EnVision.
[0461] The results are given in the table below.
[0462] A: IC 50 <1uM
[0463] B:IC 50 :1uM-10uM
[0464] C:IC 50 >10uM
[0465] Table 2
[0466]
[0467]
[0468]
[0469]
[0470] Example 26. Pharmaceutical preparations
[0471] (A) Injection vials: A solution of 100 g of the active ingredient according to the invention and 5 g of disodium hydrogen phosphate in 3 liters of double distilled water was adjusted to pH 6.5 using 2N hydrochloric acid, sterile filtered, transferred to injection vials, lyophilized under aseptic conditions, and sealed under aseptic conditions. Each injection vial contained 5 mg of the active ingredient.
[0472] (B) Suppositories: 20 g of the mixture of the active ingredient according to the invention is melted with 100 g of soya lecithin and 1400 g of cocoa butter, poured into a mold and allowed to cool. Each suppository contains 20 mg of the active ingredient.
[0473] (C) Solution: A solution is prepared from 1 g of the active ingredient according to the invention, 9.38 g of NaH2PO4·2H2O, 28.48 g of Na2HPO4·12H2O and 0.1 g of benzalkonium chloride in 940 ml of double distilled water. The pH is adjusted to 6.8, the solution is made up to 1 liter and sterilized by irradiation. The solution can be used in the form of eye drops.
[0474] (D) Ointment: 500 mg of the active ingredient according to the invention are mixed with 99.5 g of vaseline under sterile conditions.
[0475] (E) Tablets: A mixture of 1 kg of the active ingredient according to the invention, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is compressed into tablets in a conventional manner in such a way that each tablet contains 10 mg of the active ingredient.
[0476] (F) Coated tablets: Tablets are pressed analogously to Example E and subsequently coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and dye.
[0477] (G) Capsules: 2 kg of the active ingredient according to the invention are introduced into hard gelatin capsules in a customary manner in such a way that each capsule contains 20 mg of the active ingredient.
[0478] (H) Ampoules: A solution of 1 kg of the active ingredient according to the invention in 60 liters of double distilled water is sterile filtered, transferred into ampoules, lyophilized under aseptic conditions, and sealed under aseptic conditions. Each ampoule contains 10 mg of the active ingredient.
[0479] (I) Inhalation spray: 14 g of the active ingredient according to the invention is dissolved in 10 liters of isotonic NaCl solution and the solution is transferred to a commercially available spray container with a pump mechanism. The solution can be sprayed into the oral cavity or nasal cavity. One spray (about 0.1 ml) corresponds to a dose of about 0.14 mg.
[0480] Although many embodiments of the present invention are described herein, it is apparent that the basic examples can be altered to provide other embodiments utilizing the compounds and methods of the present invention. It should therefore be understood that the scope of the invention is defined by the appended claims rather than by the specific embodiments that have been shown by way of example.
Claims
1. A compound of formula I, in: Ring A is aryl or heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur; each of which is optionally substituted: Ring B is a heteroaryl group having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur; each of which is optionally substituted; R 1 Yes-CH 3 , -CF 3 or -CN; Each R 2 are independently -H, -R, halogen, -haloalkyl, -OR, -SR, -CN, -NO 2 , -SO 2 R, -SOR, -C(O)R, -CO 2 R, -C(O)N(R) 2 , -NRC(O)R, -NRC(O)N(R) 2 , -NRSO 2 R or -N(R) 2 ; Each R 3 are independently -H, -R, halogen, -haloalkyl, -OR, -SR, -CN, -NO 2 , -SO 2 R, -SOR, -C(O)R, -CO 2 R, -C(O)N(R) 2 , -NRC(O)R, -NRC(O)N(R) 2 , -NRSO 2 R or -N(R) 2 ; Each R 4 are independently -H, -R, halogen, -haloalkyl, -OR, -SR, -CN, -NO 2 , -SO 2 R, -SOR, -C(O)R, -CO 2 R, -C(O)N(R) 2 , -NRC(O)R, -NRC(O)N(R) 2 , -NRC(O)OR, -NRSO 2 R or -N(R) 2 ; Each R 5 are independently -H, -R, halogen, -haloalkyl, -OR, -SR, -CN, -NO 2 , -SO 2 R, -SOR, -C(O)R, -CO 2 R, -C(O)N(R) 2 , -NRC(O)R, -NRC(O)N(R) 2 , -NRSO 2 R or -N(R) 2 ; Each R is independently hydrogen, C 1-6 Aliphatic group, C 3-10 Aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur; each of which is optionally substituted; or Two R groups on the same atom together with the atom to which they are attached form a C 3-10 Aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur; each of which is optionally substituted; k is 0, 1, or 2: n is 0, 1, or 2; p is 0, 1, or 2; r is 1, 2, or 3; and t is 1, 2, or 3; wherein k is 0 when attached to nitrogen; and k is 1 or 2 when attached to carbon.
2. The compound of claim 1, wherein ring A is phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl or triazinyl.
3. A compound according to any one of the preceding claims, wherein Ring A is 4. The compound of any one of the preceding claims, wherein Ring B is pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, pyrrole, imidazole, isoxazole, oxazole or thiazole; each of which is optionally substituted.
5. A compound according to any one of the preceding claims, wherein Ring B is 6. A compound according to any one of the preceding claims, wherein Ring B is 7. A compound according to any one of the preceding claims, wherein each R 4 Independently C 1 - 6 Aliphatic, -OR, -C(O)R, -CO 2 R, -C(O)N(R) 2 , -NRC(O)R, -NRC(O)OR, -NRC(O)N(R) 2 , -NRSO 2 R, or -N(R) 2 ; each of which is optionally substituted.
8. A compound according to any one of the preceding claims, wherein each R 4 Independently C1- 6 Aliphatic group, -C(O)N(R) 2 , -NRC(O)R, or -N(R) 2 ; each of which is optionally substituted.
9. A compound according to any one of the preceding claims, wherein each R 4 Independently 10. A compound according to any one of the preceding claims, wherein each R 5 are independently halogen, C 1-6 Aliphatic group, C 3-10 Aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur; each of which is optionally substituted.
11. A compound according to any one of the preceding claims, wherein each R 5 is independently methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, straight or branched pentyl, or straight or branched hexyl; each of which is optionally substituted; or each R 5 is independently -F, -Cl, -Br, or -I.
12. The compound of claim 1 of formula Ia, or a pharmaceutically acceptable salt thereof.
13. The compound of claim 1 of formula Ic, or a pharmaceutically acceptable salt thereof.
14. The compound of claim 1 of formula Id, or a pharmaceutically acceptable salt thereof.
15. A compound according to any one of the preceding claims, selected from Table 1.
16. A pharmaceutical composition comprising a compound according to any one of claims 1 to 15 and a pharmaceutically acceptable adjuvant, carrier or vehicle.
17. A method for inhibiting the activity of TLR7 / 8 or a mutant thereof in a patient or a biological sample, comprising the step of administering to the patient a compound or a physiologically acceptable salt thereof according to any one of claims 1 to 15 or contacting the biological sample with a compound or a physiologically acceptable salt thereof according to any one of claims 1 to 15.
18. A method of treating a TLR7 / 8 mediated disorder in a patient in need thereof, comprising the step of administering to said patient a compound according to any one of claims 1 to 15, or a physiologically acceptable salt thereof.
19. The method of claim 18, wherein the disorder is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, osteoarthritis, systemic lupus erythematosus, lupus nephritis, ankylosing spondylitis, osteoporosis, systemic sclerosis, multiple sclerosis, psoriasis, type I diabetes, type II diabetes, inflammatory bowel disease (Crohn's disease and ulcerative colitis), hyperimmunoglobulinemia D and periodic fever syndromes, cryopyrin-associated periodic syndromes, Schnitzler syndrome, systemic juvenile idiopathic arthritis, adult-onset Still's disease, gout, pseudogout, SAPHO syndrome, Castleman's disease, sepsis, stroke, atherosclerosis, celiac disease, DIRA (deficiency of IL-1 receptor antagonist), Alzheimer's disease, Parkinson's disease, and cancer.
20. A method of treating cancer in a subject comprising the step of administering to the subject a compound of claim 1 or a physiologically acceptable salt thereof.
